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1. Introduction 
 
Matrix-Metalloproteinases : general aspects 
Matrix metalloproteinases (MMPs) are a tightly regulated family of enzymes having a 
potential to degrade the extracellular matrix and basement membrane components [Nelson et 
al., 2000]. The first report of an enzyme from vertebrate (as opposed to bacterial) sources that 
was capable of attacking the triple helix of native type I collagen was published in 1962 by 
Jerome Groos and Charles Lapiere [Groos and Lapiere, 1962] . In this first report the authors 
could demonstrate that the enzyme activity,  secreted by cultured tissue fragments of tail fin 
skin from resorbing tadpole tails in metamorphosis, was a true collagenase which was able to 
degrade collagen at 27 °C at neutral pH. Mechanistically, by these studies it was demonstrated 
that collagenase is able to cut the triple helix at a point one-quarter of the distance in from the 
C-terminal end and that the activity was metal dependent. Meanwhile, more than 20 
endopeptidases have been classified as MMPs. Historically, this enzyme family was divided 
into collagenases, gelatinases, stromelysins and matrilysins [Egeblad and Werb, 2002] The 
MMPs have several common characteristics which are as follows [Powel et al., 1996]: 1. 
Members of the MMP family have a characteristic pattern of conserved domains within their 
structure. 2. Common substrates for all MMPs members are proteins which build up the 
extracellular matrix (ECM) and the basement membrane. 3. Their proteolytic activity is 
specifically inhibited by their endogenous inhibitors, the tissue inhibitors of 
metalloproteinases (TIMPs). 4. Some MMPs are either secreted as inactive zymogen or 
transmembrane proenzymes that both require activation to exert their matrix degrading 
activities.  5. The active site contains a zinc ion and requires a second cofactor such as 
calcium. 6. The enzymatic activity of all MMPs is optimal in a physiological pH range.  As 
the list of MMP substrates has increased, a sequential numbering system has been adopted 
and MMPs are meanwhile grouped according to their substrates as shown in table 1.    Introduction 
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Enzyme Descriptve  name  Size (kDa) 
Latent/active
Collagen 
substrates 
Additional substrates 
 
   MMP-1 
 
 
   MMP-2 
 
 
   MMP-3 
 
 
 
   MMP-7 
 
 
 
   MMP-8 
 
    
   MMP-9 
 
    
   MMP-10 
 
 
    
   MMP-11 
 
   MMP-12 
 
    
   MMP-13 
 
  MMP- 18 
 
   MMP-19 
 
    
   MMP-20 
 
   MMP-23 
   
   MMP-26 
    
   MMP-28 
   
   MMP-14 
 
 
    
    
   MMP-15 
   MMP-16 
   MMP-17 
   MMP-24 
   
   
   MMP-25 
 
Interstitial collagenase  
 
 
Gelatinase A 
 
 
Stromelysin-1 
 
 
 
Matrilysin 
 
 
 
Neutrophil collagenase 
 
 
Gelatinase B 
 
 
Stromelysin-2 
 
 
 
Stromelysin-3 
 
Metalloelastase 
 
 
Collagenase-3 
 
Xenopus collagenase 
 
RASI-1 
 
 
Enamelysin 
 
CA-MMP 
 
Matrilysin-2 
 
Epilysin 
 
MT1-MMP 
 
 
 
 
MT2-MMP 
MT3-MMP 
MT4-MMP 
MT5-MMP 
 
 
MT6-MMP 
 
55/45 
 
 
72/66 
 
 
57/45 
 
 
 
28/19 
 
 
 
75/58 
 
 
92/86 
 
 
57/44 
 
 
 
51/44 
 
54/45 
 
 
60/48 
 
70/53 
 
54/45 
 
 
54/22 
 
 
 
28/19 
 
 
 
66/56 
 
 
 
 
72/60 
64/52 
57/53 
-/62 
 
I, II, III, VII,  
VIII, X 
 
I, II, III, IV, V, 
 VII, X, XI 
 
II, III, IV, IX, 
 X, XI 
 
 
IV, X 
 
 
 
I, II, III, V,  
VII,VIII,X 
 
IV, V, VII,  
X, XIV 
 
III, IV, V 
 
 
 
 
 
IV 
 
 
I, II, III, IV 
 
 
 
IV 
 
 
 
 
 
 
IV 
 
 
 
I ,II, III 
 
 
 
 
 
 
 
 
 
 
IV 
 
Aggrecan, Gelatin, MMP-2, MMP-9 
 
 
Aggrecan, Elastin, Fibronectin, 
 Gelatin, Laminin, MMP-9, MMP-13 
 
Aggrecan, Elastin, Fibronectin,  
 Gelatin, Laminin, MMP-7, 
 MMP-8, MMP-13 
 
Aggrecan, Elastin, Fibronectin,  
 Gelatin, Laminin, MMP-1, 
 MMP-2, MMP-9 
 
Aggrecan, Elastin, Fibronectin, 
 Gelatin, Laminin 
  
Aggrecan, Elastin, Fibronectin, 
 Gelatin 
  
Aggrecan, Elastin, Fibrpnectin, 
 Gelatin, Laminin, MMP-1, 
 MMP-8 
 
Aggrecan, Fibronectin, Laminin 
 
Elastin, Fibronectin, Gelatin, 
 Laminin 
 
Aggrecan, Gelatin 
 
 
 
Fibronectin, Aggrican,  
Laminin, Gelatin 
 
Aggrecan, Amelogenin 
 
  
 
Gelatin, fibrinocetin 
 
 
 
Aggrecan, Elastin, Fibronectin,  
Gelatin,  Laminin, MMP-2, MMP-13 
 
  
 
Fibrionectin, laminin, gelatin, MMP-2 
MMP-2 
Fibrin, gelatin 
 
  
 
Gelatin, Fibronectin, laminin 
  
Table 1: The family of MMPs (adapted from Matrisian, 1990, Nelson et al., 2000 and Murphy et al., 2002)    Introduction 
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The structural complexity of MMPs 
Analysis of the human genome has enabled to get insight into the MMP gene family, a gallery 
of proteinases which are encoded by 24 distinct genes [Overall and Lopez-Otin, 2002]. The 
secreted types of MMPs contain a signal peptide necessary for secretion, a propeptide which 
keeps the enzyme in an inactive state and a catalytic domain with a zinc ion (Zn
2+) in its center 
(Figure 1). Moreover, most of the secreted types of  MMPs at their carboxy terminal end 
contain a hemopexin domain (Figure 1) which is important for determining the substrate 
specificity and for the interaction with the TIMPs. A subset of MMPs, known as membrane-
type MMPs (MT-MMPs), additionally contains a transmembrane domain. Unlike the other 
members of MMP family, MT-MMPs are not secreted but instead are inserted into the plasma 
membrane by a transmembrane segment or a glycosylphosphatidylinositol (GPI). There is 
good evidence that one of the main function of MT-MMPs is to localize and activate some of 
the secreted MMPs mainly the MMP-2 (gelatinase-A) [Nelson et al., 2000].  
 
 
 
                                                                                     
 
 
 
 
 
 
 
 
 
 
 
                                                                                  Figure 1. the domain structure of MMPs 
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Further complexity is derived by addition of other protein modules or smaller inserts. For 
example, the gelatinases A and B (MMP-2 and MMP-9) similarly have an additional 
fibronectin-like domain inserted in the middle of the catalytic domain [Sternlicht and Werb, 
2001]. Unique to gelatinase B is a collagen V-like domain located  between the catalytic 
domain and the hemopexin domain [ Wilhelm et al., 1989]. 
 
Regulation of MMPs 
Generally, the proteolytic activity of MMPs is regulated mainly at three levels involving, 
transcription, proenzyme activation and inhibition by the TIMPs (Figure 2). Further 
mechanisms by which the abundance of MMPs can be modulated involve the regulation of 
MMP mRNA stability, changes in the translational efficiency, enzyme compartmentalization, 
enzyme secretion and the cell-surface recruitment (Figure 2). All MMPs are synthesized as 
latent zymogens (pro-MMPs) and are kept inactive due to the interaction between a cysteine-
sulphohydryl group present in the propeptide domain and the central Zn
+2 of the enzyme
,s 
catalytical domain [Egeblad and Werb, 2002]. Most of the MMPs are activated extracellularly 
by other active MMPs or serine proteinases whereas MMP-11, MMP-28 and MMP-14 (MT1-
MMP) can be activated intracellularly by the action of furin-like serine proteinases [Sternlicht 
and Werb, 2001]. For example, MMP-2 underlies a complex activation pathway which 
involves active MMP-14 (MT1-MMP) and TIMP-2 which binds to pro-MMP-2 at its C- 
terminus. Secondly, the activity of MMPs is tightly controlled by the action of endogenous 
inhibitors. In addition to the already mentioned  TIMPs, an other important inhibitor of MMPs 
is  α-2 macroglobulin which acts via binding to the MMP scavenger receptors thereby 
generating an inactive MMP-macroglobulin complex. A further inhibitor of MMPs are 
thrombospondin-1 and –2 which by binding to pro-gelatinases directly can inhibit their 
activation. Finally, a recently found protein called RECK (reversion-inducing cysteine-rich 
protein with kazal motifs) was characterized as the first known membrane-bound MMP    Introduction 
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inhibitor [Egeblad and Werb, 2002].The transcriptional mechanisms regulating MMP 
expression are quite complex [Fini et al., 1998; Westermarck & Kahari, 1999]. The 
expression of most MMPs under normal physiologic conditions is low in tissue but is induced 
under conditions where remodeling of ECM is required  [Westermack and Kahari,1999]. The 
expression of  MMPs is regulated at the transcriptional level and induced by various signals, 
such as cytokines, growth factors and oncogene products [Kheradmand et al., 1998]. 
Similarily, the signal transduction pathways that mediate the activity of MMP transcriptional 
activators are also diverse. These include, for example, the mitogen activated protein kinase 
(MAPK) pathways including, the p38- MAPK, the jun-N-terminal kinase (JNK) and the 
extracellular signal-regulated kinase (ERK) pathways [Westermarck & Kahari, 1999; Simon 
et al., 1998; Johansson et al., 2000; Eberhardt et al., 2000b]. All of these signal transduction 
pathways however, converge at the activation of only a few transcriptional factors which 
finally control MMP expression which actions however account for the variable inducibility 
of MMPs by several agents. Some of the common transcription factors involved in MMP 
expression include the ETS family of oncoproteins, which bind to their PEA3 sites that are 
present in most of the MMP gene promoters[Fini et al., 1998], nuclear factor kappaB (NF-κB) 
which is necessary for expression of MMP-1,3,9,13 and 14 genes [Bond et al., 1999; Han et 
al., 2001] and the binding-site for transcription factor activated protein-1 (AP-1) which also is 
present in the promoter region of most inducible MMP genes [Pendas et al., 1997].The DNA- 
binding and transactivation capacity of AP-1 and ETS transcription factors are activated by 
phosphorylation by MAPKs and the balance between the distincit MAPK pathways is thought 
to regulate cell growth, differentiation,  survival and cell death [Westermack and Kahari, 
1999]. A further important group of  transcription factors for regulating the MMP gene 
expression are the signal transducers and activators of transcription (STATs), which mainly 
mediate the effects of interferons (INFs) but also of many other cytokines [Overall and 
Lopez-Otin, 2002].     Introduction 
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Figure 2. regulation of MMPs  (Overall & Lopez-Otin, 2002) 
 
 
The biological roles of the MMPs 
MMPs are important regulators of many developmental and physiological events. Because 
MMPs can degrade ECM molecules, their main function has been presumed to be remodeling 
of the ECM. Since ECM remodeling is a critical process of tissue growth and morphogenesis, 
MMPs are thought to play important roles during embryonic development. Moreover, ECM  
remodeling is  important for  proliferation of cells  and angiogenesis since for both processes    Introduction 
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the breakdown of ECM seems to be  a prerequisite. Beyond their classical connective tissue 
remodeling functions, increasing experimental evidence has been given, demonstrating that 
MMPs are key-players in the precise regulation of many bioactive molecules, mainly by their 
proteolytic and processing activity [Overall and Lopez-Otin, 2002]. For example, MMPs can 
generate growth-promoting signals as demonstrated by the decreased cell proliferation rates 
of tumor cells injected into MMP-9 deficient mice when compared to wild-type mice 
[Coussens et al., 2000; Bergers et al., 2000]. Mechanistically, MMPs can promote cell 
proliferation by increasing the release of cell membrane-bound precursors of some growth 
factors, most importantly the transforming growth factor α (TGF-α) [Peschon et al., 1998] 
and the insulin-like growth factor (IGF) [Manes et al., 1997; 1999]. In contrast, by liberating 
transforming growth factor β (TGFß) from the latent TGFß complex some MMPs can 
additionally inhibit cancer cell growth, thus demonstrating the diversity of MMPs in 
regulation of cell growth [Egeblad and Werb, 2002]. A further biological role of MMPs is 
their contribution to regulation of  apoptosis. In this context, overexpression of MMP-3,-7,-9 
and –11 has been demonstrated to cause an increase in apoptotic cell death in mammary 
epithelial cells [Alexander et al., 1996; Witty et al., 1995]. One main mechanism by which 
MMPs can regulate apoptosis is the release of membrane-bound FAS ligand (FASL) which 
by binding to its cognate transmembrane death receptor FAS can activate the receptor 
tyrosine kinase thereby inducing apoptotic cell death [Powel et al., 1999; Mitsiades et al., 
2001]. However, release of FASL in some cell types can also lead to a reduction of  apoptosis 
demonstrating the strong cell-type specificity of MMP-related cell death [Powel et al., 1999]. 
A further pivotal function of MMPs in the carcinogenic process is the regulation of 
angiogenesis which plays a povital role in the sprouting of newly formed vessels during tumor 
growth. One of the most convincing trials proving the contribution of MMPs in tumor 
angiogenesis is the use of synthetic MMP inhibitors which are able to significantly reduce 
tumor angiogenesis in different animal experiments [Rodriguez-Manzaneque et al., 2001; Oh    Introduction 
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et al., 2001]. One of the  mechanisms by which MMPs are thought to regulate angiogenesis is 
the release of pro-angiogenic factors such as vascular endothelial growth factor (VEGF) or 
basic fibroblast growth factor (bFGF) [Bergers et al., 2000]. Mainly the contribution of MMP-
9 and -14 was demonstrated by the use of MMP-9 and MMP-14-deficient mice, which both 
showed impaired angiogenesis during development [Vu et al., 1998; Zhou et al., 2000]. In 
addition to angiogenesis, MMPs play an important role in metastasis as demonstrated by 
promoting the invasion of certain cell lines through collagen-containing matrices when MMP-
2, -3, -13 and –14 were overexpressed [Ahonen et al., 1998; Kim et al., 2000]. Experimental 
evidence for functional roles of MMPs in the metastatic processes has furthermore been 
derived from in vitro invasion assays as well as from in vivio xenograft models [Egeblad and 
Werb, 2002]. The latter is a method of transplantation of human tumor cells into immune-
deficient mice strains [Egeblad and Werb, 2002]. By these assays, it could be demonstrated 
that the number of metastatic colonies formed in the lungs of these mice was significantly 
reduced in the MMP-2 and MMP-9 null mice when compared with the wild-type mice thus 
demonstrating that both gelatinases play a critical role for the migration of metastatic cells 
[Itoh et al., 1998; 1999]. Finally, MMPs are involved in the escape of tumor cells from the 
attacks of immune responses by different mechanisms. MMP-9 e.g., can cleave the α receptor 
of interleukin-2 (IL-2Rα) and thereby suppress the proliferation of T-lymphocytes which 
strongly depends on IL-2 dependent signaling pathways [Sheu et al., 2001]. Furthermore, 
MMPs can activate TGF-ß  [Yu and Stamenkovic, 2000] an important inhibitor of the T-
lymphocyte response against tumors [Gorelik and Flavell, 2001]. In addition, MMPs can 
affect several chemokines resulting in both increased or reduced chemotaxis of leukocytes. 
MMP-9 has been shown to cleave the neutrophil chemoattractant CXCL8 and its murine 
homolog, thereby increasing its activity [Egeblad and Werb, 2002]. In contrast, MMP-2 can 
cleave CCL7 producing an inactive cleaved fragment which becomes an antagonist of the 
receptors [McQuibban et al., 2000].    Introduction 
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MMPs in renal glomerular diseases 
The tight balance between ECM synthesis and degradation is thought to be  a main 
prerequisite for maintaining the structural and functional integrity of the glomerulus [Arthur, 
1998; Lenz et al., 2000]. Thus, changes in MMP expression or activity will directly translate 
into altered ECM turnover, which may lead to glomerular scarring and a decline in renal 
function. Many forms of glomerular diseases are characterized by a change in cellularity, 
which in turn may affect ECM composition and turnover. A main mechanism how MMPs can 
influence ECM turnover is the release of  certain growth factors from their inactive precursors 
as mentioned on page 7. A regulation of growth factor activity by MMPs has been observed 
by use of MMP-9-deficient mice, which exhibit abnormal growth plate vascularization and 
ossification [Vu et al., 1998]. Furthermore, binding proteins for insulin-like growth factor 1 
have been identified as substrates of MMP [Fowlkes et al., 1995]. Especially, diseases which 
are characterized by an altered matrix composition, such as Alport disease, the increased 
susceptibility of the basement membrane to  the degradation by MMPs has been postulated to 
cause glomerular damage [Kalluri et al., 1997]. These findings illustrate that MMPs are 
involved at several levels of ECM turnover, thereby keeping a tight balance between ECM 
synthesis and degradation necessary for normal physiological function of the glomerulus. The 
role of MMPs in the development of glomerular damage has been studied in a variety of 
experimental conditions. In general terms, a downregulation of MMPs is often associated with 
the progression of noninflammatory diseases such as hypertensive glomerulosclerosis 
[Singhal et al., 1996; Trachtman et al., 1996], cyclosporin nephrotoxicity [Duymelinck et al., 
1998] and diabetic nephropathy [Abrass et al., 1998; Schnaper and Robson, 1992]. In contrast 
to noninflammatory diseases, the findings are quite different in inflammatory glomerular 
diseases. It has been reported that the increased levels of MMPs are functionally associated 
with the progression of disease and paralleled by an increased influx of inflammatory cells    Introduction 
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[Nakamura et al., 1995]. Therefore, the overall amount and duration of MMPs activity may 
critically determine the structural glomerular damage as demonstrated by  elevated levels  of 
MMPs in various forms of glomerulonephritis [Steinmann-Niggli et al., 1998; Akiyama et al., 
1997; Koide et al., 1996]. In addition, it has been reported that the inhibition of MMPs 
significantly can attenuate the formation of glomerular lesions observed during 
glomerulonephritis demonstrating a beneficial role of MMP inhibitors in the treatment of 
acute glomerulonephritis [Steinmann-Niggli et al., 1998]. 
In summary, an overall reduction of MMP level within the glomerulus seems to critically 
determine the progression and degree of glomerulosclerosis since downregulation of MMPs 
increases the matrix accumulation which consequently causes a decrease of the filtration 
capacity. In contrast, upregulation of MMPs in many cases is associated with the generation 
of glomerulonephritis. Therefore, future therapeutic strategies by selectively targeting single 
member of the MMP family and/or their endogenous inhibitors may have beneficial effects in 
preventing progressive as well as inflammatory renal diseases. 
  
The mesangial cell as an important regulator of inflammatory processes within the 
kidney  
The functional unit of the kidney, which represents the main excretory organ of mammalians 
is the nephron. Each human kidney contains about 1.0-1.5 million nephrons, that of rats 
approximately 30,000 to 34,000 (Brenner, 1996). Essential components of the nephron are the 
renal glomerulus with the adjacent vas afferens and vas efferens, the proximal and the distal 
convoluted tuble and the loop of  Henle. The glomerulus itself builts up a functional unit of 
the kidney which enables the production of a highly concentrated plasma ultrafiltrate. The 
functionality of a glomerulus is guaranteed by the action of at least four different cell-types 
which each of them perform special functions.    Introduction 
  11
1.  Glomerular endothelial cells which form the initial barrier to the passage of blood 
constituents from the lumen of the capillaries to the Bowman space (Brenner, 1996). Due to a 
negatively charged surface endothelial cell contribute to the charge-selective properties of the 
capillary wall. 
2.  Visceral epithelial cells also called podocytes, characterized by long cytoplasmatic 
processes which come into direct contact with the glomerular basement membrane. There is 
also some evidence that visceral epithelial cells are responsible for the synthesis and 
maintenance of the glomerular basement membrane. 
3. Parietal glomerular epithelial cells, which built up the main component of the Bowman’s 
capsule.  
4. Glomerular mesangial cells which together with surrounding matrix material and resident 
monocytes-macrophages constitute the mesangium. The mesangium is localized inbetween 
the capillary loops of the glomerulus and represents a separate component, which is mainly 
involved in the regulation of glomerular circulation and filtration (Brenner, 1996). 
Morphologically the mesangial cell is characterized by its irregular shape, its dense nucleus 
and the existence of elongated processes which can extend around the capillary lumen. 
Mesangial cells have also been characterized as modified smooth muscle cells as they possess 
an extensive array of contractile cytoskeletal elements as for example actomyosin, 
microtubles and intermediate filaments all of which can exert mechanical traction on the 
glomerular basement membrane in response to vasoactive agents such as angiotensin II, 
vasopressin, cAMP-and cGMP elevating hormones (Pfeilschifter, 1989). Therefore it has 
been concluded that the contractile state of mesangial cells finally regulates the glomerular 
filtration rate by a direct alteration of the filtration surface of glomerular capillaries. However, 
mesangial cells not only control glomerular filtration but are also involved in the responses to 
local injury, including cell proliferation, basement membrane remodeling and production of 
inflammatory mediators (Schlondorff, 1987). Experimental data and findings from human    Introduction 
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studies have suggested that mainly the enhanced degradation of ECM accompanying cell lysis 
in response to acute inflammatory processes  determines the extent of glomerular damage 
[Fogo, 2001]. In contrast, excessive matrix deposition seems as a paradigm of interstitial 
fibrosis and glomerulosclerosis which  count for the most common complications of the many 
renal diseases. Due to this critical involvement of MCs in glomerular response to injury much 
effort has been made to analyse mesangial cell function in normal condition as well as in 
glomerular diseases. To study the role of MCs during progression of glomerular diseases, MC 
culture is extensivly used as a powerful tool to investigate the main signaling pathways 
underlying MC responses. 
 
Aim of the work 
Progressive glomerulosclerosis leading to end-stage renal failure is a complication of a variety 
of diseases, such as diabetes mellitus, glomerulonephritis, focal sclerosis, chronic transplant 
rejection [Abrass et al., 1988; Schnaper & Robson, 1992; Jeong et al., 1996]. Although many 
studies have tried to elucidate the pathogenesis, the exact underlying mechanisms are still not 
completely understood. While increased synthesis of ECM certainly plays an important role, 
recent studies have focused on the degradative systems [Lenz et al., 2000]. The major 
physiologic regulators of ECM degradation in the glomerulus are matrix metalloproteinases 
(MMPs) [Woessner, 1991]. As described before, the tight regulation of most of these 
proteases is accomplished at different levels. The present work focuses on the regulation of 
MMP-9 which is one of the most prominent MMPs induced under inflammatory conditions 
within the renal mesangium. This work aimed to elucidate: 
 (i) the possible modulation of MMP-9 by peroxisome proliferator-activated receptors (PPAR) 
since each ligand by binding to its specific intracellular receptor can mediate a broad 
spectrum of physiological responses including lipid metabolism, glucose homeostasis,    Introduction 
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inflammatory and antiinflammatory responses, cell cycle progression, cell differentiation and 
for this work, most importantly, extracellular matrix remodeling.  
(ii) The molecular mechanisms by which NO can inhibit the expression of MMP-9 as 
described by Eberhardt et al., (2000a) since MC under inflammatory conditions similar to 
MMP-9 highly express the inducible type of NO synthase (iNOS) thereby producing high 
amounts of NO [Pfeilschifter and Schwarzenbach, 1990; Pfeilschifter et al., 1992]. The high 
output levels of NO may contribute to the excessive matrix accumulation [Cattel et al., 1993; 
Cook et al., 1994] triggering the sclerotic processes within the glomerulus in response to 
inflammatory injury [Johnson et al., 1994]. Furthermore, it has been reported that the 
adminstration of  specific iNOS inhibitors can reduce the intensity of inflammation in various 
forms of glomerulonephritis. Therefore, iNOS inhibitors may be of certain value in the future 
therapy of inflammatory diseases of the kidney [Noris and Remuzzi. 1999].  
(iii) The modulatory effects of extracellular ATP on MMP-9 expression since nucleotides can 
mediate a variety of cell responses in MC including cell growth, inhibition of apoptosis, and 
proliferation [Schulze-Lohoff et al., 1998;  Huwiler and Pfeilschifter, 1994]. Since both 
processes can be linked with excessive degradation of ECM, I tested whether extracellular 
nucleotides may influence the expression of MMP-9 in MC.  
    Materials and Methods 
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2. Materials and Methods 
I. Materials  
A. Chemicals :  
Acrylamide  solution      Roth,  Karlsruhe 
(30% acrylamide with 0.8% bisacrylamide)  
Actinomycin  D      Sigma  Aldrich  Fine  chemicals 
Agar              Gibco Life Technologies, Karlsruhe       
Agarose       Biozym,  Oldendorf 
Ammoniumpersulfate      Sigma  Aldrich  Fine  Chemicals   
Ampicillin       Sigma  Aldrich  Fine  Chemicals   
Aprotinin       Roch  Biochemicals,  Mannheim   
Bovine serum albumin, fatty acid free     Sigma Aldrich Fine Chemicals 
Cell culture media          Gibco Life Technologies  
Chemicals for luciferase reporter assay    Promega, Heidelberg  
Chemicals for sequence analysis      PE Biosystems, Weiterstadt 
(BigDye terminator premix, template supression reagent)     
Cycloheximide      Sigma  Aldrich  Fine  chemicals 
DETA-NONOate      Alexis,  Grunberg   
Diethylpyrocarbonate      Sigma  Aldrich  Fine  chemicals   
  Dithiothreitol       Sigma  Aldrich  Fine  chemicals 
ECL  reagent       Amersham  Pharmacia,  Freiburg 
Effectine transfection reagent      QIAGEN inc.,Hilden 
Ethidium  bromide      Sigma  Aldrich  Fine  chemicals 
EDTA        Sigma  Aldrich  Fine  chemicals 
EGTA        Sigma  Aldrich  Fine  chemicals 
Fetal calf serum          Gibco Life Technologies, Karlsruhe    
Glycine       Merk,  Darmstadt   
Griess  reagent       Merk,  Darmstadt 
Insulin        Roch  Biochemicals           
(source: Bovine pancreas & activity: 28.1 IU/mg)  
IL-1ß        Cellconcept,    Germany 
(recombinant human IL-ß produced in E.coli with activity 5-500 units/ml) 
Leupeptin       Roch  Biochemicals 
N
G-monomethyl-L-arginine     Alexis    Materials and Methods 
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Ly-17,1883        Alexis 
Molecular weight markers (DNA)        MBI Fermentas, St. Leon-Rot 
Molecular Weight markers (protein)       Amersham Pharmacia 
Nucleotide  triphosphates      PE  Biosystems,  Weiterstadt 
Pepstatin  A        Roch  Biochemicals,  Mannheim 
Peptone  140        Gibco  Life  Technologies   
Phenylmethylsulfonyl  fluoride     Roch  Biochemicals 
Ponceau  S        erva,  Heidelberg 
Radiolabeled nucleotide [α-
32P]ATP(6000 ci/mmol)  Amersham, Freiburg 
Radiolabeled nucleotide [α-
32P]CTP(3000 ci/mmol)  Amersham, Freiburg 
Radiolabeled nucleotide [α-
32P]UTP(3000 ci/mmol)  Amersham,  Freiburg 
 Rediprime DNA labelling Kit        Amersham, Freiburg 
SNAP         Alexis,  Grunberg 
S D S          A p p l i c h e m ,   D a r m s t a d t  
Tetramethylethylenediamine      Sigma  Aldrich  Fine  chemicals 
TritonX-100        Sigma  Aldrich  Fine  chemicals 
TRIzol  reagent      Gibco  Life  Technologies   
Tween  20        Sigma  Aldrich  Fine  chemicals 
Wy-14,643        Alexis 
All nucleotides were purchased from Sigma Aldrich Fine chemicals. 
 
B. Antibodies and antisera : 
Anti-MMP-9 (Rabbit polyclonal)        Chemicon, Hofheim, Germany    
Anti-HuR (mouse monoclonal)        Santa Cruz Biotechnology 
Anti-HuB  (goat  polyclonal)      Santa Cruz Biotechnology        
Anti-HuC (goat polyclonal)          Santa Cruz Biotechnology    
Anti-HuD (goat polyclonal)          Santa Cruz Biotechnology   
Anti-NF-κß p65 (Rabbit polyclonal)       Santa Cruz Biotechnology  
Anti.NF-κß p50 (Rabbit polyclonal)       Santa Cruz Biotechnology 
Anti-PPAR-α (Rabbit polyclonal)        Affinity Bioreagent, Inc         
Anti-ß-actin (goat, monoclonal)        Santa Cruz Biotechnology  
Anti-α-actin (mouse monoclonal)        Sigma Aldrich Fine chemicals 
Anti-goat IgG (horseradish-peroxidase coupled)    Amersham Pharmacia 
Anti-mouse IgG (horseradish-peroxidase coupled)    Amersham Pharmacia    Materials and Methods 
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Anti-iNOS : It was generated as previously described [Kunz et al., 1994] by cloning a cDNA-
fragment that represent 196 amino acids of the iNOS N-terminus into the expression vector 
pDS56 and expressed in E.coli strain M15.The His6-tagged polypeptide was purified using the 
xpress-kit (Invitrogen, Groningen, Netherlands). Female new zealand rabbits were immunized 
and the antisera were tested in Western blots. A prominent iNOS band at the expressed size of 
130 kDa was obtained when the protein was analyzed from MC treated with IL-ß.  
 
C. Enzymes : 
Pfu-DNA polymerase (5 units/ml)          Stratagene, Heidelberg  
Restriction  enzymes        MBI  Fermentas 
BamH I (Source: Bacillus amyloliquefciens H & activity: 10,000 units/ml) 
EcoRV (Source: Escherichia coli & activity: 10,000 units/ml) 
Hind III (Source: Haemophilus influenzae & activity: 10,000 units/ml) 
Xba I (Source: Xanthomonas badrii & activity: 10,000 units/ml)  
Reverse  transcriptase        MBI  Fermentas 
(source: Avian Myeloplastosis virus & activity: 10,000-100,000 units/ml)            
T4-DNA  ligase        Roch  Biochemicals     
(Source: T4-infected E-coli & activity: 500-6,000 units/ml)  
T 4 - P N K          M B I   F e r m e n t a s  
(source : E-coli strain that carries cloned T4 polynucleotide kinase gene) 
Taq-DNA polymerase            MBI Fermentas            
(Source: Thermus aquaticus & activity: 2.5 units/100µl)                                      
D p n - I           M B I   F e r m e n t a s  
(Source: Diplococcus pneumoniae & activity: 10,000 units/ml)  
 
D. Membranes : 
PVDF blotting membrane      Millipore, Eschborn 
Nylon blotting membranes      Life science, Schleicher and Schull, Dassei  
 
E. Buffers and Solutions : 
 PBS buffer (pH 7.4)        9.1 mM dibasic sodium phosphate, 1.7 mM  
monobasic sodium phosphate, 150 mM NaCl 
Denaturation buffer        63.3 % formamide, 13.3 % 10 x MOPS, 23.4 % 
Formaldehyde (37 %) 
10 x MOPS buffer        0.4 M Morpholinopropanesulfonic acid, 0.1 M     Materials and Methods 
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sodium acetate-3H2O,10 mM EDTA-Na2-2H2O 
20 x SSC buffer        3 M sodium chloride, 0.3 M sodium citrate   
dihydrate       
Prehybridization buffer      50 ml deionized formamide,25 ml 20 x SSC,  
5 ml 100 x Denhardt
,s, 5 ml 20 % SDS,  
15 ml H2O, 10 gm Dextran sulfate . 
Wash buffer–1        2 x SSC, 0.1 % SDS    
Wash buffer-2         0.2 x SSC, 1 % SDS 
Lysis buffer          20 mM Tris-HCl (pH 8.0), 2 mM EDTA (pH 8)  
137mM NaCl, 10% glycerin, 1% Triton x-100, 
0.2mM  PMSF, 0.5 mM DDT,  
5 mg/ml Leupeptin 
staining solution for RNA (pH 5.2)    0.5 M sodium acetate, 0.02 % Methylene blue  
10 x PAGE (pH 8.3)        3 % Tris-HCl, 14.4% glycine, 1% SDS  
Towbin-transfere buffer      25 mM Tris base, 192 mM glycine (pH 8.3),  
20 % Methanol  
TBS solution          10 mM Tris-HCl (pH 8.0), 150 mM NaCl,  
2 % BSA 
TBST solution        TBS plus 0.05 % Tween 20 
Blocking  solution     2  %  BSA 
2 x sample buffer        4 % SDS, 0.005 % Bromophenol blue,  
20 % glycerol, 0.5 M Tris-HCl (pH6.8) 
6 x loading buffer        30% glycerol, 0.25% bromophenol blue, 0.25% 
xylenecyanol and 60% 10x TAE buffer. 
Developing buffer        0.2 M NaCl, 5 mM CaCl2, 0.02 % Brij 35,  
0 mM Tris-HCl (pH 7.6) 
Staining soln for zymogen      30 % Methanol, 10 % glacial acetic acid, 0.5 % 
Coomassie G 250 
Destain solution        30 % Methanol, 10 % glacial acetic acid  
50 x TAE          1.6 M Tris-base, 0.8 M sodium acetate-3 H2O,  
40  mM EDTA-di-sodium-2H2O 
10 x TBE buffer        1M Tris base, 1 M boric acid,  
0.25 M EDTA (pH 8.2) 
Buffer A(hypotonic buffer)      10 mM HEPES (pH 7.9), 10 mM KCl,     Materials and Methods 
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0.1mM EDTA,  0.1 mM  EGTA, 0.5 mM PMSF
∗, 
0.1 mM DDT
∗ ,50  mg/ml Leupeptin∗  
∗ingredients were added immediately before use . 
Buffer C (Nuclear extract buffer)    20 mM HEPES (PH 7.9), 25 % glycerol,  
0.4 M NaCl, 1 mM EDTA, 1 mM EGTA,  
0.5 mM PMSF
∗, 1 mM DTT
∗, 50 mg/ml     
Leupeptin
∗ 
 ∗ ingredients were added immediately before use. 
3 x Binding buffer        12 % Ficoll, 60 mM HEPES (pH 7.9),  
150 mM KCl, 3 mM EDTA, 3 mM DTT, 
0.75 mg/ml BSA 
Buffer-1 (for DNA preparation)    50 mM Tris-HCl (pH 8.0), 10 mM EDTA,  
100 µg/ml Rnase A 
Buffer-2 (for DNA preparation)    200 mM NaOH, 1 % SDS (W/V) 
Buffer-3(for DNA preparation)    3.0 M Potassium acetate ( pH 5.5) 
Buffer N2(equilibration buffer)    100 mM Tris/H3PO4, 15 % Ethanol,  
900 mM KCl (pH6.3), 0.15 % Triton X-100 
Buffer N3 (washing buffer)      100 mM Tris/H3PO4, 15 % Ethanol,  
1150 mM KCl (pH6.3) 
Buffer N5 (elution buffer)      100 mm Tris/H3PO4, 15 % ethanol,  
100 mM KCl (pH 8.5) 
Depc-H2O      1ml  Diethylpyrocarbonate,1000  ml  dd  H2O 
Fix soln          100 ml isopropanol, 100 ml Acetic acid,  
800 ml dd H2O 
Luria Bertani (LB) media      For one liter, 10 gm Tryptone, 5 gm yeast   
extract,10gm NaCl  
 
 
II. Methods  
 
1. Cell culture : 
 Rat glomerular MC were cultured by a limited dilution procedure as described previousely 
(Pfeilschifter & Vosbeck, 1991). MC were grown at 37°C and 5% CO2 and cultured in RPMI 
1640 supplemented with 10% fetal calf serum (FCS), 2mM glutamate, 5ng/ml insulin, 100    Materials and Methods 
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U/ml Penicillin and 100ug/ml Streptomycin. To obtain quiescent cells, MC were maintained 
in serum-free Dulbecco’s modified Egale 
,s medium (DMEM) supplemented with 0.1mg/ml 
of fatty acid-free bovine serum albumin for 24 hours before cytokine treatment. For 
passaging, the cells were washed with PBS and incubated with trypsin-EDTA solution for 2 
minutes at 37°C. After cells have dislodged from the surface, culture medium was added and 
cells were diluted and transferred to new culture dishes. MC were used between passage 8 and 
19. For the experiments, 3.0-5.0Χ10
6 cells per 10 cm culture dish were used . The 
determination of cell numbers was done by the use of a Neubauer chamber. The amount of 
dead cells was determined by tryban blue exclusion. Viability of MC was not altered under 
the conditions used for the experiments described as determined by lactate dehydrogenase 
measurement using a cytotoxicity detection kit. For determination of the gelatinolytic activity 
of cellular supernatants, 1.0-1.5 Χ 10
6 MCs were grown on six-well plates and the 
experiments were performed in triplicates . 
 
2. Manipulation of DNA 
A. Molecular cloning of PCR products :  
 To get a permenent source of any foreign DNA it is often desired to clone PCR products into 
appropriate cloning vectors. 
Restriction  
restriction endonucleases isolated from bacteria specifically bind palindromic sequences with 
a subsequent cleavage of the DNA molecule at their specific recognition sites. This process 
can generate either  blunt end fragments or overhanging cohesive ends, which allow the 
generation of recominent DNA by appropriate enzymatic ligation. Blunt end PCR products 
were produced by using a Pfu DNA polymerase for the polymerase chain reaction since this 
enzyme removes single stranded ends. The cloning vector bluescript KS was linearized by 
digestion with the restriction endonuclease EcoRV which produces blunt ends. Generally, 10    Materials and Methods 
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µg of the TOPO cloning vector were incubated with 10 Units of  EcoRV and  2 µl of the 
appropriate 10 x restriction endonuclease buffer in a total volume of  20 µl for at least 2 hours 
at 37°C. Both PCR products and cloning vector were separated on a 1% agarose gel in 1 x 
TBE-buffer. The bands which correspond to the expected DNA  were excised and extracted 
from the gel using the QIA quick gel extraction kit from Qiagen (Hilden, Germany). The 
elution of this column results in a final volume of 30 µl containing the purified PCR product.  
Ligation  
 To create  recombinant plasmid DNA, 2 µl of the cloning vector and 15 µl of eluted PCR 
product, 2 µl of 10x T4 DNA ligase buffer and 1 µl of T4 DNA ligase enzyme were mixed 
and incubated overnight at 15°C. 
 
B. Introduction of plasmid DNA into E.coli (Transformation) : 
Competent bacterial cells  
To yield high transformation efficiencies, competent cells were prepared as followed. One 
single colony of E. coli was inoculated in 5 ml LB medium and incubated overnight at 37°C 
with shaking. 2 ml of the culture were inoculated into 200 ml LB medium and let grown at 
37°C until the suspension reached an optical density of 0.5 (OD 600 nm). The bacterial 
culture was pelleted by  centrifugation at 1600 x g and the pellet subsequently resuspended in 
10 ml of ice-cold CaCl2 solution. The resuspended cells were kept on ice for 30 minutes and 
centrifuged again 5 minutes at 1100 x g at 4°C. The supernatant was discarded and the pellet 
was resuspended in 2 ml ice-cold CaCl2  solution. 250 µl aliquots were dispensed into 
prechilled polypropylene tubes and frozen immediately at –70°C. 
Transformation  
For transformation, approximately 10 µl of ligation reaction (10 ng DNA) were mixed gently 
with 100 µl of competent cells and placed on ice for 30 minutes. The cells were heat shocked 
at 42°C for 45 seconds. 500 µl of LB-medium was added and the tubes were incubated at    Materials and Methods 
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37C° for 1 hour with shaking. 50 µl of the transformation culture was plated on LB/ampicillin 
plates and incubated overnight at 37C°. 
C. Isolation of plasmid DNA  
Isolation of small quantities of plasmid DNA (miniprep) : 
Isolation of small quantities of plasmid DNA was performed by alkaline lysis as described 
previously (Birnboim and Doly 1979). 2 ml sterile LB/ampicillin medium was inoculated 
with a single bacterial colony from a freshly streaked LB/ampicillin plate and let grown at 
37°C with shaking overnight. 1 ml of bacterial cells were spined 1 minute at maximum speed 
(13,000 rpm) and the supernatant was removed. The pellet was resuspended in 100 µl of 
buffer 1 and 200 µl of buffer 2 ,150 µl of buffer 3 were added and mixed. The cells were 
centrifugated 15 minutes with maximum speed at 4°C to pellet the cell debris and 
chromosomal DNA. The supernatant was transferred to a fresh tube and mixed with 800 µl of 
isopropanol to precipitate nucleic acids. The tubes were spined 15 minutes with maximum 
speed at 4°C to pellet the plasmid DNA. The supernatant was removed and the pellet was 
washed with 100 µl 96 % ethanol (by centrifugation for 10 minutes at full speed), air dried 
and resuspended in 30-50 µl H2O.  
Isolation of large quantities of plasmid DNA (maxiprep) : 
Isolation of large scale of plasmid DNA was also performed by alkaline lysis. The QIAGEN 
maxi kit was used, which uses an anion exchange resin as an additional purification step. The 
bacterial cells (100 µl) were let grown in 100 ml LB/ampicillin medium at 37°C overnight 
with vigorous shaking. The bacterial cells were harvested by centrifugation at 4,000 rpm for 
10 minutes at 4°C. The pellet of bacterial cells were resuspended in buffer 1 (12 ml), 
Subsequently buffer 2 (12 ml) was added and immediately mixed gently and incubated at 
room temp for 5 minutes. Buffer 3 (12 ml) was added and immediately mixed gently. The 
suspension was incubated on ice for 5 minutes before being centrifugated at high speed    Materials and Methods 
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(14,000rpm) for 40 minutes at 4°C. The supernatant carefully removed from the white 
precipitate and loaded onto a NUCLEOBOND AX cartilag previously equilibrated with 
buffer N2 (6 ml). The cartilage washed twice with buffer N3. The plasmid DNA was eluted 
with buffer N5 (15 ml) and precipitated by use of isopropanol (11 ml). Finally, the 
precipitated DNA was washed with 70 % ethanol and subsequently air-dried at room 
temperature before the DNA was dissolved in H2O or TE-buffer.  
 
3. Sequence analysis : 
The DNA sequencing was performed using the ABI-Prism 310 Genetic Analyser (PE 
Biosystems) based on the dideoxynucleotide chain termination method (Sanger et al., 1977). 
In the termination labeling mix, the four dideoxy terminators (ddNTPs) were tagged with 
different fluorescent dyes. This technique allows the simultaneous sequencing of all four 
reactions (A, C, G, T) in one reaction tube.The probes were separated electrophoretically 
using a micro capillary. As each dye terminator emits light at a different wavelength when 
excited by laser light, all four colors corresponding to the four nucleotides can be detected and 
distinguished within a single run. For sequencing, 250 ng DNA, 10 pmol primer and 2 µl 
BigDyeTerminator premix (PE Biosystems) were diluted to 10 µl with douple distilled H2O 
and cycled in a thermocycler (GeneAmp 2400, PE Biosystems) under the following 
conditions: 25 cycles (denaturation:96°C, 10 seconds; annealing: 55°C, 5 seconds; elongation: 
60°C, 4 minutes). The DNA was isolated by sodium acetate and precipitated using 1/10 
volume of 96% ethanol. The DNA pellet was resuspended in 25 µl template suppression 
reagent (TSR) and denatured at 95°C for 2 minutes. This sequencing reaction was subjected 
to the Genetic Analyser. 
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4. Reverse transcriptase polymerase chain reaction (RT-PCR) 
A. Reverse transcription (generation of cDNA from total RNA) :  
The enzyme reverse transcriptase synthesizes a complementary DNA strand using RNA as a 
template. 1 µg of total RNA isolated from cultured MC in 12.5 µl DEPC-treated water and 1 
µl of 20 µM oligo(dt) primer were added to a 0.2 ml PCR tube, heated to 72°C for 2 minutes 
and snap cooled on ice. The following components were added to the tube : 
                                   4 µl    5x reaction mixture 
                                   1 µl    dNTP mix (2mM) [dATP, dCTP, dGTP, dTTT ] 
                                   0.5 µl   Rnase inhibitor (20 Units) 
                                   1 µl    MMLV reverse transcriptase (40 Units) 
The content of the tube was mixed by pipetting up/down and the reaction was incubated at 
42°C for 1 hour. Subsequently the enzyme was heat inactivated by heating the reaction 
mixture at 95°C for 5 minutes and diluted to a final volume of 100 µl by adding 80 µl of 
DEPC-treated water. This reaction product is subsequently used as “ RT-product”. 
B. Polymerase chain reaction (PCR) : The polymerase chain reaction is used to amplify a 
sequence of DNA using a pair of oligonucleotide primers each complementary to one end of 
the DNA target sequence. These are extended towards each other by a thermostable DNA 
polymerase in a reaction cycle of three steps: denaturation, primer annealing and 
polymerisation. In a PCR tube the following components were mixed : 
                                            2 µl   of “ RT product “ 
                                          10 µl 5x Taq-polymerase buffer 
                                           5  µl  d NTP-mix (2mM) [dATP, dCTP, dGTP, dTTT ] 
                                           1  µl   forward primer  50 µM 
                                           1  µl   reverse primer   50 µM 
                                           1  µl  Taq-polymerase  1  Units    Materials and Methods 
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The PCR reaction was performed in a thermocycler (Gene Amp 2400 or 9600, PE 
Biosystems). The PCR products were run on 1 % agarose gels containing 0.5µg/µl ethidium 
bromide to analyze nucleic acids. Usually the identification of PCR products was confirmed 
by sequencing  analysis  using a 310 genetic analyser (Perkin Elmer Corp) as described on 
page 22. 
 
5. Quantification of nucleic acids 
Concentration of nucleic acids were determined photometrically using a wavelength of 260 
nm (Gene Quant, Amersham Pharmacia). An optical density (OD) of 1 corresponds to 
approximately 50 µg/ml double-stranded DNA or 40 µg/ml for RNA (Sambrook et al; 1989). 
 
6. Agarose gel electrophoresis 
Nucleic acids were usually separated by gel electrophoresis using agarose gels. The gel 
concentration was dependent on the molecular weight of the analyzed nuleic acids. Agarose 
was dissolved in 1x TAE gel electophoresis buffer by boiling in a microwave. The solution 
was let to cool down with moderate stirring to avoid air bubbles. Ethidium bromide was 
added to a final concentration of 500 ng/µl. Ethidium bromide binds to DNA by intercalation 
between the bases and thus enables visualization upon ultraviolet fluorescence illumination of 
nucleic acids. The DNA probes were diluted with loading buffer (6x loading buffer) and 
transferred into the appropriate gel wells. Electrophoresis was performed in 1x TAE buffer 
with a voltage of 5-10 V/cm gel. DNA fragment sizes were estimated using molecular base 
pair markers. 
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7. DNA isolation from agarose gels 
The “NucleoSpin-DNA-Extraction-kit” was used to get a pure extraction of DNA fragments 
directly from agarose gels. The system is based on a silica matrix, which binds single and 
double–stranded DNA. The DNA fragments of interest were cut from the gel with a razor 
blade and further processed according to the instructions of the manufacturer. 
 
8. cDNA clones and Plasmids :  
A cDNA insert of 0.7 kb for rat 92 kDa type IV collagenase was generated by reverse 
transcription from mRNA of MC stimulated with IL-ß using internal primers from the 
complete sequence of rat mRNA (deposited in the Genebank/EMBL Database under 
accession No. U 36476). 
            The following primers were used : 
                                                  5`-CTTAGATCATTCTTCAGTGCC-3` 
                                                  5`-GATCCACCTTCTGAGACTTCA-3` 
The blunt-ended polymerase chain reaction fragment was cloned into EcoRV cloning site of 
pBluescript-II ks to generate PKs-MMP-9 rat . A cDNA insert for HuR was a generous gift 
from Dr. Henry Furneaux (Memorial Sloan Kettering Cancer center, New York,USA). It was 
generated as described  (Ma et al.,1996). A cDNA insert for rat TIMP-1 was generated using 
internal primers of a partial coding sequence of TIMP-1 mRNA (accession No. L29512). The 
primers were 5´-CAG ACG GCG TTC TGC AAC TCG (sense) and 5´-AGA CCC AAG 
GGA TTG CCA GGT-3´ (antisense). PCR fragments was then cloned into EcoRV-cut 
pBluescript-II KS+ to generate “pKS-TIMP-1 rat”. A cDNA for rat TIMP-2 was generated 
using internal primers of coding sequence of rat TIMP-2 mRNA (accession no AJ 409332). 
The following primers were used: 5´-CGG GAA TGA CAT CTA TGG CAA CC-3´(sense) 
and 5´-AAA GCT GGA CCA GCC TCG ATG TC-3´(antisense).      Materials and Methods 
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A GAPDH cDNA clone was generated using internal primers of coding sequence of rat 
GAPDH mRNA (accession no. NM 017008). A cDNA insert from mouse 18S rRNA was 
from Ambion (Austin, TX, USA).  
 
9. Isolation of total RNA and Northern blot analysis  
A. Isolation of total RNA : Total cellular RNA was extracted from MCs using Trizol 
reagent. MCs that were cultured in 10 cm dishes were rinsed with PBS and 1ml of Trizol 
reagent was added. MC were scraped by rubber policeman and mixed several times by 
pipetting up/down and transferred to RNase-free 1.5 ml Epp. tubes. 0.2 ml chloroform was 
added, mixed by vortexing for 10 seconds and the tubes were kept at room temperature for 5 
minutes and centrifugated at 13,000 rpm for 15 minutes at 4°C. The upper aqueous phase was 
transferred to a clean tubes and precipitated with isopropanol by centrifugation at 13000 rpm 
for 30 minutes at 4°C. The pellet was washed with 70% Ethanol-Depc water and air dried by 
incubation at 37°C untile the white pellet become opaque. The pellet was redissolved in 50-80 
µl of Depc-treaed water according to the size of pellet. The RNA was quantified   
photometrically using a wavelength of 260 nm (GeneQuant, Amersham pharmacia, Freiburg, 
Germany ). 
B. Northern blot analysis (Transfer of total RNA by N.b.) 
For 150 ml gel solution : 1.5 gm agarose (final 1%) and 131 ml H2O were boiled in a 
microwave oven in a 200 ml Erlenmeyer flask and let to cool down with moderate stirring 
(using fish) to avoid air bubbles and then :  15 ml  10x MOPS ,4ml  37% formaldehyde were 
added. The prepared solution (gel solution ) was poured into gel-tray under the hood and let to 
dry for 30 minutes . 
RNA samples were prepared as followed :  20µg RNA were adjusted to a total volume of 
15 µl with Depc-treated H2O and were mixed with equal volume (15 µl ) of 2x denaturation    Materials and Methods 
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buffer (prepared freshly). The denaturating mixture was subsequently incupated at 65°C for 
15 minutes and mixed with 6µl of a  6x RNA loading dye. The RNA samples were loaded on 
the gel and run in 1x MOPS at 80 V for approximately 4 hours . The RNA was then 
transferred from the gel to a nylon membrane by upward capillary transfer with 20 x SSC 
overnight and afterwards fixed by UV cross-linking. The membrane was stained with 
methylene blue solution  to check for equal loading of RNA and destained with washing 
buffer 2 .The membrane was placed in a hybridization tube with 10 ml hybridization buffer 
and   incubated in a hybridization oven with rotation for at least 3 hours at 42°C . Labeling of 
the cDNA probe by random priming using the (rediprime) DNA labelling system. 25 ng of the 
DNA were denatured for 5 minutes at 95°C before being added to the ready to use reaction 
tube (rediprime) and mixed with 5µl [α-
32P] dCTP (3000 Ci/mmol). The rediprime reaction 
was performed at 37°C for 30 minutes. A sephadex- Nick column was used to separate the 
DNA from unincorporated 
32P-labeled nucleotides. 200µl of ssDNA (10mg/ml) was added to 
the labeling reaction and subsequently denatured at 95°C for 5 minutes. The radioactive probe 
was added to the hybridization tube and hybridization was continued with rotation overnight 
at 42°C. The membrane was washed with washing buffer 1 for 20 minutes at 42°C three times 
and one time with washing buffer 2 for 30 minutes at 65°C and exposured overnight on a 
phosphoimaging screen. Specific signals were quantitated using an automated detector system 
BAS1500 from Fujifilm (Raytest, Straubenhardt, Germany).   
 
10. Isolation of total cellular Proteins and Western blot analysis  
A. Isolation of proteins :  
MCs (approximately 3.0-5.0X10
6) cultured in 10 cm dishes were rinsed with PBS, scraped 
into 1ml of lysis buffer (with protease inhibitors) and left on ice for 15 minutes. The extracts 
were sonicated three times (10 seconds) and centrifuged at 13,000 rpm for 10 minutes.    Materials and Methods 
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Aliquots of SN (total protein) were collected, freezed in liquid nitrogen and stored at –80°C. 
The protein concentration was determined by micro-protein assay (Bio-Rad laboratories, 
Zurich, Switzerland). 
B. Quantification of proteins 
The proteins were quantified by using MicroBCAprotein assay reagent kit. 
TheMicroBCAprotein reagent is a highly sensitive reagent for the quantitative colorimetric 
determination of total protein in dilute aqueous solution. This unique reagent system utilizes 
bicinchoninic acid (BCA) as the detection reagent for Cu
+, which is formed when Cu
2+ is 
reduced by protein in an alkaline environment (Smith et al., 1985). The purple colored 
reaction product is formed by the chelation of two molecules of BCA with one cuprous ion 
(Cu
+). This water soluble complex exhibits a strong absorbance at 540 nm that is linear with 
increasing protein concentrations. A fresh set of protein standards were prepared by diluting 
the 2mg/ml BSA stock standard. BSA concentrations between10-70 µg/ml were used to 
generate a standard curve. 100 µl of each standard, unknown samples (1 µl of each sample 
diluted in 100 µl H2O) were pipetted into a 96 well plate and 100 µl of H2O were used as 
blank. 100 µl of the working reagent (25 parts of reagent A, 24 parts of reagent B and 1 part 
of reagent C) were added to each well. The plate was covered and incubated at room 
temperature for 1 hour. The optical density was measured at a wavelength of 540 nm using a 
microplate reader (Bio Rad). The absorbition values were calculated using microplate 
manager 4.0 software (Bio Rad). 
C. Western blot analysis : 
i. SDS gel electrophoresis  
Proteins were subjected to SDS-Polyacrylamide gel electrophoresis as originally described by 
Laemmli (1970). In general a total of 50-150µg of total protein from each sample was mixed 
with an equal volume of 2x electrophoresis sample buffer and incubated at 95°C for 10    Materials and Methods 
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minutes for denaturation. The samples were loaded on the gel and the gel was run at 20 mA 
for a period of 2-3 hours. 
ii. Protein transfer to nitrocellulose membrane 
After gel electrophoresis, the proteins were transfered onto a nitrocellulose (PVDF) membrane 
by semi-dry electroblotting. Prior to use , the membrane had to be activated with isopropanol, 
The SDS gel containing the separated proteins  and filter papers (Whatman 3MM) were 
damped in blotting buffer (Towbin transfer buffer). The gel was placed on top of the   
membrane. Finally, the gel was covered with one additional blotting buffer-soaked Whatman 
3MM filter. The transfer was performed at  70 mA (constant) per minigel for 70 minutes. 
After blotting, the membrane was checked by Ponceau S staining for correct electrophoresis 
transfer and equal loading. 
iii. Immunodetection  
Non-specific binding sites on the nitrocellulose membrane were blocked by shaking the 
membrane in 2% BSA overnight at 4°C. The membrane was incubated with the primary 
antibody (at the appropriate concentration as suggested by the supplier) diluted in 1x TBST-
buffer for 1 hour at room temperature and washed 4 times for 10 minutes each with 1x TBST-
buffer. Afterwards the membrane was incubated for 30 minutes with the appropriate 
secondary antibody (coupled to horseradish peroxidase) and subsequently washed 4 times for 
10 minutes with 1x TBST-buffer. For detection of the immunoreactive protein, the membrane 
was incubated in 2 ml ECL reagent and exposed for 1-5 minutes to X-ray film (Bio-Max film: 
Kodak). X-ray films were scanned by the GS 700 Imaging Densitometer (BioRad) and 
analyzed using the molecular Analyst software. 
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11. Isolation of nuclear extracts and Electromobility Shift Assay  
A. Isolation of nuclear extracts from cultured MC :  
MC were cultured in 10 cm dishes and rinsed with cold PBS. Before being harvested for 
nuclear extracts 1ml of ice-cold PBS/EDTA was added and incubated for 5 minutes on ice 
before cells  were scraped with a rubber policeman. The cells were pelleted by centrifugation 
at 6000 rpm for 2 minutes at 4°C and SN were removed completely before the pellet was 
resuspended in 300µl of ice-cold buffer A and incubated on ice for 15 minutes. 20µl of NP-40 
was added, the samples vortexed vigorously for 10 seconds and centrifugated at 13,000 rpm 
for 1 minute. The SN (cytoplasmic fraction) was collected , frozen in liquid nitrogen and 
stored at –80°C. The nuclear pellets were dissolved in 70 µl of ice cold buffer C and 
vigorously rocked on an Eppendorf shaker for 20 minutes with full speed at 4°C. Finally 
samples were centrifuged  at 13,000 rpm for 10 minutes at 4°C and the supernatants were 
collected as nuclear extracts. The protein concentration was determined by microprotein assay 
as described on page 28. 
B. Electrophoretic Mobility Shift Assay (EMSA) : 
EMSA is the method for identification and investigation of DNA-protein interaction. 
i.Gel preparation  
For 30 ml gel solution :                     28.8  ml        H2O 
                                                           1.8    ml        10 x TBE 
                                                           5.4    ml        Acrylamid gel (30%) 
                                                           30     µl         TEMED  
                                                           400   µl         10 x APS 
 ii. Endlabeling of double-stranded DNA with T4 Kinase : 
Approximately 2µl (20 pmol) of double stranded oligonucleotide was diluted with 10µl of 
distilled water, heated at 95°C for 2 minutes and quickly chilled on ice. 2µl of 10x PNK-   Materials and Methods 
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buffer, (20 units) of PNK, 5µl of [γ-
32P] dATP (6000 Ci/mmol) were added and kinase 
reaction run at 37°C for 1 hour. To allow a correct renaturation of single strand DNA the 
sample  was left to cool overnight. Nick-column was used to separate the labeled 
oligonucleotide from unincorporated label. 2µl approximately of the probe was used per 
binding reaction . 
iii. The binding reaction :  The binding reaction was assembled by combining the following 
:                             Radiolabeled probe DNA (1.0-0.5ng) 
                                   3 x binding buffer 
                                   DNA-binding protein (5µg of nuclear extract ) 
The final reaction volume was adjusted to 15-20µl with water or buffer C and incubated on 
ice for 30 minutes. For supershift analysis the antibodies were preincubated overnight at 4°C 
before addition of the labeled oligonucleotide. 
 
iv. Electrophoresis of protein-DNA complexes : 
Gel running : 4µl of 6x loading dye were added to each sample (binding reaction). The 
samples were loaded into the appropriate well of the gel using a Hamilton glass syringe and 
the gel was run at 200V (constant voltage) in 1x TBE buffer. The glass plates and side spacers 
were removed from the gel. The EMSA-gel was fixed with Fix solution for 30 minutes at 
room temperature. The gel was dried and for  autoradiography subsequently exposed to an 
intensifying screen on a phosphoimager. 
 
12. Nitrite analysis  
Nitrite contents of the cellular supernatants were measured as a readout for NOS activity. 
Confluent MC (1.0-1.5 × 10
6 cells) on six-well plates were incubated in DMEM without FCS 
and stimulated with or without agents for the indicated time periods. After the incubation    Materials and Methods 
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nitrite, the stable end product of NO, was measured in the culture medium with the Griess 
method ( Green et al., 1982 ) using a ready to use Griess reagent. 100 µl of culture media 
were mixed with 100µl of Griess reagent. The absorbance was measured at 540 nm and nitrite 
concentration was determined using a calibration curve with sodium nitrite standards. 
 
13(A). SDS-PAGE Zymography  
The gelatinolytic content of cellular supernatants was assessed by SDS-PAGE Zymography 
containing 0.1% gelatin as substrate. To ensure that the supernatants were derived from equal 
cell numbers, for each experimental condition, cell counts were obtained separately. In 
general 10-20µl of culture media were loaded on gels directly after the addition of 2 x sample 
buffer. After elecrophoresis, the denatured proteins were renatured by exchanging SDS with 
2.5% Triton X-100 in two 15-minutes incubations. The gels were subsequently incubated 
overnight at 37°C in developing buffer. At the end of incubation, the gels were stained with 
staining solution. Destaining was performed using destaining solution for 30 minutes at room 
temperature and the proteins with gelatinolytic activity were visualized as area of lytic activity 
on an otherwise blue gel. Migration properties of proteins were determined by comparison 
with that of a prestained, full-range rainbow protein markers. Photographs of the gels were 
scanned by an imaging densitometer system from Bio-Rad laboratories (München, Germany) 
. 
13(B). Cell-free incubation experiments : 
By this assay, the direct effects of an exogenously given agent on MMP-9 can be monitored 
quickly. In general, supernatants (100µl) from MC treated for 24 hours with IL-ß was 
incubated with the agent to be tested for several hours at room temperature. As a positive 
control the same volume of supernatant was incubated with the indicated concentration of     Materials and Methods 
  33
APMA for the same time. At the end of the incubation, samples were mixed with 2x sample 
buffer and directly subjected to  SDS-PAGE Zymography as described on page 32. 
 
14. Isolation of cytoplasmic extracts and RNA-EMSA  
A. Isolation of cytoplasmic extracts : Cytoplasmic extracts were prepared from rat MC by 
lysis in a hypotonic extraction buffer as described before (Page 29). Nuclei were removed by 
centrifugation and the supernatants used as cytoplasmic fractions. To achieve RNase-free 
conditions all buffers used were prepared with DEPC-treated water. 
B. RNA Electromobility Shift Assay (EMSA) and (supershift analysis) : Radiolabeling of 
single stranded RNA oligonucleotides was performed by Kinase reaction using T4 
polynucleotide kinase. Similar to the labeling protocol used for double-stranded DNA (page 
30), after kinase reaction the labeled oligonucleotides were separated by Nick-Sephadex 
columns. The radiolabeled  RNA oligonucleotides (approximately 30,000 cpm/reaction) were 
mixed with 6 µg of cytoplasmic extracts and incubated at room temperature for 15 minutes in 
the reaction buffer (containing 10 mM HEPES pH 7.6, 3mM MgCl2, 40mM KCl, 2mM DTT, 
5% glycerol and 0.5% Nonidet P-40). To reduce non-specific binding total yeast RNA (200 
ng/ml final concentration) was added. The total volume of each reaction was 10 µl. RNA-
protein complexes were separated in 6% non-denaturing polyacrylamide gels and run in 1x 
TBE buffer. The characterization of RNA-bound complexes was performed by supershift 
analysis. It was done by addition of supershift antibodies 15 minutes after addition of the 
radioactive labeled RNA oligo and incubated for a further  15 minutes at room temperature 
before the analysis was proceded as described before ( page 31). 
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15. Transient transfection and reporter gene assay        
 i. Generation of reporter plasmids 
A. Generation of PGL-MMP-9 plasmid (Cloning of rat MMP-9 promoter) : 
The 5`-flanking region of the rat  MMP-9 gene was cloned utilizing the Genome walker kit 
using internal (upstream) and external (downstream) primers from the rat MMP-9 cDNA 
(accession No. U36476) as follows :  
    MMP-9 internal primer: 5`-AGGGGCAGCAAAGCTGTAGCCTAG-3` . 
    MMP-9 external primer: 5`-TTTCAGGTCTCGGGGGAAGACCACATA-3`  
A 1.8 kb fragment from a EcoRV cut library was isolated by PCR under stringent conditions. 
The fragment was subsequently subcloned into pBluescript-KS and sequenced using the 
automated sequence analyser ABI 310 (PE Applied Biosystems, Weiterstadt, Germany). The 
sequence has been deposited in the GenBank/EMBL databases (accession No. A7438266). 
Subsequently, the 1.8 kb fragment of MMP-9 promoter was subcloned into PGL-III Basic 
vector coding for beetle luciferase (Promega, Mannheim, Germany) using Xba I and Xho I 
restriction sites. 
B. Generation of PGL-MMP-9-∆PPRE-1 : Introduction of a double point mutation into a 
putative distal PPRE- like site (GT to CA) to generate PGL-MMP-9-∆PPRE-1 was done, 
using the following (forward) primer: 5`- ATGGAGACTCAAGCACACCTATGTGT-
3`(corresponding to a region from –1763 to –1783 ).  
C. Generation of PGL-MMP-9-∆PPRE-2 :  Introduction of a double point mutation into 
second proximal laying PPRE-like binding sites to generate PGL-MMP-9-∆PPRE-2 was done 
using the following (forward) primer : 5`-TCCCATCCAGCACACCCCGAGGCTTA-
3`(corresponding to a region from –896 to –871). All mutant constructs were generated using 
the Quick Change Site-Directed Mutagenesis Kit.       Materials and Methods 
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D. Generation of 3`-UTR-MMP-9 PGL3-MMP-9 :  The PGL3-MMP-9 encompassing a  
1.3 kb fragment of the 5`-flanking region of the rat MMP-9 gene was cloned as described on 
page 34. The plasmid 3`-UTR-MMP-9 PGL3-MMP-9, 1.3 kb was generated by cloning a 670 
bp fragment from the 3`-UTR of rat MMP-9 mRNA into the PGL3-MMP-9(∆1.3kb) promoter 
plasmid. The 3`-UTR sequence of the rat MMP-9 gene was generated by PCR from reverse 
transcriptase products using the Xba  I-flanked  (underlined)  forward primer  5`-
TATTCTAGACCAACCTTTACCAGCTACTCGAA-3` and  Bam HI  flanked   (underlined ) 
reverse primer : 5`-TATGGATCCATTCATTTATTTAAAAA-AGAGTGT-3`, corresponding 
to a region from 2315-2338 and 2954-2977 of the rat MMP-9 cDNA (GenBank, accession no 
U24441). The PCR products subsequently were digested with XbaI and Bam HI restriction 
enzymes and cloned into the BamHI/XbaI cut PGL3-MMP-9(∆1.3) plasmid thereby allowing 
a forced insertion of the 3`-UTR of  rat MMP-9 mRNA at the 3`-end of the luc+coding region 
of PGL3- MMP-9(∆1.3).  
E. Generation of the 3`UTR-MMP-9 PGL3 control :  A l s o  t h e  BamHI/XbaI  cut PCR 
fragment was cloned into an empty PGL3 control vector to generate 3`-UTR-MMP-9 PGL3 
control. This vector was in parallel used in luciferase assays to test the influence of the 3`-
UTR of MMP-9 on the stability of luciferase mRNA under the control of a none-MMP-9 
related promoter sequence.        
F. Generation of triple-point mutation within 3’-UTR-MMP-9 : Introduction of triple-
point mutation into ARE-sites (ATTTA to ACCCA) to generate ∆ARE mutations were 
performed using the following (sense) primer:  
5´-TACCGGCCCTTTTACCCATTATGTATGTGG-3´ (corresponding to a region from 2494 
to 2523) to generate “3´-UTR-∆ARE1 pGL3-MMP-9 (1.3kb)” 
5´-TTCACACACATGTACCCAACCTATAGAATG-3´ (corresponding to a region from 
2529 to 2558) to generate “3´-UTR-∆ARE2 pGL3-MMP-9 (1.3kb) “    Materials and Methods 
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5´-TTAGGGACAGAGGAACCCATTGGATGTTGG-3´ (corresponding to a region from   
2735 to 2764) to generate “3´-UTR-∆ARE4 pGL3-MMP-9 (1.3kb) “. 
All mutants were generated by use of the Quick Change Site-Directed Mutagenesis Kit 
(Stratagene, La Jolla, CA). The plasmid “3´-UTR-∆ARE1-2-4 pGL3-MMP-9 (1.3kb)“ in 
which all three AREs have been mutated was generated using a construct bearing double 
mutated AREs (“3´-UTR-∆ARE1-2 pGL3-MMP-9 (1.3kb)“ which then served as a template. 
 
ii. Transient transfection of rat glomerular MC  
Transient transfection of MC on 6-well plates was performed using the Effectene transfection 
reagent. Effectene represents a new class of lipid-based transfection reagent that 
spontaneously forms micelle structures. One day before transfection approximately 400,000 
cells per well were seeded in 6-well plates. Optimally,  Cells should have reached  40-80% 
confluence on the day of transfection. The cells were washed with PBS before 1.6 ml of 
medium (RPMI, 10% FCS) was added. Per well, 0.4 µg of firefly luciferase reporter vector 
DNA and 0.1 µg of renilla luciferase control reporter vector were mixed with the DNA 
condensation buffer (EC) and 3.2 µl of enhancer. The DNA mixture was vortexed for 1 sec 
and incubated at room temperature for 5 minutes. 10 µl of Effectene transfection reagent were 
added to the DNA mixture and the tube was vortexed for 10 seconds and incubated at room 
temperature for 10 minutes to allow complex formation. Per well, 600 µl of serum-free 
medium was added to the transfection complex and mixed by pipetting up/down. Finally, the 
transfection complex was added drop-wise onto the cells. The plates were swirled gently and 
incubated overnight at 37°C / 5% CO2. The cells were washed with PBS and new medium 
with stimulating reagents was added for 24 hours.  
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iii. Reporter gene assay : To study reporter gene expression, the dual-luciferase reporter 
assay system from Promega was used. Luciferase catalyzes a bioluminescent reaction when 
mixed with a substrate, a flash of light is emitted that can be detected by a luminometrical 
detection. For analysis of gene expression, the MC (transiently transfected with a foreign 
promoter sequence) were washed with PBS before being harvested with 100 µl of cold lysis 
buffer and incubated on ice for 30 minutes. 50 µl of cell lysates were transferred into 5 ml 
Sarstedt tubes and subjected to luciferase measurement in a  Luminometer (Berthold, Bad 
Wildbad, Germany). Following this step, 100 µl of stop & glo reagent that contains an 
inhibitor of firefly luciferase and the substrate for renilla luciferase, were injected and the 
light emission was measured again, representing the renilla luciferase activity.  
 
16. Site-directed mutagenesis 
In order to create a point mutation in the MMP-9 promoter region, site-directed mutagenesis 
technique was used. By this technique,  two mutagenic primers with a length of 25-45 bases 
both containing the desired mutation and annealing to the same sequence on opposite strands 
of the plasmid are used for a PCR reaction using a highly efficient Turbo Pfu polymerase. For 
the PCR reaction, 50 ng dsDNA template, 5 µl 10 x PCR reaction buffer, 125 ng primer 1, 
125 ng primer 2, 1 µl dNTP mix (10 mM each nucleotide), 1 µl Pfu Turbo DNA polymerase 
(2.5 U/µl) and H2O ( was added to 50 µl final volume) were mixed. The reactions were cycled 
under the following conditions : 30 seconds at 95°C before 18 cycles (denaturation: 95°C, 30 
seconds; annealing: 55 °C, 30 seconds; elongation: 68°C, 10 minutes). Following temperature 
cycling, 1 µl of the Dpn-I restriction enzyme (10 U/µl) was added directly to the reaction to 
digest the methylated parental (non mutated) DNA template. The reaction was incubated at 37 
°C for 1 hour. 1 µl of this reaction was transferred to an aliquot of competent cells for 
transformation as previously described on page 20.    Materials and Methods 
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17. Transcripition assay 
Transcripitional assay is currently the most sensitive procedure for measuring specific gene 
transcripition as a function of cell status. In this assay, we combined the classical run-on 
protocol with that of the more sensitive RNase protection assay and proceded as follows. 
Nuclei were first isolated from cultured cells and frozen in liquid nitrogen. Nuclei were 
thawed and incubated with 
32P-labeled UTP and unlabeled NTPs to label nascent RNA 
transcripts. 
32P-labeled RNA was purified and used to detect specific RNA transcripts by 
hybridization to cDNA immobilized on nitrocellulose membranes. 
Isolation of Nuclei : Cells were rinsed twice with 5 ml ice-cold PBS and scraped with a 
rubber policeman. Subsequently, cells were collected in a 15-ml centrifuge tube and 
centrifuged at 1500 rpm for 5 minutes at 4°C. The supernatants were removed and the cell 
pellets were resuspended by gently vortexing 5 seconds and 4 ml of NP-40 lysis buffer A 
were added during the vortexing. After lysis buffer was completely added, the cells were 
again vortexed gently for 10 seconds. The lysed cells were incubated on ice and a few 
microliters of cell lysate were examined microscopically to ensure that cells were uniformly 
lysed and nuclei appeared free of any cytoplasmic contaminants. The lysed cells were 
centrifugated 5 minutes at 1500 rpm at 4°C. The nuclear pellets were resuspended in 4 ml of 
NP-40 lysis buffer by gentle vortexing and centrifuged 5 minutes at 1500 rpm at 4°C. The 
nuclei were resuspended in 100-200 µl of glycerol storage buffer by gently vortexing and 
finally frozen in liquid nitrogen. 
Nuclear runoff transcripition : 200 µl of frozen nuclei were thawed at room temperature 
and transferred to a 15-ml conical polypropylene centrifuge tube. 200 µl of 2x reaction buffer 
with nucleotides plus 10 µl of 10 mCi/ml [α-
32P] UTP were added and the tubes were 
incubated 30 minutes at 30°C with shaking. 40 µl of 1mg/ml RNase-free DNase I were mixed 
with 1 ml of HSB buffer. 0.6 ml of this solution was added to labeled nuclei, mixed by    Materials and Methods 
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pipetting up/down 10-15 times with a Pasteur pipet and incubated 5 minutes at 30°C. 200 µl 
of SDS/Tris buffer were mixed with 10 µl of 20 mg/ml proteinase K. 0.1 ml was added and 
incubated for 30 minutes at 42°C. 
RNA isolation :The nuclear RNA was isolated by using the Tri-reagent and subsequent 
chloroform extraction followed by ethanol precipitation. 
Hybridization of cDNA with radioactive RNA : A cDNA clone for rat MMP-9 (pKs-MMP-
9 rat) was linearized with Pvu II and used as a template for MMP-9 antisense RNA. The 
MMP-9 antisense transcript was synthesized in vitro using T7 RNA polymerase and α-
32P 
UTP (3000 Ci/mmol). Nuclear RNA and 100,000 cpm of the labeled T7-derived MMP-9 
antisense transcripit were co-precipitated by ethanol precipitation and hybridized at 42°C  
overnight in 30 µl of FAB hybridization buffer. Following hybridization, samples were 
digested with RNases A and T1 for 1 hour at 30°C. RNA samples were again extracted with 
phenol/chloroform and protected double-stranded RNA hybrids were ethanol precipitated. 
The protected fragments were separated on a 5% acrylamide/8M urea gel and analyzed using 
a phosphoimager. 
 
18. In vitro degradation assay 
Degradation assays were performed by following a protocol from Levy et al. (1996) with the 
following modifications. In stead of using in vitro transcribed radioactively labeled MMP-9 
mRNA we used cytokine-induced total RNAs containing a high levels of MMP-9 transcripts. 
20 µg of total RNA from one pool were aliquoted and subsequently incubated at room 
temperature with 130 µg of cytoplasmic extract derived from vehicle or from MC treated for 
different time points with different agents. At each time point the RNA from these 
incubations was isolated by standard procedures as described on page 25 and assessed by 
Northern blot analysis using a 
32P-labeled cDNA insert specific for rat MMP-9. The    Materials and Methods 
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remaining (undegraded) MMP-9 signals were visualized and quantified using an automated 
detector system BAS 1500 from Fujifilm (Raytest, Straubenhardt, Germany). 
 
19. HuR-neutralization experiments 
The impact of mRNA stabilizing protein (HuR) on the degradation of MMP-9 was tested by 
the addition of a neutralizing monoclonal anti-HuR antibody. 0.4 µg of the monoclonal 
antibody was added to the cytoplasmic extracts and preincubated at room temperature for 1 
hour before addition of the RNA samples. To exclude any unspecific inhibitory effects 
achieved by the mouse serum we tested in parallel normal mouse serum. Subsequently the 
RNA was isolated and degradation monitored by in-vitro degradation assay.   
 
20. Immunocytochemistry of HuR 
At approximately 60-80% confluency, mesangial cells were rendered serum-free for 24 hours 
and thereafter stimulated with nucleotides for the indicated time periods. Subsequently, cells 
were washed with ice-cold phosphate-buffered saline (PBS) and incubated for 30min at -20°C 
with methanol containing 0.02% (w/v) EDTA. Cells were then washed twice with PBS, 
blocked for 1h in PBS containing 3% (w/v) BSA and incubated for 2 hours with monoclonal 
anti-HuR antibody. Cells were then washed  several times with PBS and incubated for 1 h 
with an anti-mouse-Alexa 488-coupled secondary antibody and thereafter washed again with 
PBS. Cellular fluorescence was monitored using confocal microscopy (MicroRadiation, 
BIORAD, Hertfordshire, U.K.). 
          
21. Statistical analysis 
Results are expressed as means + S.D. The data are presented as x-fold induction compared to 
control conditions (∗) or compared to IL-1ß stimulated values (#). Statistical analysis was    Materials and Methods 
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performed using studient’s t test and ANOVA test for significance. P values < 0.05 (∗), (#) 
and < 0.01 (**), (##) were considered significant. 
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3. Results 
 
 
1. Inhibition of cytokine-induced MMP-9 expression by PPARα agonists is indirect and 
is due to a NO-mediated reduction of mRNA stability 
 
Introduction 
 
Dysregulation of extracellular matrix (ECM) turnover is an important feature of glomerular 
inflammatory processes and may result in the loss of the mechanical and functional integrity 
of the glomerulus [Davis et al.,1992; Johnson et al.,1994; Fogo, 2001]. Physiologically, the 
balance between synthesis and degradation of matrix proteins is guaranteed by the action of a 
family of zinc-dependent, neutral proteinases, designated matrix metalloproteases (MMPs). A 
tight regulation of these proteases is accomplished by different mechanisms, including the 
regulation of gene expression, the processing of the inactive zymogenes by other proteases 
and, finally, the inhibition of the active enzymes by the action of endogenous inhibitors of 
MMPs, the TIMPs [for review see Nagase et al.,1999]. Cultured mesangial cells (MC) 
respond to proinflammatory cytokines such as tumor necrosis factor (TNFα) or interleukin-1ß 
(IL-1ß) with the production of several MMPs, including MMP-9 (gelatinase B) mainly due to 
an increase in gene transcription [Yokoo et al.,1996; Eberhardt et al., 2000]. The 
transcriptional regulation of the rat MMP-9 gene by proinflammatory cytokines is localized to 
a 0.7 kb region upstream from the transcriptional start site and critically depends on the 
binding sites for AP-1 and NF-κB transcription factors, respectively [Yokoo and Kitamura 
1996; Eberhardt et al.,2000a; 2000b]. Besides MMP-9, MC under inflammatory conditions 
can express a variety of genes coding for potent inflammatory mediators, such as inducible 
nitric oxide synthase (iNOS), the cytosolic and secreted types of phospholipases A2 (PLA2), 
and cyclooxygenase 2, respectively [Pfeilschifter et al.,1991; 1993; Martin et al., 1994; 
Huwiler et al.,1997]. Metabolites of these enzymes themselves can have modulatory effects 
on MMP-9 expression as we have previously reported a NO-mediated suppression of    Results 
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cytokine-induced MMP-9 expression [Eberhardt et al., 2000a]. Pharmacologically, the 
transcriptional activation of MMP-9 is modulated by agonists of the glucocorticoid receptor 
mainly through interference with NF-κB and members of the Ets/PEA transcription factor 
family (Eberhardt et al., 2002a). We now searched for a possible modulation of MMP-9 
expression by agonists of an other member of the nuclear receptor superfamily, the 
peroxisome proliferator-activated receptors (PPARs) [for review see Corton et al., 2000]. 
Three distinct PPAR subtypes have been identified: PPARα, ß/δ, and γ, with each subtype 
showing a specific distribution, physiologic function and a specific set of endogenous as well 
as synthetic ligands. Physiologically, PPARs are key players in lipid and glucose metabolism 
and, therefore, disturbances of PPAR function have been implicated in a variety of metabolic 
disorders such as dyslipidemia and diabetes [Schoonjans et al., 1996]. In addition, PPARα, 
similar to PPARγ, has been reported to exert potent anti-inflammatory activities in various 
cell types by inhibiting the expression of inflammatory genes such as COX-2 [Staels et al., 
1998], IL-6 [Delerive et al., 1999], endothelin-1 [Delerive et al., 1999] and various acute-
phase proteins [Delerive et al., 2001] just to name a few of them. In accordance with these in 
vitro data, PPARα-deficient mice display an exacerbated response to inflammatory stimuli 
[Staels et al., 1998; Delerive et al., 1999]. Moreover, PPARα null mice exhibit a higher  
degree of kidney damage in response to ischemia/reperfusion injury when compared to wild 
type controls thus indicating that PPARα, in addition to its antiinflammatory actions, exhibits 
also cytoprotective properties in the kidney [Devchand et al., 1996; Portilla et al., 2000]. 
Interestingly, recent observations have demonstrated a role of glucocorticoids in PPARα gene 
expression in the development of rat kidney suggesting a cross-talk between both nuclear 
hormone receptor pathways [Djouadi and Bastin, 2001]. Although many studies have 
addressed the question how PPARs directly activate gene expression via PPREs, less 
information exists about negative mechanisms which mostly involve interference with    Results 
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transcriptional activators. In this study we provide an additional mechanism by which PPARα 
agonists, independent of direct transcriptional effects, indirectly, via amplification of nitric 
oxide production can efficiently regulate the level of cytokine-induced MMP-9 expression.  
Results : 
Effect of the PPARα activator WY 14,643 on cytokine-induced MMP-9 activity and  mRNA 
steady-state levels of MMP-9, TIMP-1 and TIMP-2 
The family of gelatinases includes the two genetically distinct 72 and 92 kD type IV 
collagenases MMP-2 and MMP-9, respectively, which both are expressed in MC. Whereas 
MMP-2 shows a constitutive expression, MMP-9 expression is highly induced by 
proinflammatory cytokines such as IL-1ß [Eberhardt et al., 2000a; 2000b]. Since the 
expression of MMP-9 in MC after treatment with IL-1ß reaches a maximal level after 24h we 
chose incubation times of 24h. To evaluate possible effects of PPARα activators on the 
proteolytic activity secreted into the conditioned media from cytokine-treated cells, MC were 
treated with IL-1ß (2 nM) in the presence or absence of different concentrations of WY-
14,643, a potent activator of PPARα [Corton et al., 2000]. The gelatinolytic content of 
conditioned medium of MC withdrawn after 24h of stimulation was tested by zymography 
using gelatine as a substrate. WY-14,643 reduced in a dose-dependent manner the IL-1ß-
stimulated MMP-9 activity with a maximal inhibition seen at 100 µM. WY-14,643 alone  had 
no effects on enzyme secretion (Fig. 3A). Higher concentrations used in 24h incubations 
caused cytotoxic effects as monitored by the MTT test (data not shown). The levels of the 
lytic activity of latent and active MMP-2, represented by the two lytic bands at 68-and 72 kD 
remained unchanged under all experimental conditions consitent with the constitutive 
expression of MMP-2 in rat MC [Eberhardt et al., 2000b]. To evaluate whether the reduction 
of the lytic content of MMP-9 is due to a decrease in the amount of the corresponding MMP-9 
mRNA, we performed Northern blot analysis using a cDNA probe from the rat MMP-9 gene  
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Figure 3. Inhibition of cytokine-induced MMP-9 and TIMP  levels in MC by PPARα agonists. (A) Dose-dependent inhibition of the IL-1ß-
induced gelatinase activity by WY-14,643. MC were simultaneously treated with vehicle (control) (-) or with IL-1ß (2 nM) (+) in the 
presence of  the indicated concentrations of WY-14,643. 24 hours after stimulation 10 µl of cell supernatant was subjected to SDS-PAGE 
zymography(zym.) using gelatine as a substrate. The migrating properties of lytic bands corresponding to inactive pro-MMP-9 (92 kd) and 
the inactive and active froms of MMP-2 (72 and 68 kDa) are indicated by migration properties determined with molecular weight markers. 
The data are representative for three independent experiments giving similar results. (B) Northern-blot analysis (n.b.) demonstrating a dose-
dependent modulation of IL-1ß-induced MMP-9, TIMP-1 and TIMP-2 mRNA steady-state levels by WY-14,643. MC were treated for 24 
hours as indicated and subsequently extracted for total cellular RNA. 20 µg of total RNA were hybridized to 
32P-labeled cDNA inserts from 
rat MMP-9, TIMP-1 and TIMP-2 genes. Equivalent loading of RNA was ascertained by rehybridization to an 18S ribosomal probe. The data 
are representative for three independent experiments giving similar results. (C) Dose-dependent inhibition of the IL-1ß-induced MMP-9 
mRNA steady-state level by LY-171,883. Quiescent MCs were coincubated for 24 hours with IL-1ß (2 nM) and the indicated concentrations 
of the PPARα activator LY-171,883. Total RNA (20 µg) were  hybridized to 
32P-labeled cDNA inserts from rat MMP-9 and TIMP-1 and 
TIMP-2 cDNAs and equivalence of loading was ascertained by rehybridization to a GAPDH probe. The data are representative for three 
independent experiments giving similar results. 
 
 [Eberhardt et al., 2000a]. As shown in Fig. 3B WY-14, 643 dose-dependently attenuated the 
cytokine- induced MMP-9 mRNA level with a maximal inhibition seen at 100 µM WY. WY-
14,643 given alone had no effects on the basal MMP-9 mRNA level. These data indicate that 
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the alterations of cytokine-induced zymogen activity by WY-14,643 predominatly result from 
changes in the MMP-9 expression levels. We next checked mRNA levels of TIMP-1 and 
TIMP-2, the endogenous inhibitors of MMP-9. Most interestingly, TIMP-1 followed a similar 
expression pattern as MMP-9 showing a strong increase of basal mRNA levels by IL-1ß and a 
dose-dependent attenuation of IL-1ß-induced steady-state mRNA level by WY-14, 643 (Fig. 
3B). Similarily to MMP-9, basal TIMP-1 mRNA levels were not affected by WY-14, 643. In 
contrast, TIMP-2 displayed high basal steady-state mRNA levels which were attenuated by 
IL-1ß and furthermore attenuated by the highest concentration (100 µM) of WY-14, 643 (Fig. 
3B).  Furthermore, we tested other PPARα activators on MMP-9, TIMP-1 and TIMP-2 
steady-state mRNA leves. The concentrations used were in a range known to maximally 
stimulate PPARα activation in cell culture. As shown in Fig. 3C, the prototypic PPAR ligand 
LY-171883, in a way similar to WY-14,643, dose-dependently inhibited the amounts of IL-
1ß-induced MMP-9 and TIMP-1 steady-state mRNAs, respectively. The reduction of MMP-9 
and TIMP-1 mRNA levels again was paralleled by a decrease of MMP-9 activity in the 
conditioned media (data not shown). In contrast, the high basal level of TIMP-2 mRNA, were 
reduced by IL-1ß and further attenuated by increasing concentrations of LY-171, 883 (Fig. 
3C). These data demonstrate that the inhibition of MMP-9 levels is not paralleled by an 
increased expression of TIMPs.  
 
WY-14,643 does not alter gelatinolytic activity of pro-MMP-9 
To evaluate whether PPARα agonists are able to alter the activity of secreted MMP-9 we 
performed in-vitro zymography. Conditioned media from cytokine-treated MC were 
incubated for 16 hours with or without WY-14,643 (100 µM). The lytical band at 92 kD 
which is not detectable under control conditions but inducible by IL-1ß corresponds to the 
inactive proform of MMP-9 as is demonstrated by cleavage to the active 86-kDa form by 
treatment with different concentrations of p-amino phenylmercuric acetate (APMA) (Fig. 4B).    Results 
  47
A. B.
92 kD
70 kD
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85 kD
As shown in Fig. 4A, WY-14,643 does not alter the gelatinolytic activity of pro-MMP-9, thus 
indicating that the observed WY-mediated reduction of zymogen activity is due to a reduction 
of IL-1ß-mediated expression and secretion of pro-MMP-9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. (A) WY-14, 643 does not affect extracellular IL-1ß-induced gelatinolytic activity of latent MMP-9. The conditioned media from 
MC stimulated for 24 h with IL-1ß were incubated for 16 h with WY-14,643 (100µM) at room temperature and subsequently assayed by 
SDS-PAGE zymography.  (B) In vitro activation of latent MMP-9 by p-amino phenylmercuric acetate (APMA). The IL-1ß-inducible band 
corresponds to the inactive proform of MMP-9, which is cleaved to the active 86 kDa from by treatment with APMA. Supernatants form MC 
treated for 24 h with IL-1ß (2 nM) were incubated for an additional 3h with the indicated concentrations of APMA before being subjected to 
SDS-PAGE zymography. The results shown are representative for three independent experiments giving similar results. 
 
 
 
Modulation of cytokine-induced MMP-9 promoter activity by PPARα agonists 
To evaluate whether the PPARα-mediated inhibition of IL-1ß-induced MMP-9 steady-state 
mRNA level resulted from an inhibition of MMP-9 gene transcription, we cloned a 1.8 kb 
promoter fragment of the rat MMP-9 gene by genome walking using MMP-9 gene specific 
antisense primers as described in Materials and Methods. In addition to a multitude of 
putative elements involved in the cytokine-mediated regulation of MMP-9 expression we 
found by computational analysis two regions which displayed a high homology to PPRE-like 
motifs and which were denoted as “PPRE-1” and “PPRE-2”, respectively (Fig. 5A). Transient 
transfection of MC with pGL-MMP-9 (1.8) comprising the 1.8 kb promoter fragment fused to 
a luciferase reporter gene was followed by a 24 h treatment with either vehicle, IL-1ß (2nM), 
WY-14,643 (100µm), or both compounds in combination and assayed for luciferase activity. 
IL-1ß significantly stimulated luciferase activity (2.67-fold, p< 0.01) and, surprisingly, this  
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-1802 CTGGG  -1798 
-1797 CATGGCACCC ATGTGTGCGT CCCCTGCACG GCAGATGGAG ACTCAAGGTC  -1748 
-1747 ACCTATGTGT GTATCTCCAA TACAGACAGA TGGAGACTCA GAGACAGGAT  -1698 
       PPRE-1 
-1697 TACCAAGGCT TGTTGGCTGC CGGCCTGTCT GCAAGTAATG GGCTCTAAGT  -1648 
-1647 TTAGGGAGAG ACTCTGCCTC AAAGGGGGAA AAAAAAGGAA AGATGACAGA  -1698 
-1597 GATGACAACC AACATCTCCT CTTGTCTTAT CAGTTATGGA TGTGCGTCCC  -1548 
-1547 TGCATACACG CATGTACGCA TACACACATA CCCCCTAAGA CGAATTAACA  -1498 
-1497 GACAAAAACA AGGGCTAGGA ACAGCTCAGT TGTAGAGTGC TTGCCTAGCA  -1448 
-1447 TGTGTAAGCA CTTTCTTTGG GCTGCCCAAC ACACACACAC ACACACACAC  -1398 
-1397 ACACACTCTC TCTCTCTCTC TCACAGACTC ATACGTCCCT TTAGGAGATA  -1348 
-1347 GGATAGAGAG AGCACATCAT AATGCTCAAC ACAATAAATC ATAAAAAGTG  -1298 
-1297 AATTATCACT GTGGCTTGAA GGCGAAATGC TTTGCCCAAG GTGACAAAGT  -1248 
-1247 TGGGAAATGG TGAGGTTGGG AAATGGTGGA CCCAGGACTG CAATTCAGTG  -1198 
      NFIL-6(9/9)     NFIL-6(9/9) 
-1197 CTGAAGACCA TTGTCAGAAG CATATAAGAG AAGCTGGGGA GCACGTCCAG  -1148  
-1147 CCTCCCCGCC CGTCTCACAG GTCTGTACAT TAGGAAGCAT ACGACAGTCT  -1098  
-1097 GAACACAGGA GGCTCAATCA GAACAGCTTA CTGAAGGCAC ATTAAGACCC  -1048  
-1047 TGCTTCACTG TGGTGGCAGG CTGGGAAGAG GGAAGGCACG GAGGCTGCTG  -998  
-997  GCCTTCGACA AGACTTTGGA AAAAGCTTTC CTGATTGGAG CAGGGCTGGA  -948  
-947  GGAGGGGAAG GGTCCATAAA GAATTCATAG CTCGGGAGAA GAAGGTGTAT  -898  
-897  GTCCCATCCA GGTCACCCCG AGGCTTAGAG CCAAGACCCC AGTCTAGTTT  -848  
                      PPRE-2 
-847  CCAGTCACAA ACCTGACACC ATCAACTGAG GTCTCGTGAA CACGGTGGCT  -798  
    MYB(6/6) 
-797  GAAAGCATTT CTGTGTTTCC TGAGTCTCAT TTTATCCTCA GATCAACATG  -748 
-747  GGGACAAAGG CTTGAGGGAC AAAGGCTTGA GGGACAAAGG CTTGAGGGAC  -698  
-697  aagggtctgt cttttgttct ttaaacagaa gaggaacgat gttagccagc  -648  
-647  CTGAGAAGGT GAAGCTTCTG CCTGCTTCCA CATGCCCCTG AGGCTTCCCC  -598 
-597  AAGGAGTCAG.CCTGCTGGGG.TTAGGGGGTT.GCCCCGTGGA.ATTCCCCCAA  -548 
          NF-kB  (11/11) 
-547  ATCCTGCTTC.AAAGAGCCTG.CTCCCAGAGG.GCAGGAGAGG.AAGCTGAGTC  -498 
        ETS  (6/6)AP-1(7/7) 
-497  AAAGACACTA.ACAGGGGGTG.GGAATGAGAG.GATAGAACCT.ACAGTGTGGG  -448 
 
-447  GAGGGGCTCC.AGGCTGCCCT.CTGGTCAGGG.AGAGGGGTAT.CTCAGAAGCC  -398 
 
-397  CAAGGAAGAG.TGGTCTTGGG.CTTCAGGTCT.TCCAGTCCTA.TACAAGGCTG  -348 
 
-347  ACCACTCAGG.GCCTTCAGAC.CTAGGACTAG.ATGGCCCCTC.CACCATGCGT  -298 
 
-297  ACCCTCCTTC.CTTTTCCCAC.AGATTCTGCA.GTTTGCAAAA.ACTCAACCAC  -248 
 
-247  TTCCCTGAGT.GCTGTGGTTT.CCTGTGGGTC.TGGGGTCCTG.CCTGACTTGG  -198 
 
-198  CAAGTGGGGG.ACTGTGGGCA.GGGCATAAAG.GAGTGGGTAG.TGTAAGCACT  -148 
 
-147  TTCTTTGGGC.TGCCCAACAC.ACACACACAC.ACACACACAC.ACACACACAC   -98 
 
-97   ACACACACCC TGAGTCAGCG.TAAGCCTGGA.GGGAGGGGCG.GGGACACTGA   -49 
      AP-1 (7/7) 
-47   TTCAGTTTTC.GTGCCTCTTT.AAAACCTCCG.CAAATTCTGC.TTCACCCAGA    +3 
       TATA box                +1 
 +3   AGCTTCGGTTCTCACCATGAACCCCTGGCA +33 
          Met 
 
 
 
Figure 5. (A) Sequence of the upstream 1.8 kb of the rat MMP-9 gene promoter. Potential binding sites involved in the signaling of IL-1ß 
are underlined.  
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was further amplified by addition of WY-14,643 (4.1-fold, p< 0.01) which on its own had a 
moderate stimulatory effect on MMP-9 promoter activity (1.8-fold, p< 0.01, Fig. 5B). We 
recently have idenitified AP-1 and NF-κB-response elements, being crucially involved in the 
IL-1ß-mediated transcriptional activation of MMP-9 [Eberhardt et al., 2000b]. To test for a 
functional role of the two putative PPREs in the amplification of cytokine-induced MMP-9 
promoter activity by PPARα ligands, each PPRE was point mutated by an exchange of 2 base 
pairs and tested for remaining promoter inducibility (Table 2). Mutation of the proximal 
PPRE at –888/ –872 (“PPRE-2”) had no effect on promoter inducibility independent of which 
stimulus was used (Fig. 5C). In contrast, mutation of a distal laying PPRE at –1752/–1738 
(“PPRE-1”) prevented the potentiation of cytokine-induced MMP-9 promoter activity by 
WY-14,643 without affecting promoter activation by IL-1ß (Fig. 5D). These data suggest, that 
PPRE-1 in contrast to PPRE-2, is functionally involved in the amplification of cytokine-
induced MMP-9 promoter activity by PPARα without affecting cytokine-induced 
transcription of MMP-9. Furthermore, these data demonstrate that the modulation of cytokine-
induced mRNA steady-state level by PPARα agonists cannot be explained by regulatory 
events occuring in the upstream 1.8 kb MMP-9 promoter context.  
 
PPARa activators enhance the cytokine-induced DNA-binding to PPRE-1 
To further confirm the functionality of a cognate PPRE promoter binding site in the 
transcriptional amplification of MMP-9 we performed EMSA using a 
32P-labeled 
oligonucleotide comprising the critical PPRE-1 binding-site. Treatment of cells with IL-1ß (2 
nM) or WY-14,643 (50, 100 µM) caused binding of a single slow migrating complex (Fig. 
6A, left panel). Importantly, the intensity of DNA-binding was strongly increased when both 
reagents were given in combination (Fig. 6A, left panel). Similar results were obtained with a 
PPRE consensus oligonucleotide (data not shown). The identity of the DNA-bound complex     Results 
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Figure 5 (B) A 1.8 kb wild type pGL-MMP-9 promoter construct 
and its corresponding promoter activation by IL-1ß and WY-14-
643. Subconfluent MC were transiently cotransfected with 0.4 µg 
of pGL-MMP-9 (1.8) and with 0.1 µg of pRL-CMV coding for 
Renilla luciferase. After an overnight transfection MC were 
treated for 24 hours with vehicle (control), IL-1ß (2 nM), WY-
14,643 (100 µM) or a combination of IL-1ß and WY-14,643 as 
indicated. The values for beetle luciferase were related to values 
for Renilla luciferase and are depicted as relative luciferase 
activities. Data are means ±     S.D. (n=6). *P≤0.05; **P≤0.01 
compared with vehicle, or IL-1ß-stimulated conditions (## 
P≤0.01). 
 
 
Figure 5 (C)  pGL-MMP-9∆PPRE-2 and its corresponding 
promoter activation by IL-1ß and WY-14-643.   Subconfluent 
MC were transiently cotransfected with 0.4 µg of pGL-MMP-9 
∆PPRE-2  and with 0.1 µg of pRL-CMV coding for Renilla 
luciferase. After an overnight transfection MC were treated for 
24 hours with vehicle (control), IL-1ß (2 nM), WY-14,643 (100 
µM) or a combination of IL-1ß and WY-14,643 as indicated. 
The values for beetle luciferase were related to values for 
Renilla luciferase and are depicted as relative luciferase 
activities. Data are means ± S.D. (n=6).  *P≤0.05; **P≤0.01 
compared with vehicle, or IL-1ß-stimulated conditions (## 
P≤0.01) 
 
 
 
 
Figure 5 (D) pGL-MMP-9∆PPRE-1 and its corresponding 
promoter activation by IL-1ß and WY-14-643.   Subconfluent 
MC were transiently cotransfected with 0.4 µg of pGL-MMP-9 
∆PPRE-1 and with 0.1 µg of pRL-CMV coding for Renilla 
luciferase. After an overnight transfection MC were treated for 
24 hours with vehicle (control), IL-1ß (2 nM), WY-14,643 
(100 µM) or a combination of IL-1ß and WY-14,643 as 
indicated. The values for beetle luciferase were related to 
values for Renilla luciferase and are depicted as relative 
luciferase activities. Data are means ± S.D. (n=6). *P≤0.05; 
**P≤0.01 compared with vehicle, or IL-1ß-stimulated 
conditions (## P≤0.01).  
 
-1802 X
-1802X
-2034 
AGCACCTATGTGTA GTGT  AGCACCCCGAGG GT    Results 
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IL-1ß:
IL-1ß
PPRE-1
+ WY[50µM]
 WY[50µM]
+ anti-PPARα
1:10
1:10
1:100
1:100
1:1000
1:1000
+ anti-PPARγ
+ WY[100µM]
+ WY [100µM]
      +   +    +         +     +     +    +    +      - - -       +    +     +    +     
 
                       A. 
 
 
 
 
 
 
 
 
Figure 6.(A) Cytokine-induced PPAR binding is enhanced by WY-14,643. For EMSA serum-starved MC were stimulated with either 
vehicle (-), IL-1ß (+) (2 nM), WY-14,643 (50 and 100 µM) or IL-1ß plus WY (100 µM) as indicated for 5h before being harvested for 
nuclear extract preparations. The experiments were performed three times and representative experiments are shown. Supershift analysis 
identifying PPARα but not PPARγ  as  IL-1ß-/WY-inducible complex in MC (right panel). For supershift analysis the antibodies were 
preincubated overnight at 4°C before addition of the labeled oligonuclotide. The altered migration property of  the supershifted complex is 
indicated by an arrow. The same gel shows a representative competition study  by using different molar excess (depicted as different 
dilutions of an oligonucleotide stock solution) of unlabeled wild-type (wt PPRE) or mutated PPRE (mut PPRE) consensus oligonucleotides 
(sequences are shown in Table 2). 
 
was confirmed by shifting the EMSA band through the addition of a PPARα-specific 
antibody (Fig. 6A) whereas the addition of a PPARγ-specific antibody had no effects on DNA  
binding (Fig. 6A, right panel). Interestingly, the disappearance of the PPRE-1 positive band 
after addition of the PPARα antibody was paralleled with the appearance of a strong band 
with faster migration properties (arrow in Fig. 6A). Probably, the binding of the antibody 
triggers a conformational change that allows for the binding of a further transcription factor to 
this promoter binding site which is normally competed by PPARα . Furthermore, the 
specificity of the DNA-bound complex was underlined by competition assays. Addition of 
different concentrations of unlabeled wildtype consensus PPRE oligonucleotide (wt PPRE) 
dose-dependently impaired DNA binding whereas the addition of cold mutant PPRE 
oligonucleotide only in a very high concentration (1:10) competed with the labeled PPRE-1 
probe which is most probably due to an unspecific competition by the oligonucleotide (Fig. 
6A, right panel).  
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WY-14,643 inhibits the IL-1- induced DNA-binding of NF-κB  
PPARα agonists can inhibit the transcription of proinflammatory genes indirectly by 
interfering with the activation of  NF-κB as it has been shown for the human IL-6 promoter 
[Delerive et al.,1999]. Previously we have demonstrated that NF-κB is critically involved in 
the activation of a 0.6 kb promoter portion of MMP-9 by IL-1ß [Eberhardt et al., 2000b]. To 
test whether activators of PPARα could modulate the activation of NF-κB binding in MC, we 
performed EMSA using a MMP-9 gene-specific  oligonucleotide described in Table 2. 
Treatment of MC with IL-1ß (2 nM) induced DNA-binding of a single complex, and a weaker 
binding by WY-14,643 (Fig. 6B, left panel). Supershift analysis revelaed that the cytokine-
induced complex containes both p50 and p65 subunits and the p65 antibody totally inhibited 
DNA binding. This indicates activation of a p50-p65 heterodimeric complex which mediates 
the potent transactivating activity of NF-κB (Fig. 6B, right panel). The formation of this IL-
1ß-induced complex was markedly attenuated in cells which were simultaneously treated with 
WY-14,643 indicating that PPARα−dependent  signaling cascades interfere with the DNA-
binding of NF-κB (Fig. 6B, left panel). It should be noted that WY-14,643 alone induced a 
pronounced increase in NF-κB binding which, however, was significantly less than the effects 
observed with IL-1ß.  
 
 
Table 2. Oligonucleotides used in EMSA and for point mutations generation.  Consensus binding sites are underlined, and mutations are 
bold and italicized.  
 
 
Oligonucleotides     Primer sequence (sense)  
 
PPRE-1                       5´-ATG GAG ACT CAA GGT CAC CTA TGT GT-3´ 
∆-PPRE-1       5´-ATG GAG ACT CAA GCA CAC CTA TGT GT-3´ 
PPRE-2                       5´-TCC CAT CCA GGT CAC CCC GAG GCT TA-3´ 
∆-PPRE-2       5´-TCC CAT CCA GCA CAC CCC GAG GCT TA-3´ 
wt PPRE                       5´-CAA AAC TAG GTC AAA GGT CA-3´ 
mut PPRE       5´-CAA AAC TAG CAC AAA GCA CA-3´ 
NF-κB (MMP-9)                     5´-TTG CCC CGT GGA ATT CCC CCA AAT-3´ 
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Figure 6. (B) Cytokine-induced NF-κB binding is inhibited by WY-14,643. Supershift analysis identifying an IL-1ß-inducible p50 and p65-
containing complex (right panel).  
 
Taken together these results demonstrate that activators of PPARα show mixed effects on 
NF-κB activity depending on the presence or absence of a simultaneous cytokine stimulus. 
However, their positive effects through PPRE dominate and result in  the potentiation of  
MMP-9 gene expression. 
 
Inhibition of cytokine-induced MMP-9 expression by PPARα agonists is switched to a 
potentiation in the presence of the NOS inhibitor L-NMMA 
Since the data of the promoter studies do not reflect the reduction of the cytokine-induced 
MMP-9 mRNA steady-state level by PPARα agonists we hypothesized that PPARα 
activators may alter  posttranscriptional events regulating MMP-9 mRNA stability. 
Previously, we have described the inhibitory effects of NO on the IL-1ß-induced MMP-9 
steady-state mRNA level in rat MC. Correspondingly, we found that inhibition of iNOS leads 
to a marked potentiation of cytokine-induced MMP-9 mRNA levels thus proving a potent 
inhibitory action of endogenously produced NO [Eberhardt et al., 2000a]. To test whether the 
inhibitory effects of the PPARα activators on the IL-1ß-induced MMP-9 mRNA level depend 
NF- B (MMP-9) κ
- - -   Results 
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on NO production, MC were treated with IL-1ß and different PPARα agonists in the presence 
or absence of the NOS inhibitor L-NMMA. We first measured by zymography the 
gelatinolytic content of conditioned medium of MC withdrawn 24h after stimulation. 
Strikingly, the reduction of cytokine-induced MMP-9 content, most prominently seen with the 
highest concentration of the PPARα agonists WY-14, 643 (100 µM) or bezafibrate (500 µM), 
was not only reversed but even potentiated in the presence of L-NMMA (Figure 7A). The 
amplification of cytokine-mediated zymogen contents by L-NMMA was approximately 3-
fold, demonstrating that PPARα activators in the absence of cytokine-triggered NO 
generation potently augment the cytokine-induced level of MMP-9 (Fig. 7A). Similar to the 
amplification of gelatinolytic contents, addition of PPARα agonists plus L-NMMA results in 
a strong amplification of the IL-1ß-mediated MMP-9 steady-state mRNA level (Fig. 7B) 
whereas L-NMMA by its own had no effects on the basal MMP-9 mRNA level (data not 
shown). Similarly to MMP-9, cytokine-induced TIMP-1 mRNA levels were inhibited by both 
PPARα agonists but strongly amplified in the presence of L-NMMA (Fig. 7B). In contrast, 
the high level of basal TIMP-2 mRNA was weakly reduced by IL-1ß and the reduction by IL-
1ß was weakly enhanced by addition of WY-14,643 whereas bezafibrate had no further 
modulatory effect on this attenuation of TIMP-2 steady-state mRNA level. Similar to the 
amplification of gelatinolytic contents, addition of PPARα agonists plus L-NMMA results in 
a strong amplification of the IL-1ß-mediated MMP-9 steady-state mRNA level (Fig. 7B) 
Whereas L-NMMA by its own had no effects. Furthermore, the presence of L-NMMA had no 
effects on the TIMP-2 mRNA level, thus demonstrating that TIMP-1, but not TIMP-2 
expression similarly to MMP-9 is negatively affected by PPARα agonists in a NO-dependent 
manner.  To further confirm that the modulation of cytokine-induced MMP-9 mRNA level by 
PPARα activators negatively correlates with endogenous NO production we stimulated MCs 
with increasing concentrations of IL-1ß to  gradually increase iNOS expression  [Mühl et at .,    Results 
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92kD
L-NMMA [3 mM]
WY[µM] bezafibrate[µM]
10 30 100 100
++ +
1993; Kunz et al., 1994] in the presence of a fixed concentration of WY-14,643 (100 µM) 
(Fig. 8). Whereas the low dose of IL-1ß (0.1 nM) was not able to induce detectable levels of 
MMP-9 mRNA, concentrations between 0.5 nM and 2 nM IL-1ß caused a strong induction of 
MMP-9 mRNA which was paralleled by a dose-dependent increase of nitrite accumulation in 
the cell culture supernatants (Fig. 8). Interestingly, although the addition of WY-14,643, to all 
IL-1ß concentrations caused a further increase in nitrite levels, WY differentially affected the 
                              A. 
 
 
 
 
 
 
 
Figure 7. (A) MC were incubated for 24 hours with vehicle (control), IL-1ß (2 nM), IL-1ß plus the indicated concentrations of WY-14,643 
or bezafibrate. In the presence of IL-1ß and the highest concentration of PPARα activator cells were additionally treated with (+) the NOS 
inhibitor L-NMMA (3 mM). 10 µl of aliquots from cell supernatants were assessed by SDS-PAGE zymography and migration property of 
the lytical band determined using standard m.w. markers.  
 
 
Figure 7 (B) MC were incubated for 24 hours with vehicle (control), IL-1ß (2 nM), IL-1ß plus the indicated concentrations of WY-14,643 or 
bezafibrate. In the presence of IL-1ß and the highest concentration of PPARα activator cells were additionally treated with  the NOS 
inhibitor L-NMMA(3 mM) as indicated. Northern blot analysis was performed using 20 µg of total RNA from the very same cells assayed 
for lytical activity which was successively hybridized with specificDNA  probes for rat MMP-9, TIMP-1 and TIMP-2, respectively. 
Equivalent loading of RNA was ascertained by a final rehybridization to an 18S ribosomal probe. 
 
TIMP-2
L-NMMA 
WY [100µM]
bezafibrate[300µM]
MMP-9
TIMP-1
WY bezafibrate
10 30 100 
B.   Results 
  56
IL-1ß-induced MMP-9 mRNA level, depending on the concentration of IL-1ß applied (Fig. 
8). Whereas at low concentrations of IL-1ß (0.1 and 0.5 nM) WY-14,643 clearly enhanced  
the cytokine-induced MMP-9 mRNA level in the presence of a higher concentration of IL-1ß 
(2 nM) WY-14,643 caused a significant reduction of cytokine-induced MMP-9 mRNA level.  
 
 
Figure 8. IL-1ß-induced MMP-9 steady-state mRNA levels are differentially modulated by WY-14,643, depending on the concentration of 
cytokine used for stimulation. Quiescent MC were coincubated for 24 hours with the indicated concentrations of IL-1ß in the presence (+) or 
absence (-) of a constant concentration of WY-14,643 (100 µM). Northern blot analysis demonstrates a dose-dependent modulation  of 
cytokine-induced MMP-9 mRNA steady-state level. 20 µg of total RNA were  hybridized to a 
32P-labeled cDNA insert from KS-MMP-9. 
Equivalent loading of RNA was ascertained by rehybridization to an 18S ribosomal probe.  The stable endproduct of NO was measured by the 
Griess assay and the amount of  total nitrite release by MC is given at the bottom of the Figure. The experiment was performed three times and 
one representative experiment is shown. 
 
In summary, these data indicate, that WY-14,643 principally potentiates the level of cytokine-
induced MMP-9 mRNA but this effect is antagonized by the negative effect of NO produced 
endogenously in large amounts upon stimulation with high concentrations of IL-1ß.  
 
 
The cytokine-induced increase in nitrite production is amplified by WY-14,643 and is due to 
enhanced iNOS expression   
The experiments with L-NMMA clearly demonstrate a causal role of NO in the PPARα-
dependent repression of MMP-9 mRNA steady-state level. In order to elucidate whether 
activators of PPARα similarily to MMP-9, also influence iNOS expression we performed 
Western blot analysis using a N-terminal iNOS-specific antibody [Kunz et al., 1994].   
IL-1[x nM]
Nitrite [µMol]
WY[100µM]
0.1 nM
12.2  25.9 43.5  66.9 51.2  78.4
0.5 nM 2 nM
-   -   -   +   +   +  
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Figure 9. Cytokine-induced expression of inducible NO synthase is potentiated by WY-14,643 and results in an amplification of nitrite 
release. Quiescent MC were  treated for 24 hours with vehicle (-), IL-1ß (2 nM), WY-14,643 (100 µM) or IL-1ß plus WY-14,643 as 
indicated. Total cellular protein lysates (50 µg) were subjected to SDS-PAGE and immunoblotted using an anti-iNOS N-terminal antibody 
[Kunz et al., 1994] (upper panel). The lower panel shows the nitrite levels in the corresponding cell supernatants as measured by the Griess 
assay. Equal loading of protein was ascertained by Ponceau S staining. Similar results were obtained in two independent experiments. 
 
Treatment with IL-1ß for 24h results in the appearance of an iNOS band at 130 kD, which 
was not detectable in the extracts from untreated or WY-14,643-treated MC, respectively 
(Fig. 9, upper panel). When cells were simultaneously treated with IL-1ß plus WY-14,643 
cytokine-triggered iNOS expression was strongly enhanced and paralleled by an amplification  
of nitrite production (Fig. 9, lower panel). These results indicate that PPARα activators 
potentiate cytokine-mediated iNOS expression and subsequent nitrite production. 
 
The amplification of cytokine-induced MMP-9 mRNA level by WY-14,643 in the presence of 
L-NMMA is independent of the 1.8 kb-MMP-9 promoter context   
We tested whether the modulation of MMP-9 promoter activity by WY-14,643 was affected by 
NO. To this end MC were transiently transfected with pGL-MMP-9 (1.8) and stimulated with 
IL-1ß to trigger endogenous NO formation or with DETA NONOate as an exogenous source of 
NO. As shown before, treatment of MC with IL-1ß in the presence of WY-14,643 caused a 
potentiation of cytokine-dependent pGL-MMP-9 luciferase activatity (Fig. 10A). Moreover,  
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the addition of either L-NMMA or DETA-NONOate  did not affect cytokine or cytokine plus 
PPARα-induced MMP-9 promoter activity (Fig. 10A) and also had no effects on the basal 
promoter activity of pGL-MMP-9 (1.8) (data not shown). These data suggest that not a 
transcriptional but a posttranscriptional mechanism mediates NO suppression of cytokine- 
stimulated MMP-9 mRNA steady-state levels.  
 
 
Figure 10. (A) Exogenous and endogenous NO does not affect the potentiation of cytokine- induced MMP-9 promoter activity by WY-14,643. 
Subconfluent MC were transiently cotransfected with 0.4 µg of pGL-MMP-9 (1.8) and with 0.1 µg of pRL-CMV coding for Renilla luciferase. 
After an overnight transfection MC were treated for 24 hours with vehicle or with IL-1ß (2 nM) in presence or absence of WY-14,643 (100 
µM); L-NMMA (3 mM); DETA-NONOate (500 µM) as indicated. The values for beetle luciferase were related to values for Renilla luciferase 
and are depicted as relative luciferase activities. Data represent means ± S.D. (n=6). *P≤0.05; **P≤0.01 compared with vehicle, or IL-1ß-
stimulated conditions (# P≤0.05;  ## P≤0.01). 
 
Nuclear MMP-9 mRNA level are increased  by the PPARα agonsit WY-14,.643   
  The promoter studies indicate that PPARα agonists have a positive effect on the 
transcriptional activity of IL-1ß-triggered MMP-9. However, the use of partial promoter 
fragments in reporter gene assays does not necessarily reflect the real transcriptional 
regulation. Therefore, in addition to promoter studies we used a modified transcription assay 
with intact nuclei. MC were treated for 4 hours with either vehicle (control), or IL-1ß (2 nM), 
or WY-14,643 (100 µM) or both in combination before cells were lysed for nucelar 
fractionation. The quality of nuclei was tested by microscopy and only fractions containing 
pure and intact nuclei were used for the assay. We used a combination of classical nuclear run 
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on with that of RNase protection assay since the sensitivity  of RNase protection assay is 
severalfold higher than that of conventional protocols involving hybridization of labeled RNA 
to blots containing immobilized cDNA probes. As shown in Fig. 10B, MMP-9 shows a 
relatively high basal expression which corresponds well with the high basal promoter activities 
of the MMP-9 promoter constructs and which suggests a strong posttranscriptional regulation 
that might explain the observed low basal MMP-9 steady-state mRNA level. Concomitantly, 
IL-1ß treatment caused a moderate increase of MMP-9 gene expression which was further 
amplified by addition of WY-14,643. In the protection assay we observed a second band with 
faster migrating properties (Fig. 10B, asterix) most probably reflecting a splicing variant of 
nascent MMP-9 mRNA also observed in the Northern blots (Fig. 8). In agreement with the data 
from reporter gene assays, WY-14,643 by its own caused an increase in nucelar MMP-9 
mRNA level.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 (B) WY-14,643 increases the content of nuclear MMP-9 mRNA. RNase protection assay demonstrating that the cytokine-induced 
content of nuclear MMP-9 mRNA is further amplified by WY-14,643. MC were either treated with vehicle (control) or stimulated with IL-1ß 
(2 nM), WY-14,643 (100 µM) or with both agents in combination for 4 h. The amount of nuclear MMP-9 transcripts in isolated nuclei was 
determined by hybridizing the RNA transcripts with a radiolabeled antisense RNA from rat MMP-9. Equal counts of radiolabeled samples 
were loaded on acrylamide/urea gels and analyzed by Phosphorimager analysis. A band which possibly corresponds to hybridization of a 
smaller MMP-9 splicing variant is indicated by an asterix. Similar results were obtained in two independent experiments. 
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Since posttranscriptional events regulating mRNA stability mainly occur in the cytoplasm 
these results clearly demonstrate that the increase in nuclear MMP-9 mRNA level results from 
an increased transcription rate. In summary, these data clearly demonstrate that the inhibitory 
effects by PPARα agonists on the cytokine-induced steady-state MMP-9 mRNA level result 
from indirect, posttranscriptional events.  
  
Effect of NO on MMP-9 mRNA-stability 
To test whether NO could affect the stability of cytokine-induced MMP-9 mRNA we used the 
transcription inhibitor actinomycin D. MC were stimulated for 20 hours with IL-1ß (2 nM) 
and subsequently cells were treated with vehicle or different NO donors. The reduction in 
MMP-9 mRNA observed under cytokine-stimulated conditions occurred with a half-life of 
approximately 8 h (Fig. 11A, upper panel). Interestingly, addition of NO by either DETA 
NONOate (Fig. 11A) or SNAP (Fig. 11B) markedly decreased MMP-9 mRNA stability with 
a half-life of approximately 4 h. This is most impressively documented by the complete loss 
of the MMP-9 transcripts 8h after addition of  the NO donors. Importantly, WY-14,643 in a 
similar experimental setting did not affect the mRNA half-life of MMP-9 (data not shown). 
Furthermore, we addressed the question whether endogenously produced NO was, similar to 
exogenously added NO donors, able to reduce the stability of  MMP-9 mRNA. To this end 
MC were treated with IL-1ß (IL-1ß) for 20 h either in the presence or absence of the NOS 
inhibitor L-NMMA (3 mM) before de novo transcription was blocked by actinomycin D ( 
Fig.12A). As expected from the effects observed for exogenous NO, inhibition of endogenous 
NO production by L-NMMA caused a significant retardation of MMP-9 mRNA degradation 
(Fig. 12A). These data clearly demonstrate that endogenous NO levels similar to exogenous 
applied NO are sufficient to alter MMP-9 mRNA degradation.  In a further approach we tested 
whether iNOS inhibition affects MMP-9 protein stability and /or activity. MC were treated for 
20 h with IL-1ß (2 nM) in the presence or absence of L-NMMA (3 mM) before protein      Results 
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                   A. 
                           
 
 
 
 
 
 
 
 
Figure 11. The stability of cytokine-induced MMP-9 mRNA is strongly diminished by the NO donors DETA-NONOate (A) and SNAP (B). 
Quiescent MC were treated for 20 hours with IL-1ß (2 nM). After incubation cells were washed twice and incubated with actinomycin D 
(5µg/ml). After a short preincubation of 30 min, cells were additionally treated for the indicated time points without (-NO) or with (+NO) the 
different NO donors (500 µM). At the time points indicated after start of actinomycin D treatment cells were harvested and extracted for total 
cellular RNA. 20 µg of total cellular RNA were hybridized to a 
32P-labeled MMP-9 probe. The equivalent loading of RNA was ascertained 
by subsequent hybridization with an 18 S rRNA probe. The densitometrical analysis of three independent experiments with DETA-NONOate 
is shown in the upper panel of Fig. 8A. The MMP-9 mRNA levels from MC treated with IL-1ß in the absence (filled bars) or presence (open 
bars) of NO donor after 30 min of  actinomycin-D (0 hours) were set as 100%. Data in B. are representative for two experiments giving 
similar results.  
   
 
synthesis was blocked by addition of cycloheximide (10 µg/ml). After the indicated time 
points conditioned media were collected for measurement of gelatinase activity and protein 
levels were assayed by Westernblot analysis using a specific MMP-9 antibody (Fig. 12 B).  
0
10
20
30
40
50
60
70
80
90
100
0h 2h 4h 6h 8h 12h
m
R
N
A
 
l
e
v
e
l
s
 
(
%
 
o
f
 
c
o
n
t
r
o
l
)
B. 
MMP-9
MMP-9
0h 0h 2h 2h 4h 4h 6h 6h 8h 8h 12h 12h
- NO 
- NO 
MMP-9 18 S
18 S
MMP-9 +NO 
+NO 
0h 0h 2h 2h 4h 4h 6h 6h 8h 8h 12h 12h
18 S
18 S   Results 
  62
- L-NMMA  + L-NMMA 
MMP-9
18S
n.b.
0h 0h   4h  4h  6h  6h 8h  8h  12h  12h
- L-NMMA  + L-NMMA 
92 kD
0h 0h   4h  4h  6h  6h  8h  8h  12h  12h   10h  10h
w.b.
zym.
 24h   24h
 
 
 
 
 
 
 
 
 
 
 
Figure 12. (A) The stability of cytokine-induced MMP-9 mRNA is inhibited by endogenously produced NO. Quiescent MC were treated for 
20 hours with IL-1ß (2 nM) in the presence or absence of the NOS inhibitor L-NMMA (3 mM) as indicated. After incubation cells were 
washed twice and incubated with actinomycin D (5µg/ml) and harvested for RNA extraction after the indicated time points. 20 µg of total 
cellular RNA were hybridized to a 
32P-labeled MMP-9 probe. The equivalent loading of RNA was ascertained by subsequent hybridization  
with an 18 S rRNA probe. Similar results were obtained in two independent experiments.  
 
 
 
 
 
 
 
 
 
 
Figure 12.(B) The stability of MMP-9 protein and zymogen activity of secreted MMP-9 is not affected by endogenously produced NO. 
Quiescent MC were treated for 20 hours with IL-1ß (2 nM) in the presence or absence of the NOS inhibitor L-NMMA (3 mM) as indicated. 
After incubation cells were washed twice and incubated with cycloheximide (10µg/ml) and harvested for isolation of total protein lysates 
after the indicated time points. Protein lysates (100 µg) were subjected to SDS-PAGE and immunoblotted using a MMP-9 specific antibody 
(upper panel). Equal protein loading was ascertained by Ponceau S staining. The blot is representative of two independent experiments 
giving similar results. In parallel 10 µl of cell culture supernatants were collected after the indicated time-points and subjected to SDS-PAGE 
zymography (lower panel). The indicated band migrated at 92 kDa and corresponds to the latent form of MMP-9.  
 
 
We observed that the stability of MMP-9 protein is quite high when compared to its 
corresponding mRNA since even a blockade of protein synthesis for 24 h did not change the 
total content of MMP-9 protein. Similarly to the cellular content of MMP-9, cycloheximide 
had no effects on the lytical content in the cell supernatants (Fig. 12B, lower panels). Most 
interestingly, there was no change in the MMP-9 protein contents when cells were grown in    Results 
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the presence of the NOS inhibitor L-NMMA thus demonstrating that NO has no effects on the 
protein stability and gelatinolytic content of MMP-9.   
 
Discussion 
Increased expression of matrix metabolizing enzymes is a hallmark of many inflammatory 
processes and may lead to irreversible alteration of tissue architecture. Particularly MMP-9 
has been shown to be centrally involved in the dysregulation of ECM turnover associated with 
severe pathologic conditions such as rheumatoid arthritis [Cawston, 1998] or fibrosis of lung, 
skin and kidney [Lemjabbar et al., 1999; Madlene et al., 1998; Davies et al., 1992]. The 
inflammatory cytokines IL-1ß and TNFα are among the most potent inducers of MMP-9 gene 
expression, mainly through the involvement of MAP kinase pathways leading to increased 
activity of NF-κB and AP-1 transcription factors [Yokoo et al., 1996; Eberhardt et al., 2000b]. 
Interference with these signaling cascades therefore has been suggested as a promising 
strategy to prevent aberrant matrix turnover. Here we have focused on possible modulatory 
effects of PPARα agonists on cytokine-induced MMP-9 expression since the PPARα 
signaling pathway exerts critical control functions in acute inflammation as shown by the 
exacerbated inflammatory response in PPARα null mice [Devchand et al., 1996]. We 
demonstrate that various structurally different PPARα agonists such as WY-14,643, LY-
171883 and fibrates potently suppress cytokine-induced MMP-9 expression in renal MC. A 
downregulation of LPS-induced MMP-9 secretion by the PPARα agonist fenofibrate was 
recently documented in the human monocytic THP-1 cell line without addressing the 
underlying mechanisms [Shu et al., 2000]. The anti-inflammatory action by PPAR 
transcription factors is well established and in many cases occurs by antagonizing the pro-
inflammatory action of nuclear factor κB (NF-κB) [Staels et al., 1998; Delerive et al., 1999; 
Poynter and  Daynes 1998] as well as activator protein-1 (AP-1) [Delerive et al., 1999]. In line 
with these observations, we demonstrate that in MC the cytokine-induced binding of a    Results 
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p50/p65 containing complex to a MMP-9-specific NF-κB binding site at –560/-550 is 
substantially reduced by PPARα agonists. However, the reduction of cytokine-induced NF-κB 
binding was not complete and somehow contrasts with the stimulatory effects on NF-κB 
binding by the PPARα agonist alone (Fig. 3B). Obviously, this reduced level of NF-κB 
activity is still sufficient to allow for a potentiation of the cytokine-triggered MMP-9 
expression. Activation of NF-κB is crucially involved in IL-1ß-mediated MMP-9 promoter 
activation [Eberhardt et al., 2000b]. Whether the inhibition in DNA binding is caused by a 
physical interaction of PPARα with Rel-A transcription factors or indirectly, by the increased 
expression of the inhibitor of NF-κB (IκB) by PPAR-α activators remains to be evaluated. 
Recently, Delerive and coworkers have shown that both mechanisms of NF-κB activation are 
targeted by PPARα [Delerive et al., 1999]. In line with these considerations the inhibition of 
NF-κB DNA binding by PPARα agonists in the context of a 1.8 kb portion of rat MMP-9 
promoter did not influence the PPARα-dependent amplification of IL-1ß-triggered MMP-9 
promoter activity by the PPRE like binding-site at -1752/-1738. Interestingly, the PPRE 
sequence motif which is defined as two direct AGG(T/A)CA repeats and separated by one to 
five nucleotides is shared by other nuclear receptors, such as the thyroid hormone and the 
vitamin D receptors [Corton et al., 2000]. Like PPARs these receptors bind to direct repeats in 
a complex with the retinoic acid receptor (RXR). It is worth mentioning that although the 
PPRE like motif within the MMP-9 promoter contains only one half-site which completely 
matches a PPRE sequence motif, EMSA and supershift analysis indicate PPAR binding 
comparable to that observed with a complete consensus motif. The observation that PPARα 
agonists by their own increased the nuclear content of MMP-9 transcripts and  have a weak 
stimulatory effect on MMP-9 promoter activity paralleled by increased DNA binding to PPRE 
and NF-κB sites somewhat contrasts with the finding that PPARα activators do not affect the 
basal MMP-9 mRNA steady-state and zymogen levels. Obviously, the PPARα-triggered    Results 
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signals do not completely cover the cytokine-induced signaling pathways in rat MC. 
Moreover, in the complete promoter context additional regulatory events affecting 
transcriptional activators or repressors may explain the lack of MMP-9 mRNA increase in the 
absence of cytokine-induced signals. In line with these observations the potentiating effects of 
PPARα agonists on cytokine-induced sPLA2 promoter activity in rat MC which, similarily to 
their effects on MMP-9 expression, cause activation of the sPLA2 promoter without having 
significant effects on the basal sPLA2 mRNA steady-state level [Scholz-Pedretti et al., 2002]. 
In summary, these experiments clearly demonstrate that PPARα agonists synergistically with 
IL-1ß amplify MMP-9 promoter activity through a PPRE-dependent DNA binding despite a 
partially reduced NF-κB signaling. As found by a modified nuclear run-on assay, the PPARα-
mediated decrease in MMP-9 mRNA steady-state and zymogen levels is not attributable to an 
inhibition of MMP-9 gene expression but points to possible posttranscriptional regulatory 
events. In addressing this hypothesis we most interestingly found that the reduction in 
cytokine-induced MMP-9 mRNA and zymogen levels by PPARα agonists is switched to 
strong potentiation in the presence of an inhibitor of NO synthesis. Furthermore, we 
demonstrate that  treatment with PPARα agonists causes  a strong increase of cytokine-
induced iNOS expression  and subsequent NO formation. These data suggest that PPARα-
dependent effects on MMP-9 expression level primarily result from alterations in NO 
production. This is in a line with our  previous finding that NO, either given exogenously or 
endogenously by stimulation of iNOS expression, potently inhibits the mRNA steady-state 
level of cytokine-induced MMP-9 in MC [Eberhardt et al., 2000a]. The  negative modulation 
of MMP-9 expression has been confirmed in other cell types and suggests a general 
mechanism of NO-triggered tissue remodeling [Upchurch et al., 2001; Gurjar et al., 2001; 
Pfeilschifter et al., 2001]. When testing a 1.8 kb of the promoter region of the rat MMP-9 
gene by reporter gene assay we found that NO had no direct effects on cytokine-induced 
MMP-9 promoter activity although the expression of many genes has been shown to be    Results 
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transcriptionally modulated by NO in rat MC [Walpen et al., 2001; Pfeilschifter et al., 2001]. 
However, a transcriptional control of MMP-9 gene expression seems unlikely since in our 
hands none of the NO-sensitive candidate transcription factors, including AP-1 and NF-κB 
[Lander et al., 1993; Peng et al., 1995; von Knethen et al., 1999] were significantly affected 
by NO (data not shown). Whether regulatory regions upstream from -1.8 kb of the MMP-9 
gene may be negatively influenced by NO is the subject of ongoing investigations. The 
3´untranslated region (3´-UTR) of the rat MMP-9 gene bears several “AUUUA” motifs 
allowing for a posttranscriptional regulation of MMP-9 on the level of mRNA stability. In 
many genes AU-rich elements are specifically targeted by proteins of the ELAV-like protein 
family which has been implicated in the regulation of mRNA stability [Zhang et al., 1993; Ma 
et al., 1996; Rodriguez-Pascual et al., 2000]. Using actinomycin D, an inhibitor of eukaryotic 
gene transcription, we found that exogenous NO significantly reduced the half-life of MMP-9 
mRNA (Figs. 9 and 10) whereas PPARα agonist had no influence on MMP-9 mRNA 
stability. Similar to MMP-9, the expression of transforming growth factor ß3 (TGFß3) is 
reduced by NO via destabilization of its mRNA [Abdelaziz et al., 2001]. Additional 
experimental work is required to more precisely evaluate the molecular mechanism of 
posttranscriptional regulation of MMP-9 expression by NO. In summary our study provides 
convincing evidence that PPARα agonists exert dominant negative effects on the steady-state 
level of MMP-9 mRNA and enzyme levels in addition to their positive transcriptional effects. 
The action of PPARα agonists on MMP-9 mRNA is indirect and due to an NO-triggered 
reduction of MMP-9 mRNA half-life. The overall effects of exogenous or endogenous 
PPARα activators on secretion of MMP-9 will critically depend on the simultaneous 
production of NO by cells exposed to an inflammatory environment. High-output levels of 
NO may account in part for the protective roles of PPARα agonists on the altered remodeling 
of ECM observed in many pathologies. 
    Results 
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2. Nitric oxide increases the decay of MMP-9 mRNA by inhibiting the expression of 
mRNA stabilizing factor HuR 
 
Introduction 
Remodeling of extracellular matrix (ECM) is an important feature of normal growth and 
developmental processes. Consequently, an imbalance of ECM synthesis and degradation is 
associated with many diseases. Although changes in the synthesis of ECM may play a certain 
role in dysregulation of matrix turnover, recent studies have underlined the paramount role of 
ECM degradative systems. The main proteases regulating physiological degradation of ECM 
are the matrix metalloproteinases (MMPs), a family of zinc-dependent enzymes, which 
include the interstitial collagenases, stromelysins, elastases, membrane-type MMPs and 
gelatinases [Brinckerhoff and Matrisian. 2002; Nagase and Woessner 1999; Woessner,1998; 
Woessner, 1991]. A tight regulation of most of these proteases is accomplished by different 
mechanisms, including the regulation of MMP gene expression, the processing and 
conversion of the inactive zymogens by other proteases and, finally, the inhibition of active 
MMPs by endogenous inhibitors of MMPs, the tissue inhibitors of metalloproteinases 
(TIMPs) [for review see  Nagase and Woessner, 1999]. Cultured mesangial cells (MC) 
respond to proinflammatory cytokines such as tumor necrosis factor α (TNFα) or interleukin-
1ß (IL-1ß) with the production of several MMPs, including MMP-9 (gelatinase-B) mainly by 
an increase of gene expression [Yokoo and Kitamura, 1996 Eberhardt et al., 2000b ]. In 
addition to MMPs, MC exposed to cytokines produce high levels of NO through the 
expression of the inducible NO synthase (iNOS) gene [Kunz et al., 1994; Pfeilschifter and 
Schwarzenbach, 1990]. Whereas the early and rapid actions of NO signaling affect post-
translational modifications of cellular proteins, long-term regulation is executed primarily on 
the level of gene transcription [Pfeilschifter et al., 2002]. Interestingly, in MC NO can 
regulate the expression of a variety of ECM-related genes including secreted protein acidic    Results 
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and rich in cysteine (SPARC) [Walpen et al., 2000], tissue inhibitor of metalloproteinase 1 
(TIMP-1) [Eberhardt et al., 2000a], tissue plasminogen activator (tPA) [Eberhardt et al., 
2002c], MMP-13 [Zaragoza et al., 2002] and MMP-9 [Eberhardt et al., 2000a]. However, the 
detailed mechanisms of these events are still unknown. By examining a 1.8 kb region of the 
rat MMP-9 promoter by reporter gene assays we could demonstrate that NO, either given by 
exogenous NO donors or endogenously produced after induction of the iNOS, has low effects 
on cytokine-induced MMP-9 promoter activity [Eberhardt et al., 2002b]. Moreover, in rat MC 
none of the candidate NO-sensitive transcription factors, including nuclear factor κB (NF-κB) 
or activated protein-1 (AP-1) [Lander et al., 1993; Pineda-Molina and Lamas, 2001; von 
Knethen and Brüne,  2000] are altered by NO, thus demonstrating that the NO-mediated 
effects on MMP-9 expression are mainly due to post-transcriptional effects. Post-
transcriptional regulation of mRNA in the cytoplasm is recognized as an important control 
point in mRNA turnover and includes the localization and stability of mRNA but also 
translation of mRNA [Dreyfuss et al., 1996; Peng et al., 1998;   Wang et al., 2002]. The 
control of selective mRNA degradation of many inducible genes including those for 
cytokines, nuclear transcription factors and proto-oncogenes seems to be localized within the 
3´-untranslated regions (UTRs) of genes by sequence motifs which contain AU-rich 
sequences also denoted as AU-rich elements (AREs) [Chen and Shyu, 1995; Peng et al., 1998;  
Ross, 1995]. The 3´-untranslated region of the rat MMP-9 gene bears several copies of 
AUUUA motifs thus indicating that MMP-9, similarly to a variety of other genes expressed 
during inflammation, may also be regulated on the level of mRNA stability. By use of RNA-
binding assays, several studies have identified proteins specifically binding to AREs, most 
interestingly proteins which play a role in stabilizing mRNAs. Most prominently are members 
of the embryonic lethal abnormal vision (ELAV) protein family [for review see Antic et al., 
1999; Brennan and Steitz, 2001.] but also factors which can destabilize mRNA such as 
members of the AUF1 or hn RNPD families [Ehrenman et al., 1994; Wilson et al., 1999].    Results 
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Members of both families have therefore been implicated in the regulation of mRNA turnover 
[Henics et al., 1994; Zhang et al., 1993]. We recently have reported that activators of the 
peroxisome proliferator-activated receptor α (PPARα) indirectly via increased induction of 
NO synthesis significantly reduce the stability of MMP-9 mRNA [Eberhardt et al., 2002b]. 
With regard to the presence of several AREs in the 3´-UTR of MMP-9 we now elucidated the 
involvement of the RNA stabilizing factor HuR (HuA), a member of the ELAV family in the 
modulation of MMP-9 mRNA stability by NO. 
 
Results : 
Nitric oxide reduces  the mRNA stability of MMP-9 
MMP-9 is synthesized in response to diverse stimuli including cytokines, growth factors, and 
hormones. Most importantly, the induced expression of MMP-9 can be modulated by 
oxidative and nitrosative stress conditions [Eberhardt et al., 2000a; 2000b]. We now 
demonstrate that the inhibitory effects of NO on the cytokine-induced levels of MMP-9 
mRNA and gelatinolytic content of rat glomerular mesangial cells are mainly due to a 
reduction of the stability of MMP-9 mRNA since actinomycin D experiments indicated a 
potent acceleration in the MMP-9 mRNA degradation as demonstrated by Northern blot 
analysis (Fig. 13). MC were stimulated for 20 h with IL-1ß (2 nM) before being treated with 
the NO donor DETA NONOate (500 µM). The reduction of MMP-9 mRNA in the absence of 
NO occured with a half-life of ~ 7 hours. Interestingly, the addition of DETA NONOate 
markedly decreased MMP-9 mRNA stability, with a half-life of ~ 4 hours (Fig. 13, lower 
panel). The decrease in mRNA stability is most impressively documented by the complete 
loss of MMP-9 transcripts 8 hours after the addition of the NO donor (Fig. 13). Similarly, we 
found that the endogenous NO level produced by the induction of iNOS is sufficient to 
stimulate MMP-9 mRNA degradation [Eberhardt et al., 2002b]. Concomitantly, the presence     Results 
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Figure 13. Accelerated degradation of cytokine-induced MMP-9 mRNA by DETA-NONOate. Quiescent MC were treated for 20 hours with 
IL-1ß (2 nM) and then washed twice before the addition of actinomycin D (5µg/ml). After a short preincubation of 30 min, cells were 
additionally treated for the indicated time points without (-NO) or with (+NO) DETA NONOate (500 µM) before being harvested and 
extracted for total cellular RNA. For Northern blot analysis 20 µg of total cellular RNA were hybridized to a 
32P-labeled MMP-9 probe. The 
equivalent loading of RNA was ascertained by subsequent hybridization with an 18 S rRNA probe. A representative experiment is shown in 
the lower part of the figure. The upper panel shows means ± S.D. (n=3) of three independent experiments and depicts the % of remaining 
MMP-9 transcripts after addition of DETA NONOate (NO). 
 
of DETA-NONOate does not affect either cytokine-induced or basal promoter activity of a 
luciferase reporter gene encompassing 1.8 kb of the 5´-flanking region of the rat MMP-9 gene 
[Eberhardt et al., 2002b]. These data strongly suggest the involvement of posttranscriptional 
mechanisms in the regulation of MMP-9 expression by NO.  
 
The 3´UTR of MMP-9 mRNA confers NO responsiveness to the stability of different 
mRNAs  
An important paradigm for posttranscriptional regulation is the control of cytoplasmic mRNA 
stability which is mediated by the 3´-untranslated region (UTR) of mRNAs. Therefore, we 
focused on the 3´-UTR of the rat MMP-9 mRNA which contains four copies of AUUUA 
pentameric motifs potentially involved in the regulation of MMP-9 mRNA turnover (Fig. 14). 
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                                  2128 ACT AAGGCTCCTC TTTTGCTTCA GCGGTGCAGC 
 
     2161 GCAAGCCTCT AGAGACCACC CCTGAGGGGG AGGAGCTAGT TTGCCGGATA CAAACTGGTG 
 
     2221 ATCTCTTCTA GAGACTAGGA AGGAGTGGAG GCGGGCAGGG CCCTCTCTGC ACGCTGTCCT 
 
     2281 TTCTTGTTGG ACTGTTTCTA ATAAACACGG ATCCCCCAAC CTTTACCAGC TACTCGAACC 
 
     2341 AATCAGCTTG TCTGTAGTTG TATACACATC CAAGCCTGTG GTTGGTCAGA AGACAACTTT 
 
     2401 GTAGGGTCGG TTCTGACCTT TTGTTTTTAT GGGGCATCTG GGGATTGAAC TCAGCTGGCT 
            
  ARE-1 
     2461 TTTGTGACAA GTACTTCACC CGCTGCACCA CCTTACCGGC CCTTTTATTT ATTATGTATG 
 
             ARE-2 
     2521 TGGTCATGTT CACACACATG TATTTAACCT ATAGAATGCT TACTGTGCGT CGGGCGCTGC 
 
     2581 TCCAACTGCT GTATAAATAT TAAGGTATTC AGTTACTCCT ACTGGAAGGT ATTATGTAAC 
 
             ARE-3 
     2641 CATTTCTCTC TTACATCGGA GGACACCACC GAGCTATCCA CTCATCAAAC ATTTATTGTG 
 
                  ARE-4 
     2701 AGCATCCCTA GGGAGCCAGG CTCTCTACTG GGCATTAGGG ACAGAGGAAT TTATTGGATG 
 
     2761 TTGGTTCTTC CTTCAAGAAT CGCTCAGGGA TTCTCAGTGT CCTCAAAACA TGCTGAAACC 
 
     2821 GGACCCCAGA CTCCACTCTG GAGAATCCAA CCCACTCACA GGGGAAACAG CCCGTTTAAA 
 
     2881 GTGCATGTGT GCTAGAGAGG TAGGGTAGCC GAGATGATCC CTCAGTGGAA GGATAACCAA 
 
     2941 GTATCTTCCT CGGACACTCT TTTTTAAATA AATGAATAAA TGAAAA 
 
Figure 14. Sequence of the 3´-UTR of the rat MMP-9 gene (GenBank
TM accession no U24441). Potential ARE binding sites involved in the 
posttranscriptional regulation of MMP-9 mRNA are depicted in boxes. The numbers of ARE were used to distinguish between the different 
ARE motifs within the MMP-9 UTR. The underlined sequence indicate the region encompassed by the RNA oligonucleotides used for 
EMSA.  
 
The impact of this region on changes in mRNA stability by NO was investigated by transient 
transfection of a luciferase reporter gene driven by a 1.3 kb fragment of the rat MMP-9 
promoter either containing the 3´-UTR of MMP-9 downstream of the luciferase reporter gene 
(3´-UTR-MMP-9pGL3MMP-9-1.3 kb) or no additional 3´-regulatory sequences (pGL3-
MMP-9-1.3 kb). Therefore, the final luciferase activity measured in MC transiently 
transfected with luciferase constructs bearing the 3´-UTR of MMP-9 is not only the result of 
the activity of the passenger MMP-9 promoter but in addition will depend on the stability of 
luciferase mRNA regulated by the 3´-UTR of MMP-9. Transient transfection of MC with 
pGL3MMP-9-1.3 kb was followed by a 24-h treatment with either vehicle, IL-1ß (2 nM),    Results 
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DETA NONOate (500 µM) or IL-1ß plus DETA-NONOate. Stimulation of MC with IL-1ß (2 
nM) lead to a significant increase of MMP-9 promoter activity (2.4 –fold, p≤0.05) while NO 
had only weak modulatory effects on either cytokine-stimulated (3.1 –fold, p≤0.01) or basal 
(1.8 –fold, p≤0.05) MMP-9 promoter activities (Fig. 15A). Most interestingly, the same 
promoter construct under additional control of the 3´-UTR of MMP-9 displayed a strong 
reduction on MMP-9 promoter activity since the basal (6.2 –fold reduction, p≤0.01) as well as 
cytokine-induced MMP-9 promoter activity (2.1 –fold reduction, p≤0.01) was markedly 
reduced by addition of the NO donor (Fig. 15B). It is important to note that the basal promoter 
activity was higher in the 3´-UTR-MMP-9 pGL construct (2.42 RLU ± 0.54 compared to 0.32 
RLU ± 0.02) which presumably results from the increase in mRNA stability confered by this 
regulatory region. The stronger inhibitory effects of NO on basal and IL-1ß-mediated 
luciferase activity suggests that NO can counteract the positive effects of IL-1ß on MMP-9 
promoter activity only in the presence of the MMP-9-specific 3´-UTR. The negative 
posttranscriptional effects also exerted by endogenously produced NO observed upon IL-1ß 
stimulation may explain the weak induction of 3´-UTR-MMP-9-pGL3MMP-9-1.3 kb by IL-
1ß in comparison to that observed with the pGL3MMP-9-1.3 kb construct (Fig. 15A and 
15B). Furthermore, we tested whether the 3´-UTR of MMP-9 under control of a foreign 
promoter was still able to confer a NO-dependent negative regulatory function on  luciferase 
gene expression. To this end, we chose the pGL3 control vector which contains the luciferase 
gene under the control of the constitutively active SV 40 promoter and enhancer sequences, 
confering a strong expression of luciferase when transfected into mammalian cells. A main 
advantage of this plasmid is that it displays a significant basal promoter activity without 
responding to cytokine stimuli. Therefore this reporter gene is most useful for monitoring the 
contribution of 3´-UTR regions on mRNA stability in the absence of any influence of an 
inducible enhancer region. Transient transfection of MC with 3´-UTR –MMP-9 pGL3-control 
comprising 600 bp of the MMP-9 3´-UTR downstream from the luciferase coding region     Results 
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Figure 15. Influence of the 3´-UTR of MMP-9 on the MMP-9 promoter driven luciferase activities. Subconfluent MC were transiently 
cotransfected with 0.4 µg of pGL-MMP-9 (1.3) (A) or alternatively with 0.4 µg of 3´-UTR-MMP-9 pGL-MMP-9 (1.3) (B) containing 
additionally the 3´-UTR of MMP-9 downstream of the luciferase coding sequence. In each transfection 0.1 µg of pRL-CMV coding for 
Renilla luciferase was simultaneously added. After an overnight transfection MC were treated for 24 hours with vehicle (control) or with IL-
1ß (2 nM) in presence or absence of DETA NONOate (500 µM) as indicated. The values for beetle luciferase were related to values for 
Renilla luciferase and are depicted as relative luciferase activities. Data (means ± SEM) represent the results of three different experiments. 
P=0.05 and P=0.01  compared with control conditions (*) and (**) or to IL-1ß-stimulated values (##). P=0.01  
 
followed by a 24h treatment with DETA-NONOate (500 µM) resulted in a significant 
reduction of the basal promoter activity (53 % reduction, p≤0.05) of 3´-UTR-MMP-9 pGL3 
control promoter (Fig. 16B) whereas the basal promoter activity of the same promoter (pGL3-
control) but without the 3´-UTR of MMP-9 was not significantly affected by DETA 
NONOate  (Fig. 16A). Taken Taken together these data indicate that the 3´-UTR of MMP-9 is 
a target of NO-mediated mRNA destabilization.  
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Figure 16. Influence of the 3´-UTR of MMP-9 on SV-40 driven Luciferase activities. Subconfluent MC were transiently cotransfected with 
0.4 µg of empty pGL3-control vector (A) or with 0.4 µg of 3´-UTR-MMP-9 pGL3-control (B) containing additionally the 3´-UTR of MMP-9 
downstream of the luciferase coding sequence. Each plasmid was cotransfected with 0.1 µg of pRL-CMV used to equilibrate differences in 
transfection efficiencies. After transfection MC were treated for 24 hours with vehicle or with DETA NONOate (500 µM) as indicated. 
Values for beetle luciferase were related to values for Renilla luciferase and are depicted as relative luciferase activities. Data (means ± 
SEM) represent the results of three different experiments. P=0.05 compared with control conditions (#).  
 
 
Nitric oxide inhibits constitutive complex formation of AU-rich motifs (AREs) within the 
3´-UTR of MMP-9  
The stability of most short-lived mRNAs is modulated through the specific binding of 
proteins to the AU-rich motifs (AREs) present in the 3´-untranslated region (UTR) of these 
mRNAs [Chen and Shyu,1994;  Ford et al., 1999; Ross, 1995.]. To elucidate whether i) the 
motifs within the 3´-UTR of MMP-9 display any RNA binding capacity and ii) RNA binding 
could be affected by treatment of MC with NO, we performed RNA gel shift assays using 
32P-
labeled RNA oligonucleotides comprising the different AREs of MMP-9 denoted as ARE-1, 
ARE-2, ARE-3 and ARE-4 (Table 3). MC were either left untreated or treated for 4 h with 
different concentrations of DETA NONOate before being lysed for preparation of cytosolic 
fractions. We found that the cytosolic extracts of MC contained proteins which formed two 
major constitutive complexes of high electrophoretic mobility (Fig. 17, C1 and C2) with the 
ARE 1, ARE-2 and ARE 4 containing oligos but no complex binding to the oligonucleotide 
encompassing ARE-3 (data not shown). Although each of the four motifs consist of a single     Results 
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Figure 17 (A). DETA NONOate inhibits the constitutive RNA binding of cytoplasmic complexes to different ARE motifs from the 3´-UTR 
of MMP-9 .RNA binding was analyzed by EMSA using gene specific oligonucleotides (Table 3). MC were either left untreated (-) or 
stimulated for 4 hours with the indicated concentrations of DETA NONOate before being lysed for preparation of cytoplasmic extracts. 
Equal amounts of cytoplasmic extracts were incubated with a 
32P-labeled RNA probe derived from the corresponding AU-rich region of the 
3´-UTR of rat MMP-9 (UTR-ARE-1,UTR-ARE-2 and UTR-ARE–4) and RNA binding assessed by using 6.0 % native PAGE gels. C1 and 
C2 indicate two main complexes constitutively binding to UTR-ARE-1, UTR-ARE-2 and UTR-ARE-4. The results shown in each panel are 
representative for three independent experiments giving similar results. 
 
AUUUA pentanucleotide core sequence the composition of the 5´- flanking bases differs. 
Whereas ARE –1,-2 and ARE-4 are flanked by an upstream uracil or adenosine, ARE-3 at the 
3´-position is flanked by the pyrimidine base cytosine (Table 3). A recent study elucidating 
the polymorphism of the 3´-UTR of TNFα mRNA has demonstrated the complexity of 
different HuR binding motifs [Di Marco et al., 2001]. Most interestingly, treatment of MC 
with DETA NONOate dose-dependently attenuated the constitutive RNA binding to all 
MMP-9-specific ARE motifs and a weak but significant reduction is seen already with a 
concentration of 100 µM DETA NONOate. Maximal inhibition was observed with a 
concentration of 500 µM DETA NONOate (Fig. 17A). Similar results were obtained with the 
NO-donor SNAP (data not shown). To further evaluate whether the observed inhibitory 
effects of NO on ARE binding are of physiological relevance, MC in addition to NO donating 
compounds, were alternatively treated with IL-1ß (2 nM), a potent activator of iNOS 
expression in rat MC [Pfeilschifter and Schwarzenbach, 1990]. Therefore MC were incubated 
in the presence or absence of the NOS inhibitor L- NMMA. MC were stimulated for 24 hours 
to ensure a high level of nitric oxide produced by the cells in response to IL-1ß [Kunz et al.,  
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Figure 17 (B).  Cytokine-mediated inhibition of constitutive RNA binding to different MMP-9-specific AREs is attenuated in the presence 
of L-NMMA. MC were either left untreated (control) or stimulated for 24 hours with IL-1ß (2 nM), L-NMMA (2 mM),  or both in 
combination as indicated before being collected for extraction. Equal amounts of cytoplasmic extracts were incubated with the 
32P-labeled 
RNA probes specific for the 3´-UTR of rat MMP-9 depicted in Table 3. The conditions used for EMSA were described in A. The result 
shown is a representative experiment out of three giving similar results. 
 
1994]. Treatment with IL-1ß (2 nM) resulted in a marked attenuation of constitutive RNA 
binding of the cytosolic fractions to the ARE-1, ARE-2 and ARE-4 motifs (Fig. 17B). In 
contrast, the two main complexes C1 and C2 from MC simultaneously treated with IL-1ß and 
L-NMMA retained a high constitutive RNA binding to ARE-1, ARE-2 and ARE-4 motifs 
whereas L-NMMA alone had no effects on the basal constitutive RNA binding capacities to 
any of the MMP-9-derived ARE probes (Fig 17B). These data indicate that NO, either given 
from an exogenous source or endogenously produced by the iNOS, potently inhibits the 
constitutive binding of complexes formed with AUUUA motifs from the 3´- UTR of the rat 
MMP-9 gene. 
 
Complexes interacting with the ARE motifs of the 3´-UTR of MMP-9 contain the ELAV-
like protein HuR (HuA) but no other members of the Hu protein family   
In search for potential proteins possibly involved in the regulation of mRNA turnover we 
focused on the ELAV-like RNA binding protein HuR (HuA) which is able to specifically 
interact with AU- rich elements found in the 3´ UTR of many genes [Ma et al., 1996]. To test 
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Table 3.  RNA oligonucleotides comprising the different AREs of MMP-9 denoted as  
ARE-1, ARE-2, ARE-3 and ARE-4. 
 
UTR-ARE-1   2500   5´-CCCUUUUAUUUAUUAUGUAUG-3´ 2520  
UTR-ARE-1mut  2500 5´-CCCUUUUGGGCCUGAUGUAUG-3´ 2520 
UTR-ARE-2   2536 5´-ACAUGUAUUUAACCUAUAGAA-3´ 2556 
UTR-ARE-3   2683 5´-CAUCAAACAUUUAUUGUGAGC-3´ 2704 
UTR-ARE-4   2742  5´-CAGAGGAAUUUAUUGGAUGUU-3´ 2762 
 
whether members of the Hu protein family were present in the complexes bound to the ARE 
motifs of the 3´-UTR of MMP-9, we performed supershift analysis using antibodies 
recognizing specific epitopes within the murine and rat Hu proteins, respectively. 
Furthermore, to exclude the possibility that the complex seen in the EMSA resulted from 
unspecific binding of any protein present in the extracts we additionally tested the effects of 
an antibody raised against the p65 subunit of the DNA binding transcription factor NF-κB  
Most interestingly, addition of the anti-HuR antibody resulted in a complete disappearance of 
the complexes C1 and C2 and the concomitant formation of two supershifted complexes (Fig. 
18A, “UTR-ARE-1”). In contrast, addition of anti-HuB, anti-Hu-C, anti-Hu-D or anti-p65 
(NF-κB) antibodies did not affect the constitutive RNA binding of C1 and C2 complexes (Fig. 
18A). Supershift analysis with the UTR-ARE-2- and UTR-ARE-4-specific oligonucleotides 
similar to the supershifts obtained with UTR-ARE-1 caused a complete disappearance of both  
constitutive bound complexes upon addition of the anti-HuR antibody (Fig. 18A, “UTR-ARE-
2”, “UTR-ARE-4”) although incubation with the UTR-ARE-2 containing oligonucleotide in 
some experiments caused no supershifted bands (Fig. 18A; “UTR-ARE-2”). Similar to the 
supershifts obtained with the UTR-ARE-1 oligonucleotide addition of anti-HuB, anti-Hu-C, 
anti-Hu-D or anti-p65 (NF-κB) did not affect the RNA-binding to UTR-ARE-2 or UTR-ARE-
4-specific probes (Fig. 18A). These data indicate that in MC the ubiquitously expressed    Results 
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ELAV-protein HuR, but not the Hu-family relatives Hu-B, Hu-C, and Hu-D, is the main 
constituent of complexes binding to AU-rich motifs of the 3´-UTR of MMP-9. Furthermore, 
the specificity of RNA-bound complexes present in the cytoplasmic extracts of MC was 
underlined by competition assays using wild-type or mutant UTR-ARE-1 oligonucleotides 
depicted in Table 3. For competition analysis different dilutions (1:10, 1:20, 1:100, 1:500) of 
either unlabeled wild-type or mutant UTR-ARE-1 oligonucleotide were added to the binding 
reaction 1h prior to the addition of the radiolabeled UTR-ARE-1 probe. As shown in Fig. 18B 
competition with the nonlabeled wild type oligo (“UTR-ARE-1wt”) prevented binding of 
complex C1 when dilutions of 1:10, 1:20, and 1:100 of competitor wild-type oligonucleotide 
were added whereas binding of C2 was only weakly competed. In contrast, competitions with 
the unlabeled mutant oligonucleotide (“UTR-ARE-1 mut”) in none of the dilutions tested 
were able to compete with the RNA binding to the radioactively labeled wild-type 
oligonucleotide. These data demonstrate that the AUUUA motif is necessary for retaining a 
full competition capacitiy of RNA binding. Similarly to UTR-ARE-1 RNA binding to UTR-
ARE-2 and UTR-ARE-4 probes was competed by addition of cold wild-type ARE-1 
competitor oligonucleotide suggesting a high redundancy between the different ARE motifs 
of 3´-UTR of MMP-9 (data not shown). 
          
Recombinant HuR protein strongly binds to ARE-motifs of the 3´-UTR of MMP-9 
In a next experiment we tested the  RNA binding capacity of recombinant GST-coupled HuR 
protein to different ARE-motifs of the 3´-UTR of MMP-9. For EMSA 100 ng of GST-HuR 
was incubated with the radioactively labeled UTR-ARE-1, UTR-ARE-2 or UTR-ARE-4 
oligonucleotides, respectively As shown in Fig. 18C GST-HuR formed one major complex 
with similar migration properties independent of which UTR-ARE oligo was used  in the 
binding reaction. Similar to the findings obtained by EMSAs with cytoplasmic fractions,     Results 
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Figure 18.(A)  HuR (HuA) is the main constituent of RNA-binding complexes within the cytoplasmic extracts of MC and binds with a high 
affinity to AU-rich elements of the 3´-UTR of MMP-9. For supershift analysis the 
32P radiolabeled UTR-ARE-1, UTR-ARE-2 and UTR-
ARE-4 comprising oligonucleotides were incubated with 6 µg of cytoplasmic extract derived from resting MC in the presence or absence of 
different supershift antibodies indicated. The antibodies were added 15 min after addition of the radiolalabeled oligonucleotide and incubated 
for a further 15 min at room temperature. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18 (B) Competition capacities of wild type and mutant UTR-ARE-1 oligonucleotides. The gel shows a representative competition 
study using different dilutions (as indicated) of either unlabeled wild type (UTR-ARE-1wt) or unlabeled mutated ARE-1 (UTR-ARE-1 mut) 
oligonucleotides (the sequences are shown in Table 3). The unlabeled competitor oligonucleotides were added 60 min before the addition of  
32P-labeled UTR-ARE-1 wt oligonucleotide. 
 
addition of an HuR-specific antibody caused a complete disappearance of the RNA-bound 
complex and appearance of two supershifted  complexes with reduced migration properties 
whereas antibodies specifically raised against HuB, HuC, HuD or p65 (NF-κB) did not affect 
the RNA binding of GST- HuR (Fig. 18C).   
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Figure 18 (C). GST-HuR binds with a high affinity to AU-rich elements of the 3´-UTR of MMP-9. EMSA analysis demonstrating that 
recombinant GST-HuR protein binds with a high affinity to ARE-elements of the 3´-UTR of MMP-9. For EMSA 200 ng of purified crude 
protein (GST-HuR) were incubated with the indicated oligonuclotides specific for different AREs of MMP-9 as described in table 3. For 
supershift analysis the 
32P radiolabeled UTR-ARE-1, UTR-ARE-2 and UTR-ARE-4 comprising oligonucleotides were incubated with the 
same amount of GST-HuR protein and 200 ng of supershift antibody as indicated. The antibodies were added 15 min after addition of the 
radiolabeled oligonucleotide and incubated for a further 15 min at room temperature. Similar results were obtained in three independent 
experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18 (D) EMSA analysis demonstrating that recombinant GST-HuR protein binds with a high affinity to ARE-elements of the 3´-UTR 
of MMP-9, whereas GST alone has only a weak unspecific RNA binding affinity. 
 
These data document the high level of binding affinity of HuR to AREs of the 3´-UTR of 
MMP-9. In contrast to GST-HuR, the same amount of GST alone displayed only a very weak 
RNA binding independent of the ARE-motif used as probe (Fig. 18D). In summary, these data 
demonstrate that the ELAV-like protein HuR strongly can bind to AU-rich elements within 
the 3´-UTR of MMP-9.  
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The cytoplasmic fractions of NO-treated MC affect MMP-9 mRNA turnover  
To further prove that the treatment of MC with exogenous NO correlates with the increased 
MMP-9 mRNA turnover we performed in vitro degradation assays. By this assay the time 
course of MMP-9 mRNA degradation exhibited by any trans-acting factor accumulated in the 
cytoplasmic extracts of MC treated for 4h with DETA NONOate (500 µM) was compared to 
the degradation profile derived from the incubation with cytoplasmic extracts from untreated 
MC. To this end, similar volumes of each extract (with a total protein content of 130 µg) were 
incubated with equal amounts of total RNA isolated from a common pool of cytokine-treated 
MC. Northern blot analysis performed after a second RNA isolation step revealed that 
primary undegraded MMP-9 transcripts exposed to the cytoplasmic fractions from NO-treated 
MC displayed an accelerated degradation when compared to the transcripts which had been 
exposed to cytoplasmic extracts from untreated cells (Fig. 19A). The differences in MMP-9 
mRNA stability are clearly seen by the different time course of MMP-9 mRNA decay (Fig. 
19A). 
 
 
 
 
 
Figure 19 (A). HuR protects MMP-9 mRNA from a rapid decay within the cytoplasmic fractions of MC. For in vitro degradation assay 
portions of 20 µg of total RNA from a common pool of total RNA isolated from cytokine-stimulated MC were mixed with 130 µg of 
cytoplasmic extract derived from either untreated (vehicle) or alternatively, from MC treated for 4 hours with (+) DETA NONOate (500 µM) 
as indicated. After different time points (time in minutes) incubations were stopped by isolation of total RNA. RNA samples were collected 
and assessed for the amounts of remaining  MMP-9 mRNA level by Northern blot analysis using a 
32P-labeled cDNA insert specific for rat 
MMP-9. Furthermore, the blots were rehybridized with a 
32P-labeled cDNA from GAPDH to prove equivalent mRNA amounts. The lower 
panel show a densitometric analysis of MMP-9-specific signals. Similar results were obtained in three independent experiments. 
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Additionally, the blot was rehybridized with a GAPDH-specific cDNA probe since the rat 
GAPDH mRNA contains no typical AU-rich elements within its 3´-UTR. In contrast to 
MMP-9, the level of GAPDH mRNA remained unchanged thus indicating that the changes in 
mRNA stability were specific for MMP-9 mRNA (Fig. 19A). Furthermore, these data suggest 
that endonucleolytic cleavage of MMP-9 transcripts is specifically attributable to factors 
predominantly present (or absent) in the cytoplasmic extracts of NO-treated MC. 
 
Neutralization of HuR leads to an accelerated decay of MMP-9 mRNA in an in vitro 
degradation assay 
As shown by RNA EMSAs the mRNA stabilizing protein HuR is a main constituent of the 
complexes constitutively bound to MMP-9-specific ARE motifs. To prove the functional 
relevance of HuR in MMP-9 mRNA stabilization we investigated by an in vitro degradation 
assay whether the half-life of MMP-9 mRNA is modulated by addition of a neutralizing anti-
HuR antibody. To this end, cytoplasmic fractions from untreated MC were preincubated for 
1h with a monoclonal anti-HuR antibody (a total amount of 400 ng antisera) and mixed with 
the total RNA from cytokine-treated MC for a further 60 min. As a negative control the same 
volume of mouse control serum was added to the cytoplasmic fractions instead of the antisera 
and also pretreated for 60 min. Additionally, to check for direct effects of the NO donors we 
tested whether cytoplasmic extracts derived from untreated MC but treated with NO after 
extraction procedures affect on the stability of MMP-9 mRNA. As demonstrated in Fig. 19B 
the degree of MMP-9 mRNA decay is increased when the cytoplasmic extracts had been 
pretreated with the neutralizing anti-HuR antibody (Fig. 19B, + anti-HuR (mAb) ) whereas 
the mouse control serum on its own had no modulatory effects on the MMP-9 mRNA decay 
(Fig. 19B, + mouse serum). Similarly, extracts isolated from untreated cells which had been 
incubated with DETA NONOate after extraction had no modulatory effect on the MMP-9 
mRNA amount (Fig. 19B, +DETA-NONOate). MMP-9 mRNA were exclusively confered by     Results 
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Figure 19 (B) The degradation of cytokine-induced MMP-9 transcripts is accelerated by a neutralizing anti-HuR antibody. Portions of 20 µg 
of total RNA from a common pool of total RNA isolated from cytokine-stimulated MC were mixed with 130 µg of cytoplasmic extract 
derived from untreated cells.The cytoplasmic extracts were kept either untreated (vehicle), or pretreated for 1 hour alternatively, with 0.4 µg 
of a monoclonal anti-HuR antibody (vehicle + anti-HuR) or with the same volume of vehicle (vehicle + mouse serum), or with DETA 
NONOate (500 µM) (vehicle + DETA NONOate) before the cytoplasmic extracts were incubated with the total RNA portions. Incubation 
with the RNA was stopped after 60 min before RNA was extracted for further Northern blot analysis. Samples derived from one cytoplasmic 
extract were subjected to RNA in duplicates. Furthermore, the blots were rehybridized with a 
32P-labeled cDNA from GAPDH to prove 
equivalent mRNA amounts. The lower panel shows a densitometric analysis of MMP-9-specific signals. The result shown is a representative 
experiment out of three giving similar results. 
 
 
 
 
 
 
 
 
 
Figure 19 (C) Neutralization of HuR but not that of other Hu family members leads to a reduction in  MMP-9 mRNA stability. Portions of 
20 µg of total RNA isolated from cytokine-stimulated MC were mixed with 130 µg of cytoplasmic extract derived from untreated cells.The 
cytoplasmic extracts were kept either untreated (vehicle), or pretreated for 1 hour with 0.4 µg of the Hu-specific antibodies as indicated 
before the cytoplasmic extracts were incubated with the total RNA portions. Incubation with the RNA was stopped after 60 min before RNA 
was extracted for Northern blot analysis. Samples derived from one cytolasmic extract were subjected to RNA in duplicates. To prove 
specificity of the effects on MMP-9 mRNA blots were rehybridized with a 
32P-labeled cDNA from GAPDH. Similar results were obtained in 
two independent experiments. 
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HuR but not by other proteins of the ELAV- family (Fig, 19C). Finally, we tested  whether 
the addition of recombinant HuR protein could modulate the stability of MMP-9 transcripts in 
the in vitro degradation assay As shown in Fig. 19D addition of GST-HuR protein (200ng) 
markedly inhibited the mRNA decay of MMP-9  (Fig. 19D; GST-HuR, 2h) whereas the 
addition of GST alone (200 ng) had no protective effects on the MMP-9 mRNA decay (GST, 
2h).  
 
 
 
  
 
 
 
 
Figure 19 (D) GST-HuR protein protects MMP-9 mRNA from rapid decay. 20 µg of total RNA from cytokine-stimulated MC were mixed 
with 130 µg of cytoplasmic extract derived from untreated MC in the absence (vehicle) or presence of 200 ng of GST-HuR (GST-HuR) or 
GST (200 ng). After the indicated time points (0h and 2h) incubations were stopped by isolation of total RNA. Subsequently the RNA was 
assessed by Northern blot analysis using a MMP-9-specific probe. Furthermore, to prove specificity of the decay of MMP-9 mRNA blots 
were rehybridized with a 
32P-labeled cDNA from GAPDH . 
 
Nitric oxide reduces HuR protein and mRNA levels  
To further evaluate whether the reduction of HuR RNA binding caused by NO is due to a 
decrease in the amount of total HuR protein we performed Western blot analysis using the 
same monoclonal anti-HuR antibody used for supershift analysis. According to the time-
course of NO-dependent MMP-9 mRNA decay (Fig. 13), MC were stimulated for 4 h with 
different concentrations of the NO donor DETA NONOate before cells were lysed for 
Western blot analysis. MC were found to express constitutively high levels of HuR protein. 
Interestingly, in addition to a major band migrating at 34 kDa the antibody detected a second 
minor band at 32 kDa which indicates a possible posttranslational modification of HuR.  
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Figure 20. Inhibition of HuR expression in MC by different NO donors. MC were treated for 4 hours with different concentrations of either 
DETA NONOate (left panel) or SNAP (right panel) before cells were lysed for Western blot analysis  50 µg of total protein were subjected 
to Western blot analysis using a monoclonal antibody raised against full length HuR. Migration properties were determined using standard 
molecular weight markers. The Western blots shown in A were stripped and rehybridized to assess total ß-actin levels as a control for sample 
loading and protein transfer. Similar results were obtained in two independent experiments  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20 (B) Northern blot analysis demonstrating a dose-dependent modulation of HuR mRNA steady-state level by different NO donors. 
Total cellular RNA (20 µg) was hybridized to a 
32P-labeled cDNA insert from the plasmid “HuR9” and analyzed by Northern blot analysis. 
Equivalent loading of RNA was ascertained by rehybridization to a 18 S ribosomal probe. The blot shown is representative for two 
independent experiments giving similar results.  
 
Expression of HuR was dose-dependently reduced by DETA NONOate with a maximal 
inhibition seen with 500 µM DETA NONOate (Fig. 20A, left panel). Similar to DETA 
NONOate, treatment of MC with SNAP, a chemically different NO donor, caused a dose- 
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dependent reduction of the HuR reactive bands (Fig. 20A, right panel). Furthermore, to 
determine whether the reduction of HuR protein was due to a decrease in the amount of the 
corresponding HuR mRNA, we performed Northern blot analysis using a probe from the 
human HuR cDNA [Ma et al., 1996]. As shown in Fig. 20B, both NO donors, DETA 
NONOate (left panel) and SNAP (right panel), dose-dependently attenuated the basal steady-
state HuR mRNA level with a maximal inhibition achieved with 500 µM of each NO donor 
(Fig. 20B). These data demonstrate that the NO-mediated alterations in HuR RNA binding 
predominantly result from the changes in the HuR expression levels.   
 
Endogenously  produced nitric oxide  inhibits the steady-state mRNA and protein levels of 
HuR 
We recently have demonstrated that NO either given by exogenous sources or  endogenously 
produced by the cytokine-evoked iNOS expression can reduce the cytokine-induced MMP-9 
level [Eberhardt et al., 2000a]. To test whether endogenously produced NO also is able to 
inhibit the constitutive level of HuR, MC were treated for 24h with IL-1ß in the presence or 
absence of the NOS inhibitor L-NMMA. Measurement of nitrite, the stable endproduct of NO 
formation, in cell supernatants has revealed that the amounts of NO produced by the IL-1ß-
stimulated MC are in the range released by the NO donors DETA NONOate and SNAP 
[Eberhardt et al., 2000a]. Stimulation of MC with IL-1ß caused a marked reduction of the 
basal HuR protein and mRNA levels as shown in Fig. 21A and Fig. 21B, respectively. The 
reduction of HuR mRNA level by IL-1ß was abrogated in the presence of the NOS inhibitor, 
which by its own had no effects on basal HuR levels (Fig. 21). These findings demonstrate 
that the cytokine-mediated attenuation of HuR expression depends on mesangial iNOS 
activity. 
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Figure 21. Cytokine-mediated inhibition of steady-state level of HuR mRNA (A) and protein (B) is blocked in the presence of the NOS 
inhibitor L-NMMA. Quiescent MC were treated for 24 hours with vehicle (control), IL-1ß (2 nM), L-NMMA (2 mM) or both in combination 
as indicated before being harvested for either total RNA isolation (A) or Western blot analysis (B) (A). 20 µg of total RNA was hybridized to 
a 
32P-labeled cDNA insert from the plasmid “HuR9” and analyzed by Northern blot analysis. Equivalent loading of RNA was ascertained by 
rehybridization to a 18 S ribosomal probe. The blot shown is representative for two independent experiments giving similar results. (B). 50 
µg of total protein were subjected to Western blot analysis using a monoclonal HuR-specific antibody. The Western blot shown in B was 
stripped and rehybridized to assess the total ß-actin levels as a control for sample loading and protein transfer. 
 
NO-mediated effects on HuR expression are mimicked by cGMP and depend on 
endogenous guanylyl cyclase activity 
A broad spectrum of physiologic actions exerted by NO depends on the generation of cGMP 
and is mechanistically linked due to an activation of guanylyl cyclase through the direct 
binding of NO to the enzyme´s prosthetic heme group [for review see Schmidt and Walter, 
1994]. To elucidate whether the inhibiton of HuR expression by NO is mediated by cGMP we 
tested for effects of the membrane-permeable analog 8-Bromo-cGMP. Similar to the NO 
donors, 8-Bromo cGMP in a dose-dependent manner reduced the total protein content of HuR 
with the maximal effect observed with 1 mM 8-Bromo-cGMP (Figure 22A). Concomitantly, 
8-Bromo-cGMP dose-dependently reduced the steady-state level of HuR mRNA (data not 
shown). Finally, we elucidated whether the NO-mediated inhibitory effects on HuR 
expression depend on cGMP generation. Therefore, we tested whether NO could still reduce 
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HuR expression in the presence of LY-83583 (500 nM), a specific inhibitor of  soluble 
guanylyl cyclase. As shwon in Fig. 22B, the reduction of HuR in DETA-NONOate-treated 
cells was strongly antagonized when cells were pretreated with LY-83583. LY-83583 had no 
effects on the basal HuR protein level (Fig. 22B). In summary, these data demonstrate that the 
reduction of HuR mRNA and protein steady-state level by NO primarily depend on the 
activity of guanylyl cyclase and the subsequent increase in cellular cGMP level.  
 
 
 
 
 
 
 
 
 
 
Figure 22: . (A). Suppression of cellular HuR level by 8-Bromo-cGMP.  MC were treated for 4 hours with vehicle (control, -) or with the 
different concentrations of the cGMP analog 8-Bromo-cGMP as indicated before cells were lysed. 50 µg of total protein were subjected to 
Western blot analysis using a monoclonal antibody raised against full length HuR. Migration properties were determined using standard 
molecular weight markers. (B). The reduction of HuR protein level by DETA NONOate is antagonized in the presence of the guanylyl 
cyclase inhibitor LY-83583. Quiescent MC were treated for 4 hours with vehicle (control, -), DETA NONOate (500 µM), LY-83583 (500 
nM) or both in combination as indicated before being harvested for preparation of total protein extracts. The level of total cellular HuR 
content was assessed with a monoclonal anti-HuR antibody. All Western blots were finally stripped and rehybridized to assess total ß-actin 
levels as a control for sample loading and protein transfer. Similar results were obtained in two independent experiments.  
 
Discussion 
MMP-9 is a protease which is critically involved in the regulation of ECM turnover and an 
imbalanced regulation is functionally correlated with numerous pathologic conditions 
associated with altered matrix turnover such as atherosclerosis, rheumatoid arthritis and 
fibrosis of lung, skin and kidney [for review see Brinckerhoff and Matrisian, 2002; Cawston, 
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1998; Davies et al.,1992]. Inflammatory cytokines such as IL-1ß and TNFα are among the 
most potent transcriptional inducers of MMP-9 gene expression, mainly through signaling via 
the MAP kinase pathway and triggering the activation of NF-κB and AP-1 transcription 
factors [Eberhardt et al., 2000b]. The free radical gas NO has been shown to modulate the 
expression and activity of different MMPs including MMP-9 [ Eberhardt et al., 2000a; 
Murrell et al., 1995;  Pfeilschifter et al., 2001; Trachtman et al., 1996;  Zaragoza et al., 2002]. 
In this study we demonstrate that posttranscriptional mechanisms account for the NO-
mediated inhibition of MMP-9 expression in rat MC. Using actinomycin D experiments we 
found that exogenously applied NO as well as endogenously produced NO significantly 
accelerates degradation of MMP-9 mRNA [Eberhardt et al., 2002b]. Furthermore, we 
demonstrate that cytoplasmic extracts derived from NO-treated MC displayed increased 
degradative properties upon MMP-9 mRNA transcripts when compared to the effects of 
cytosolic fractions from untreated cells. Similar to MMP-9, a recent study has demonstrated a 
NO-dependent attenuation of basal and angiotensin II-stimulated expression of transforming 
growth factor ß-3 by increased destabilization of the corresponding mRNA [Abdelaziz et al., 
2001]. However, the underlying mechanisms of the NO-evoked mRNA decay had not been 
further characterized.  Increasing evidence has accumulated demonstrating that selective 
mRNA turnover plays an important role in the tight control of eukaryotic gene expression 
[Brennan and Steitz, 2001;  Chen and Shyu, 1995; Fan and Steitz, 1998; Grzybowska et al., 
2001; Ma et al., 1996]. Regulation of mRNA stability has been demonstrated to contribute to 
the strong and rapid changes of RNA abundance observed mainly for genes of the 
inflammatory- and stress-induced response, among them mRNAs coding for TNFα [Biragyn 
and Nedospasov, 1995; Dean et al., 2001], IL-2 [Bohjanen et al., 1991; Henics et al., 1994], 
IL-3 [Nair et al., 1994], IL-8 [Stoeckle, 1991;  Villarete and  Remick, 1996], c-Fos [Chen et 
al., 1995; Perez-Sala et al., 2001], c-Myc [Dani et al., 1985, Rabbitts et al., 1985], cyclin A 
and B1 [Wang et al., 2000], granulocyte/macrophage colony stimulating factor (GM-CSF)    Results 
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[Aharon and Schneider, 1993; Chen et al., 1995], vascular endothelial cell-derived growth 
factor (VEGF) [Levy et al., 1996], cyclooxygenase-2 (COX-2) [Dixon et al., 2001], and iNOS 
[Perez-Sala et al., 2001; Rodriguez-Pascual et al., 2000] just to name a few of them. The 
complex processes of transcript degradation in most cases includes a poly (A)-shortening 
endonucleolytic cleavage which is controlled by trans-acting factors binding to the cis-acting 
elements within the 3´-UTR of mRNAs [Chen and Shyu, 1994; Grzybowska et al., 2001; 
Ross, 1995; Xu et al., 1997]. Therefore, the half-lifes of most mRNAs are influenced by this 
region. We demonstrate that the 3´-UTR of MMP-9 confers a NO-dependent reduction of 
basal and cytokine-induced MMP-9-driven luciferase activity when fused downstream of the 
luciferase reporter gene. Similarly, the 3´-UTR of MMP-9 was able to convey a negative NO 
responsiveness to a constitutively active luciferase gene when fused downstream of the 
luciferase coding sequence. From these data it becomes evident that the reduction of 
luciferase activities induced by NO is conferred by the 3´-UTR of MMP-9. A common feature 
of most short-lived mRNAs is the presence of AU-rich elements (AREs) which are considered 
as cis-regulatory determinants of RNA turnover [Chen and Shyu, 1994; Malter, 1989; Xu et 
al., 1997]. Also the 3´-UTR of MMP-9 contains several copies of the pentameric AUUUA 
motif. This sequence motif was initially described as a destabilizing determinant in the 3´-
UTR of GM-CSF [Aharon and Schneider, 1993; Chen et al., 1995] and the immediate early 
genes c-fos and c-myc [Chen et al., 1995; Rabbitts et al., 1985]. Meanwhile numerous ARE-
binding proteins have been implicated in mRNA turnover, among them proteins which can 
destabilize mRNA such as AUF1 [Zhang et   al., 1993] but interestingly also proteins which 
can reduce mRNA degradation, most prominently members of the embryonic lethal abnormal 
vision (ELAV) protein family [Levy et al., 1996; Ma et al., 1996; Peng et al., 1998]. By native 
RNA-EMSA we could identify HuR, an ubiquitously expressed member of the ELAV RNA-
binding proteins, exhibiting a strong constitutive RNA binding to three different ARE motifs 
(“MMP-9-ARE-1, MMP-9-ARE-2, MMP-9-ARE-4”) within the 3´-UTR of rat MMP-9.    Results 
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Interestingly, a fourth AUUUA repeat (“MMP-9-ARE-3”) did not display any binding 
affinity. Sequence comparison of the bases directly flanking the AUUUA pentamer indicates 
that the presence of a neighbouring uracil or adenosine base at the 3´-end of MMP-9-AREs 
seems critical for RNA binding. In line with these observations previous studies have 
suggested that AU-rich elements alone are necessary but not sufficient for mRNA 
destabilization and thereby underlined the importance of neighbouring sequences [Rodriguez-
Pascual et al., 2000]. Similar to externally expressed HuR protein the crude cytoplasmic 
extracts of MC displayed a strong constitutive RNA binding to MMP-9-specific AREs. The 
identity of these complexes was confirmed by supershift analysis using antibodies raised 
against different members of the Hu protein family. Interestingly, only addition of anti-HuR 
resulted in the shifting of all complexes and appearance of two supershifted complexes 
whereas antibodies against HuB, HuC and HuD had no effects. We observed the appearance 
of two supershifted complexes independent of the source of protein (recombinant vs. MC-
derived) used in the binding reaction. Obviously, HuR is the sole protein in both supershifted 
complexes and the different migration properties rather result from HuR oligomerization than 
from complexation with other ARE-binding proteins. Furthermore, we demonstrate that the 
constitutive RNA binding to MMP-9 ARE motifs by the HuR-containing complexes is 
drastically reduced in cells treated with different NO donors. Most importantly, these 
experiments displayed a dose-dependent reduction in RNA binding thus suggesting that RNA 
binding to the 3´-UTR of MMP-9 is susceptible even to low NO concentrations. Moreover, 
we prove the physiological relevance of these modulatory effects of NO on HuR binding as 
similar to exogenous NO, cytokine-treated MC exhibited a reduction in RNA binding 
dependent on endogenous NO formation. So far little is known about the mechanisms by 
which HuR can regulate mRNA stability. Unlike the other members of the ELAV family 
(HuB, HuC and HuD) which show a tissue-specific expression, HuR is ubiquitously 
expressed and shows a predominant nuclear distribution [Atasoy et al., 1998; . Dean et al.,    Results 
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2001  ; Peng et al., 1998]. However, a change of distribution between the nuclear and 
cytoplasmic compartment is considered as the main mechanism by which HuR can modulate 
mRNA decay [Ford et al., 1999;  Peng et al., 1998]. A previous study has demonstrated a 
downregulation of HuA in quiescent 3T3 fibroblasts but upregulated HuA levels after serum 
stimulation thus corroborating the important roles of ELAV proteins during cell growth and 
differentiation (Atasoy et al., 1998). Since we have chosen serum free preincubations for all 
experimental conditions it seems most unlikely that the rapid negative effects on HuR 
expression by NO or cGMP are indirectly due to negative growth effects. Recent studies have 
highlighted the role of the p38 MAP kinase pathway in the regulation of cytoplasmic HuR 
abundance [Winzen et al., 1999]. Using confocal fluorescence microscopy we found that HuR 
is most abundant in the nucleus and the nuclear distribution is not changed by treatment of 
MC with NO (W.Eberhardt and A.Huwiler, unpublished observations). In contrast, EMSA 
revealed that the RNA-binding properties exhibited by crude nuclear extracts were several 
times weaker than the RNA-binding exhibited by cytoplasmic fractions. These data suggest 
that although HuR is mainly localized in the nucleus, NO-mediated alterations in mRNA 
binding predominantly occur in the cytoplasmic compartment but are not attributable to a 
modulation of the nucleo-cytoplasmic shuttling properties of HuR. In this context, the recent 
finding that the AMP-activated kinase (AMPK) regulates the cytoplasmic HuR and 
consequently modulates the binding of HuR to its target mRNAs is of special interest [Wang 
et al., 2002]. Whether the activation of the AMPK or MAP kinase pathways is also involved 
in the regulation of MMP-9 mRNA turnover is currently investigated in our laboratory . Here 
we present an alternative mechanism by which a reduction of RNA binding is caused by the 
altered expression of HuR. We demonstrate that treatment of MC with different NO donors 
results in a significant reduction of the cellular HuR protein content. Furthermore, we found 
that the reduction in HuR protein is due to a reduction in the corresponding steady-state 
mRNA level. Similarly, the 24-hour exposure of cells to IL-1ß caused a significant reduction    Results 
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of HuR on both, the protein and mRNA level, and this reduction could be blocked by the NOS 
inhibitor L-NMMA thus indicating that the cytokine-mediated inhibition of HuR expression is 
triggered by NO. These data demonstrate that the reduced RNA binding of HuR 
predominantly results from a decrease in the HuR expression levels. Consistent with our 
findings, alterations of HuR expression also determine the half-life of COX-2 mRNA and 
change COX-2 synthesis in colon cancer cells [Dixon et al., 2001]. Furthermore, an aberrant 
expression of HuR was demonstrated in human teratocarcinoma cells [Antic et al., 1999] and 
malignant brain tumors [Nabors et al., 2001]. The most common intracellular messenger 
system activated by NO is the soluble guanylyl cyclase/cGMP system which is activated by a 
direct binding of NO to the prosthetic heme group of the enzyme [Schmidt and Walter, 1994]. 
We demonstrate that the NO-mediated reduction of constitutive HuR expression level can be 
mimicked by the cGMP analog 8-Bromo cGMP. Furthermore, we found that the NO-
dependent reduction of HuR is blocked in the presence of the specific guanylyl cyclase 
inhibitor LY-83583 thus demonstrating that the NO-mediated decrease in HuR expression 
depends on the activation of guanylyl cyclase and thus complements the mainly 
transcriptional regulation driven by NO in an cGMP-independent manner [Pfeilschifter et al., 
2001; Schmidt and Walter, 1994]. In conclusion, the experiments presented here demonstrate 
for the first time that the expression of MMP-9, in addition to a transcriptional regulation, is 
controlled by post-transcriptional mechanisms including the modulation of mRNA stability by 
the mRNA stabilizing factor HuR. Moreover, NO reduces in a cGMP-dependent manner the 
expression of HuR. Whether the decrease of HuR mRNA in turn is due to transcriptional or 
posttranscriptional mechanisms remains to be elucidated. The excessive accumulation of 
extracellular matrix is an important feature in the progression of fibrotic pathologies and is 
most likely due to a reduced expression of matrix-metabolizing enzymes. In this context the 
increased production of NO often accompanying inflammatory processes may have a    Results 
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causative role in the progression of fibrotic processes by altering matrix turnover via 
transcriptional as well as posttranscriptional mechanisms. 
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3. ATP potentiates IL-1ß-induced MMP-9 expression in mesangial cells via recruitment 
of the ELAV protein HuR 
 
Introduction 
The matrix metalloproteinases (MMPs) are members of a family of zinc-dependent 
endopeptidases which specifically degrade components of the extracellular matrix (ECM). 
Therefore, MMPs have mainly been implicated in various diseases accompanied with an 
altered turnover of ECM. Besides the altered synthesis of single ECM components the 
increased expression and/or activity of MMPs seems of paramount importance for 
pathological remodeling processes within the kidney such as acute proliferative 
glomerulonephritis [Edelstein et al., 1997;  Lenz et al., 2000]. Mainly the altered expression 
of MMP-2 and MMP-9, which are also denoted as gelatinases, is crucially involved in the 
progression of glomerular inflammatory processes [Lenz et al., 2000; Davies et al., 1992]. In 
addition to various inflammatory cytokines, the expression of MMP-9 can be activated by 
many other stimuli such as mitogens, growth factors, and activators of the Ras oncogene  [for 
review see: Woessner, 1991; Nagase and Woessner, 1999]. Although most of these stimuli 
can modulate gelatinolytic activity by influencing MMP-9 gene expression the regulation of 
MMP-9 activity is also achieved by the processing of the inactive proenzyme by the action of 
other proteases and by an inhibition of the active enzyme by its endogenous inhibitors, the 
tissue inhibitors of MMPs (TIMPs) [Woessner, 1991;  Nagase and Woessner, 1999]. 
Previously, we have demonstrated an additional mode of posttranscriptional regulation of 
MMP-9 which involves the reduction of cytokine-induced MMP-9 via reduction of mRNA 
stability exerted by exogenous and endogenously produced NO [Eberhardt et al., 2002b]. A 
variety of inducible genes including proto- oncogenes, transcription factors, cell cycle 
regulating proteins and cytokines have been demonstrated to be regulated by a modulation of 
mRNA turnover. Recent evidence has revealed that AU-rich sequences also denoted as AU-   Results 
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rich elements (AREs) located in the 3´-untranslated regions (UTRs) of these genes comprise 
specific cis-regulating elements which target mRNAs for rapid degradation [for review see: 
Chen and Shyu 1995; Ross, 1995; Fan and Steitz, 1998; Peng et al., 1998]. Several studies 
have identified proteins specifically binding to AREs, among them RNA stabilizing factors of 
the embryonic lethal abnormal vision (ELAV) protein family especially the ELAV-like 
protein HuR [Fan and Steitz, 1998; Peng et al., 1998; Brennan and Steitz, 2001]. 
Overexpression and subsequent binding of HuR was shown to result in an efficient 
stabilization of ARE-containing mRNAs in vivo [Fan and Steitz, 1998]. Besides the 
proinflammatory cytokines, MC are able to respond to a variety of other biological mediators 
including eicosanoids, growth factors, reactive oxygen species, NO and to extracellular 
nucleotides such as ATP and UTP [Pfeilschifter and Merriweather, 1993; Pfeilschifter et al., 
2003]. Previously, we have reported that in renal mesangial cells, extracellular ATP via the 
P2Y2 receptor can cause a mobilization of intracellular calcium  and subsequent activation of 
protein kinases C [Pavenstädt et al., 1993; Pfeilschifter and Huwiler, 1996]. The cellular long-
term responses towards ATP and UTP include a variety of pathophysiological key functions 
most importantly the inhibition of programmed cell death  and an increase in cell proliferation 
[Huwiler et al., 2002; Schulze-Lohoff et al., 1998; Huwiler and Pfeilschifter, 1994]. Both 
processes, cell proliferation and the excessive ECM degradation are hallmarks of many 
chronic progressive glomerular diseases [Edelstein et al., 1997; Lenz et al., 2000; Davies et 
al., 1992; Fogo, 2001]. For this reason we tested whether extracellular nucleotides can 
influence the expression of MMP-9 in MC. Our data provide the first report that ATP and 
UTP can potentiate the cytokine-induced expression and activity of MMP-9. Furthermore, we 
implicate modulation of the nuclear-cytosolic shuttling of the RNA stabilizing factor HuR in 
the posttranscriptional regulation of MMP-9 by extracellular nucleotides. 
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Results : 
Extracellular nucleotides potentiate IL-1ß-induced lytic activity and mRNA steady-state 
levels of MMP-9  
To evaluate possible effects of extracellular nucleotides on the activity of MMP-9, MC were 
treated with IL-1ß for 24 h in the presence or absence of either ATP (30 µM) or UTP (30 
µM). Furthermore, we tested for possible effects of adenosine, a degradation product of ATP, 
as well as γ-thio-ATP (γ -S-ATP), a stable ATP analog. The gelatinolytic contents in the 
conditioned medium of MC were tested by zymography using gelatin as a substrate 
[Eberhardt et al., 2000a]. We chose a 24 h treatment to allow accumulation of extracellular 
MMP-9 which is high enough to be detected by gelatine zymography [Eberhardt et al., 
2000a]. The cytokine-mediated gelatinolytic content of latent MMP-9, which is represented 
by one lytic band at 92 kDa, is strongly increased when MC were cotreated with γ -S-ATP or 
UTP (Fig. 23A). No effect on the IL-1ß-caused lytic content is seen with ATP and its 
degradation product adenosine (Fig. 23A). We suggest that under cell culture conditions the 
rapid degradation by ectonucleotidases efficiently removes ATP and therefore prevents 
sustained signaling by ATP. We observed that the levels of lytic bands migrating at 68 and 72 
kDa which corresponds to latent and active MMP-2 were not significantly changed which is 
consistent with the constitutive expression of MMP-2 in rat MC [Eberhardt et al., 2000a]. In 
the absence of IL-1ß, none of the tested nucleotides or nucleoside was able to induce MMP-9 
activity (Fig. 23A). Furthermore, the stimulatory effect of γ-S-ATP occurred in a dose-
dependent manner with a maximal effect seen with 30 µM of γ-S-ATP (Fig. 23B). In contrast, 
the higher concentrations did not further augment the cytokine-induced gelatinolytic content 
in the conditioned media (Fig. 23B, upper panel). To evaluate whether the increased level of 
gelatinolytic activity of MMP-9 is preceeded by an enhanced expression of MMP-9 mRNA, 
we performed Northern blot analyses using a cDNA from the rat MMP-9 gene. As shown in 
Fig. 23B (lower panel) similar to the changes in the gelatinolytic contents, γ-S-ATP dose-   Results 
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dependently augmented the cytokine-induced MMP-9 mRNA level with a maximal effect 
seen at 30 µM γ-S-ATP whereas concentrations higher than 30 µM blunted the amplification 
of  cytokine-induced MMP-9. No MMP-9 mRNA was detected in the absence of IL-1ß when 
stimulating with the nucleotide alone (Fig. 23B, lower panel). To test the time-dependency of 
cytokine-induced MMP-9 by γ-S-ATP we monitored the  time-course of MMP-9 induction by 
Northern blot analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23 (A). Effects of extracellular nucleotides on IL-1ß-induced MMP-9 activity in mesangial cells. Quiescent mesangial cells were 
stimulated with either vehicle (Control) or IL-1ß (2nM) in the presence or absence of γ -S-ATP, ATP, UTP, and adenosine (each at 30µM). 
24 hours after stimulation, 10 µl of supernatants were subjected to SDS-PAGE-zymography. The migration properties of lytic bands, 
corresponding to inactive pro MMP-9 (92 kD), and the inactive and active forms of MMP-2 (72 and 68 kDa) were determined using standard 
m.w. markers. The data shown are representative for three experiments giving similar results. (B). Dose-dependent amplification of IL-1ß-
induced MMP-9 activity and MMP-9 mRNA level  by γ-S-ATP. Quiescent mesangial cells were stimulated with either vehicle (-) or IL-1ß 
(2nM) (+) in the presence of the indicated concentrations (in µM) of γ-S-ATP. After 24 hours 10 µl of supernatants were collected for SDS-
PAGE zymography (zym) and cell monolayers collected for mRNA isolation and Northern blot analysis (n.b.). Total cellular RNA (20 µg) 
was hybridized to a 
32P-labeled cDNA insert from KS-MMP-9. Equivalent loading of RNA was ascertained by rehybridization to a 18 S 
rRNA probe. Data are representative of 3 independent experiments giving similar results.     Results 
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As shown in Fig. 23C the indcution of MMP-9 mRNA as caused by the treatment of MC with 
either IL-1ß or with IL-1ß plus γ-S-ATP did not occur at the early time points tested (4h and 
12h) thus indicating that γ-S-ATP can not induce MMP-9 mRNA expression by its own. 
Furthermore, these data indicate that the alterations of cytokine-induced gelatinolytic activity 
by γ-S-ATP predominantly result from changes in the MMP-9 expression levels.  
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                          18 S 
 
Fig.23 (C). Time-course of IL-1ß-induced MMP-9 steady-state mRNA level  in the presence or absence of γ-S-ATP. Mesangial cells were 
stimulated with the IL-1ß (2nM)  with or without γ-S-ATP (30 µM) for the indicated time periods before mRNA was isolated for Northern 
blot analysis. Total cellular RNA (20 µg) was hybridized to a 
32P-labeled cDNA insert from KS-MMP-9. Equivalent loading of RNA was 
ascertained by rehybridization to a 18 S rRNA probe. Data are representative of 2 independent experiments giving similar results. 
 
Involvement of the P2Y2 receptor in the amplification cascade of MMP-9 by ATP 
Many of the physiologcial actions exerted by ATP involve the G-protein coupled P2Y2 
subtype of purinoceptors. We therefore tested by a pharmacological approach for the 
involvement of the P2Y2  purinoreceptor in the amplification of cytokine-induced MMP-9 
expression by use of suramin, a putative antagonist of P2Y2 but not of P2Y4 purinoceptors 
[Boarder and Hourani, 1998]. As shown in Fig. 24, suramin dose-dependently inhibited the γ-
S-ATP-mediated potentiation of IL-1ß gelatinolytic activity of MMP-9 without affecting the 
4 h  12h  24 h    Results 
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cytokine-caused gelatinolytic content of MMP-9. This suggests an involvement of the P2Y2 
subtype of purinoceptor in the ATP signaling of MMP-9 expression.  
 
                                                                         + suramine 
                                                                                  10µM  100µM 
                                                                            
                
 
 
 
 
Fig. 24. The γ-S-ATP-triggered amplification of cytokine-induced gelatinolytic activity of MMP-9 is inhibited by suramin. Quiescent 
mesangial cells were simultaneously treated for 24 hours with either vehicle (control) or IL-1ß (2nM), IL-1ß (2nM) plus γ-S-ATP (30 µM) in 
the presence of the indicated concentrations of suramin before 10 µl of cell supernatants were subjected to SDS-PAGE zymography. 
Migration properties of lytic bands were determined with molecular weight markers. The data are representative for two independent 
experiments giving similar results.  
   
 
Nucleotides have no effects on cytokine-induced MMP-9 promoter activity 
To further evaluate whether the ATP-mediated amplification of IL-1ß-induced MMP-9 
expression resulted from an increase in MMP-9 gene transcription we assessed promoter 
activites derived from a 1.3 kb fragment of the rat MMP-9 promoter region (pGL-MMP-9 1.3 
kb) by luciferase reporter gene assays. This promoter region contains several functional 
elements necessary for cytokine-mediated regulation of MMP-9 expression most important 
one NF-κB binding site and one AP-1 response element which is close to a functional Ets-1 
binding site [Eberhardt et al., 2002a]. Transient transfection of MC with pGL-MMP-9 1.3 kb 
comprising the 1.3 kb promoter fragment fused to the luciferase reporter gene, was followed 
by a 24 h treatment with either vehicle, IL-1ß (2 nM), with or without either γ-S-ATP (30 
µM), or UTP (30 µM) or with each nucleotide alone and subsequently assayed for luciferase 
activity (Fig. 25). IL-1ß significantly stimulated luciferase activity (1.9-fold, p< 0.01) but the 
promoter activity was only weakly enhanced by either nucleotide. These data demonstrate that    Results 
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the amplification of cytokine-induced mRNA steady-state levels by γ-S-ATP can not be 
located to the upstream 1.3 kb MMP-9 promoter context. 
 
 
 
 
 
 
Figure 25. The extracellular nucleotides γ-S-ATP and UTP do not affect cytokine-mediated promoter activity of a 1.3 kb portion of rat 
MMP-9 promoter. MC were transiently cotransfected with 0.4 µg of pGL-MMP-9 1.3 kb and with 0.1 µg of pRL-CMV coding for Renilla 
luciferase. After overnight transfection, MC were treated for 24hours with vehicle (control), IL-1ß (2 nM), γ-S-ATP (30 µM), UTP (30 µM) 
or a combination of IL-1ß and the nucleotides as indicated before being harvested for measurement of dual luciferase activities, as described 
in Material and Methods. Values for beetle luciferase were related to values for Renilla luciferase and are depicted as relative light units 
(RLU). Data are the means ± S.D. (n=6) **, p ≤ 0.01, compared to control. 
 
γ-S-ATP inhibits the decay of cytokine-induced MMP-9 mRNA 
To test whether the ATP effects relay to some posttranscriptional events we performed 
actinomycin D experiments. MC were stimulated for 20 h with IL-1ß (2 nM) before 
transcription was blocked by actinomycin D (5 µg/ml). Subsequently, cells were either 
directly homogenized (vehicle , 0h) or left untreated (vehicle, 12 h) or alternatively treated 
with the stable ATP analog γ-S-ATP (30 µM). After 12 h cells were homogenized for the 
isolation of total RNA. The MMP-9 mRNA from untreated MC displayed a strong reduction 
by almost 80 % (p< 0.005) in the mRNA steady-state level (Fig. 26A). Most interestingly, the 
decay of MMP-9 mRNA was completely blocked in the presence of γ-S-ATP, thus indicating 
that γ-S-ATP can stabilize the IL-1ß-induced MMP-9 mRNA (Fig. 26A). Furthermore, time-
course experiments revealed that the mRNA stabilizing effects on MMP-9 transcripts by γ-S-
ATP already occurred at 4 h and were maximal 12 h after the blockade of transcription by 
actinomycin D (Fig. 26B). 
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Figure 26 : (A). γ-S-ATP prevents the decay of cytokine-induced MMP-9 mRNA. Quiescent MC were treated for 20 hours with IL-1ß (2 
nM) to reach maximal level of MMP-9 transcripts. Thereafter cells were washed twice and incubated with actinomycin D (5 µg/ml) for 30 
min. This time point was set as 0 hours and cells were additionally treated for either 12 hours or left untreated (vehicle 12h). (B) Quiescent 
MC were treated for 20 hours with IL-1ß (2 nM) to reach maximal level of MMP-9 transcripts. Thereafter cells were washed twice and 
incubated with actinomycin D (5 µg/ml) for 30 min. This time point was set as 0 hours and cells were additionally treated for the indicated 
time points without (vehicle) or with  30 µM γ -S-ATP before being harvested and extracted for total cellular RNA. 20 µg of total cellular 
RNA were hybridized to 
32P-labeled MMP-9 or 18S cDNA probes, respectively. The lower panel of Fig. 26A shows a densitometric analysis 
of three independent experiments.  
 
Recently it has been reported that transcription blockage by actinomycin D can induce a 
redistribution of the mRNA stabilization factor HuR from the nucleus to the cytoplasm and 
therefore may cause an increase in the mRNA half-life [Peng et al., 1998]. However, in our 
experiments all cells were equally treated with actinomycin D and, therefore, the net effect on 
MMP-9 decay exclusively depends on the presence or absence of extracellular γ-S-ATP. In 
contrast, IL-1ß by itself had no effect on the stability of cytokine-induced MMP-9 mRNA 
since the addition of IL-1ß(2nM) after transcriptional blockade did not change the mRNA 
decay of MMP-9 (Fig. 26C).  In summary, these data indicate that γ-S-ATP can augment the 
cytokine-induced MMP-9 expression by an increase of MMP-9 mRNA stability.  
 
The cytoplasmic fractions of ATP-treated MC stabilize MMP-9 mRNA in vitro 
The involvement of cytoplasmic factors exerting MMP-9 mRNA stabilizing properties was 
furthermore tested by an in vitro degradation assay. By this assay the time-course of 
degradation of purified MMP-9 mRNA exhibited by any trans-acting factor accumulated in  
       Results 
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Figure 26 (C) Quiescent MC were treated for 20 hours with IL-1ß (2 nM) before cells were washed twice and incubated with actinomycin D 
(5 µg/ml) for 30 min. This time point was set as 0 hours and cells were additionally treated for  the indicated time points without (+vehicle) 
or with  2 nM IL-1ß (+IL-1ß) before being harvested and extracted for total cellular RNA. 20 µg of total cellular RNA were hybridized 
successively to 
32P-labeled MMP-9 or 18S cDNA probes, respectively. The blot is representative for two independent experiments. 
 
the cytoplasmic extracts from γ-S-ATP-treated MC was compared to the degradation profile 
derived from untreated MC. Similar volumes of each cytoplasmic extract (with a total protein 
content of 130 µg) were incubated with 20 µg of total RNA isolated from a common pool of 
cytokine-treated MC containing a high level of MMP-9 mRNA. Subsequently, we isolated 
total RNA after the indicated time points and performed Northern blot analysis using a probe 
from the rat MMP-9 cDNA (Fig. 27). As shown before γ-S-ATP alone is not able to induce 
endogenous MMP-9 mRNA levels (Fig. 23). Therefore, most of the MMP-9 mRNA detected 
by degradation assay is derived from the exogenous pool of MMP-9 mRNA but not from 
endogenous MMP-9 transcripts within the cytoplasmic extracts. We observed that the primary 
undegraded MMP-9 transcripts which had been exposed to the cytoplasmic fractions from 
ATP-treated MC displayed a delayed degradation when compared to MMP-9 transcripts 
exposed to cytoplasmic extracts from untreated cells which is indicated by the different time-
courses of decay of MMP-9 mRNA (Fig. 27). In contrast, the amount of the stable GAPDH 
mRNA was not affected by none of the extracts tested, thus suggesting that the effects on 
mRNA decay are specific for MMP-9 mRNA. These data indicate that the cytoplasmic 
0h 12h 12h
MMP-9 
+vehicle  +IL-1β 
0h 4h  8h 8h 4h 
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extracts from γ-S-ATP-treated MC contain RNA  protective factors responsible for the 
delayed decay of MMP-9 mRNA.   
 
 
 
 
 
 
 
Figure 27. Cytosolic lysates of ATP-treated MC exert anti-degradative properties on MMP-9 mRNA in an in vitro RNA degradation assay.  
Portions of 20 µg of total RNA from a common pool of total RNA isolated from cytokine-stimulated MC were mixed with 130 µg of 
cytoplasmic extract derived from either untreated (vehicle) or  γ-S-ATP-treated MC (+γ-S-ATP). After the indicated time periods incubations 
were stopped by isolation of total RNA. RNA samples were collected and assessed for the amounts of remaining  MMP-9 mRNA level by 
Northern blot analysis using a 
32P-labeled cDNA insert specific for rat MMP-9. In order to prove specificity of the effects we furthermore 
hybridized the blots  with    a 
32P-labeled cDNA from GAPDH. Similar results were obtained in three independent experiments. 
 
  The 3´-UTR of the MMP-9 gene specifically confers an ATP-dependent increase in 
promoter activity 
Regulation of mRNA stability is in many cases determined by AU-rich sequences (AREs) 
within the 3´-UTR of genes [Chen and Shyu, 1995;  Ross, 1995;  Brennan and Steitz, 2001]. 
Since MMP-9 contains four copies of ARE motifs within its 3´-UTR (ARE1, ARE2, ARE3, 
ARE4 in fig. 14) we tested whether the increase in MMP-9 mRNA stabilitization by γ-S-ATP 
depends on the presence of these ARE motifs downstream of the coding region of the gene 
(CDS). To this end the promoter activitiy of a luciferase reporter gene, which was driven by 
the pGL-MMP-9 1.3 kb upstream promoter region (Fig. 28A), was compared to that derived  
from transient transfection of a similar MMP-9 promoter construct containing an additional 
662 bp from the 3´-UTR of the MMP-9 gene cloned downstream of the Luciferase CDS (3´-
UTR- pGL MMP-9-1.3kb ín Fig. 28B). Transient transfection of MC with both MMP-9 
reporter genes was followed by a 20h treatment with either vehicle (control), IL-1ß (2 nM), γ-   Results 
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S-ATP (30 µM) or both in combination. Stimulation of MC with IL-1ß leads to a significant 
increase of MMP-9 promoter activity (3.4-fold, p< 0.005) (Fig. 28A). Addition of γ-S-ATP 
did not further increase the IL-1ß-induced pGL-3-MMP-9 luciferase activity (3.5-fold, p< 
0.005) but caused a significant enhancement of cytokine-triggered promoter activity when the 
luciferase coding region was under the additional control of the 3´-UTR of MMP-9 (Fig. 
28B). Similarly, stimulatory effects on basal luciferase activity by γ-S-ATP alone were 
significantly increased when the luciferase gene was under the additional control of the 3´-
UTR of MMP-9 (from 1.6 ± 0.02-fold, p<0.05; to 2.3 ± 0.015-fold induction; p<0.005; mean 
± SD, n=3). Most probably this is due to the stabilization of the constitutively expressed 
luciferase mRNA by γ-S-ATP via the inserted 3´-UTR of MMP-9. Accordingly, the high level 
of basal promoter activities measured with all pGL-MMP-9 reporter constructs to some extent 
may cover the strong stimulatory effects by IL-1ß (in the presence or absence of γ-S-ATP) 
observed for the endogenous MMP-9 expression. 
 
   
 
 
 
 
 
 
 
 
 
 
Figure 28. Influence of the MMP-9 3´-UTR on MMP-9 promoter-driven Luciferase activity. (A). Subconfluent MC were transiently 
cotransfected with 0.4 µg of pGL-MMP-9 -1.3kb and 0.1 µg of pRL-CMV coding for Renilla luciferase. After an overnight transfection MC 
were treated for 20 hours with vehicle (control) or with IL-1ß (2 nM) or γ-S-ATP (30 µM) or both in combination as indicated. (B). To assess 
the influence of the 3´UTR of the MMP-9 mRNA MC were alternatively transfected with 0.4 µg of 3´-UTR-MMP-9 pGL-MMP-9 -1.3kb 
containing additionally the 3´-UTR of MMP-9 downstream of the luciferase coding sequence before being treated with vehicle, IL-1ß (2 
nM), or ATP (30 µM) or both in combination. The values for beetle luciferase were related to values for Renilla luciferase and are depicted 
as relative light units (RLU). Data (means ± SEM) are the results of triplicates and are representative for three independent experiments. (*) 
P≤ 0.05, (**) P≤0.01, (***) P≤0.005  compared with unstimulated control values and  or to IL-1ß-stimulated values (##) P≤0.01     Results 
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In contrast, the low basal expression of endogenous MMP-9 may explain the lack of ATP 
effects on basal MMP-9 levels demonstrated by Northern blot and zymography, respectively 
(Fig. 23).  
 
Mutagenesis studies with MMP-9 reporter genes bearing mutated AREs  
To investigate the impact of each single ARE-motif on the ATP-dependent mRNA 
stabilization we generated different point mutations by replacing the pentameric “AUUUA” 
motif of ARE-1, ARE-2 and ARE-4 to an inactive “ACCCA” sequence (table 4) which 
impairs its RNA-binding affinity. As shown in Fig. 29, MC transiently transfected with 3´-
UTR-MMP-9 promoter constructs bearing one mutated ARE motif displayed similar 
induction profiles by ATP and IL-1ß as those derived  from the wild-type 3´-UTR pGL MMP-
9 promoter although the absolute rates of luciferase activities differed between single 
constructs (compare RLU in Fig. 29 with RLU in Fig. 28B). In contrast, mutation of all three 
putative ARE-motifs (3´-UTR-∆ARE-1-2-4 pGL3-MMP-9) resulted in a complete loss of 
ATP-dependent effects on reporter gene activities (Fig. 29) similar to those observed with the 
wild-type MMP-9 promoter construct lacking the 3´-UTR (Fig. 28A). These data indicate that 
none of the ARE motifs within the 3´-UTR of MMP-9 is indispensable for the ATP-
dependent MMP-9 mRNA stabilization. However, mutation of all three ARE motifs results in 
a complete loss of the ATP-dependent increase in luciferase activities without affecting the 
stimulatory effects of IL-1ß. This indicates that the ATP-dependent effects via 3´-UTR are 
mainly attributable to AREs but not to the presence of 3´-enhancer elements. 
 
ATP augments binding of HuR protein to AU-rich elements (AREs) within the 3´-UTR of 
MMP-9 
The stability of many short-lived mRNAs is modulated through specific binding of proteins to 
the AREs present in their 3´-UTR. We therefore used electrophoretic gel mobility shift assay     Results 
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Figure 29   Relative Luciferase activities of mutated 3´-UTR –MMP-9 promoter constructs. Subconfluent MC were transiently cotransfected 
with 0.4 µg of the indicated point-mutated 3`-UTR-MMP-9 promoter constructs and 0.1 µg of pRL-CMV coding for Renilla luciferase. After 
an overnight transfection MC were treated for 20 hours with vehicle (control) or with IL-1ß (2 nM) or γ-S-ATP (30 µM) or both in 
combination as indicated.Values for beetle luciferase are related to values for Renilla luciferase and are depicted as relative light units 
(RLU). Data are (means ± SEM) for three independent experiments. (*) P≤ 0.05, (**) P≤0.01, (***) P≤0.005 compared with unstimulated 
control values and  or to IL-1ß-stimulated values (##) P≤0.01,  (###) P≤0.005. 
 
 
 
 
 
 
 
 
Table 4: 
 
UTR-ARE-1    2500 5´-CCCUUUUAUUUAUUAUGUAUG-3´   2520 
UTR-∆ARE-1   5´-CCCUUUUACCCAUUAUGUAUG-3´    
UTR-ARE-2   2536 5´-ACAUGUAUUUAACCUAUAGAA-3´   2556 
UTR-∆ARE-2   5´-ACAUGUACCCAACCUAUAGAA-3´    
UTR-ARE-4    2742 5´-CAGAGGAAUUUAUUGGAUGUU-3´ 2762 
UTR-∆ARE-4   5´-CAGAGGAACCCAUUGGAUGUU-3´   
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(EMSA) to determine if treatment of cells with γ-S-ATP would cause an increase in the 
constitutive binding of HuR-containing complexes bound to different ARE motifs within the 
3´-UTR of MMP-9 [Akool et al., 2003]. The protein binding to MMP-9-specific AREs was 
monitored by using 
32P-labeled RNA oligonucleotides comprising the different wild-type or 
mutant AREs of MMP-9 (denoted as UTR- ARE or UTR-∆ARE as depicted inTable 4). MC 
were either left untreated or treated for 4 h with different concentrations of γ-S-ATP and 
subsequently lysed for cytosolic fractions. Using an RNA oligonucleotide containing the 
wild-type ARE 1 motif from the 3´-UTR of MMP-9 we observed the constitutive binding of 
three major complexes of high electrophoretic mobility and, interestingly, the binding of all 
complexes was dose-dependently increased when cells had been treated with γ-S-ATP (Fig. 
30A). Similar to ARE-1, a constitutive binding of two main complexes to ARE-2 and ARE-4 
encompassing oligos was dose-dependently increased by γ-S-ATP and a maximal binding 
capacity was observed with 30 µM γ-S-ATP (Fig. 30B and C). As we have described 
previously, an ARE-3 containing RNA oligo displayed no in vitro binding capacity most 
probably due to the different bases flanking this ARE-motif [Akool et al., 2003]. Additionally, 
the binding affinity of RNA oligos bearing  a mutated ARE motif (ACCCA in stead of 
AUUUA, Tab. 4)  was strongly reduced when compared to oligos bearing the wild-type ARE 
(Fig. 30A-C) demonstrating the functionality of each ARE motif. In contrast to the effects 
observed with γ-S-ATP,  the short-term treatment of MC with IL-1ß (4 hours) did not 
modulate the constitutive binding to any of the ARE-motifs tested (Fig. 30D).  
 
ATP-inducible complexes binding to MMP-9-specific AREs contain the mRNA stabilizing 
factor HuR 
 We have described previously that the ELAV-like RNA binding protein HuR is critically 
involved in the regulation of MMP-9 mRNA stability [Akool et al., 2003]. To test whether the 
γ-S-ATP-inducible complexes interacting with the ARE motifs of MMP-9 contain any HuR-    Results 
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Figure 30 (A). γ-S-ATP causes an increase in the constitutive RNA binding of HuR to AU-rich motifs within the 3´-UTR of MMP-9. RNA 
binding was analyzed by EMSA using gene specific wild-type oligonucleotides (UTR-ARE) or oligos bearing mutations of three bases 
within the AU-rich elements  (UTR-∆ARE) as depicted in Table 4. MC were either left untreated (-) or stimulated for 4 h with the indicated 
concentrations of γ-S-ATP before cells were lysed for preparation of cytoplasmic extracts. 4 µg of cytoplasmic extracts were incubated with 
a 
32P-labeled RNA probe derived from the corresponding AU-rich region of the 3´-UTR of rat MMP-9. UTR-ARE-1 and RNA binding was  
assessed in 6.0 % native PAGE gels. The results shown in each panel are representative for three independent experiments giving similar 
results. Supershift analysis was done by incubating the 
32P radiolabeled oligonucleotides with 6 µg of cytoplasmic extract derived from γ-S-
ATP-treated MC (30 µM) in the presence of 1 µl (200 ng) of a monoclonal anti-HuR antibody (anti-HuR). The antibody was added 15 min 
after addition of the radiolabeled oligonucleotide and incubated for a further 15 min at room temperature. Arrowheads indicate the 
supershifted complexes. Similar results were obtained in three independent experiments.  
 
 
 
 
 
 
 
 
 
 
 
Figure 30 (B).  γ-S-ATP causes an increase in the constitutive RNA binding of HuR to AU-rich motifs within the 3´-UTR of MMP-9. RNA 
binding was analyzed by EMSA using gene specific wild-type oligonucleotides (UTR-ARE) or oligos bearing mutations of three bases 
within the AU-rich elements  (UTR-∆ARE) as depicted in Table 4. MC were either left untreated (-) or stimulated for 4 h with the indicated 
concentrations of γ-S-ATP before cells were lysed for preparation of cytoplasmic extracts. 4 µg of cytoplasmic extracts were incubated with 
a 
32P-labeled RNA probe derived from the corresponding AU-rich region of the 3´-UTR of rat MMP-9. UTR-ARE-2 and RNA binding  was 
assessed in 6.0 % native PAGE gels. The results shown in each panel are representative for three independent experiments giving similar 
results. Supershift analysis was done by incubating the 
32P radiolabeled oligonucleotides with 6 µg of cytoplasmic extract derived from γ-S-
ATP-treated MC (30 µM) in the presence of 1 µl (200 ng) of a monoclonal anti-HuR antibody (anti-HuR). The antibody was added 15 min 
after addition of the radiolabeled oligonucleotide and incubated for a further 15 min at room temperature. Arrowheads indicate the 
supershifted complexes. Similar results were obtained in three independent experiments.     Results 
  110
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30 (c). γ-S-ATP causes an increase in the constitutive RNA binding of HuR to AU-rich motifs within the 3´-UTR of MMP-9. RNA 
binding was analyzed by EMSA using gene specific wild-type oligonucleotides (UTR-ARE) or oligos bearing mutations of three bases 
within the AU-rich elements (UTR-∆ARE) as depicted in Table 4. MC were either left untreated (-) or stimulated for 4 h with the indicated 
concentrations of γ-S-ATP before cells were lysed for preparation of cytoplasmic extracts. 4 µg of cytoplasmic extracts were incubated with 
a 
32P-labeled RNA probe derived from the corresponding AU-rich region of the 3´-UTR of rat MMP-9. UTR-ARE-4 and RNA binding was 
assessed in 6.0 % native PAGE gels. The results shown in each panel are representative for three independent experiments giving similar 
results. Supershift analysis was done by incubating the 
32P radiolabeled oligonucleotides with 6 µg of cytoplasmic extract derived from γ-S-
ATP-treated MC (30 µM) in the presence of 1 µl (200 ng) of a monoclonal anti-HuR antibody (anti-HuR). The antibody was added 15 min 
after addition of the radiolabeled oligonucleotide and incubated for a further 15 min at room temperature. Arrowheads indicate the 
supershifted complexes. Similar results were obtained in three independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30 (D). Short-term stimulation with IL-1ß does not affect the constitutive  binding to AREs within the 3´-UTR of MMP-9.  MC were 
either left untreated (-) or stimulated for 4 h with the indicated concentrations of IL-1ß before cells were lysed for preparation of cytoplasmic 
extracts. The procedures for EMSA were similar to those described in (A). The different RNA probes (UTR-ARE-1, UTR-ARE-2 and UTR-
ARE-4) were derived from the corresponding AU-rich region of the 3´-UTR of rat MMP-9. The EMSAs shown are representative for two 
independent experiments giving similar results.     Results 
  111
like protein we performed supershift analysis. We focused on HuR (HuA) which participates 
in the regulation of ARE-mediated RNA turnover [Peng et al., 1998]  and which has been 
identified as a target of NO-dependent MMP-9 mRNA decay in rat MC [Akool et al., 2003]. 
As shown in Fig. 30 A-C (right panels), the addition of anti-HuR antibody caused the 
appearance  of two supershifted bands (arrowheads) independent of which ARE-
oligonucleotide was used in the binding assay. Most interestingly, the addition of supershift-
antibody results in an almost complete shift of all  complexes indicating that HuR is a main 
constituent of the ATP-regulated complexes. Similar to the EMSAs with cytoplasmic 
fractions, recombinant HuR protein displays a strong in vitro binding affinity to all three wild-
type ARE motifs from rat MMP-9 mRNA (UTR-ARE-1, UTR-ARE-2 and UTR-ARE-4) 
[Akool et al., 2003]. These data indicate that γ-S-ATP by increasing the constitutive HuR 
binding to AREs stabilizes the cytokine-induced MMP-9 mRNA. 
 
The mRNA stabilizing  factor HuR (HuA) is critically involved in nucleotide-induced 
MMP-9 mRNA stabilization  
In a previous study we have demonstrated that neutralization of HuR by addition of anti-HuR 
antisera results in the accelerated decay of MMP-9 mRNA whereas addition of recombinant 
HuR has an opposite effect on the  mRNA decay of MMP-9 [Akool et al., 2003]. To further 
test the functional role of HuR in the γ-S-ATP-mediated stabilization of MMP-9 mRNA we 
examined the effect of the neutralizing Anti-HuR antibody by in vitro degradation assays. To 
this end, the cytoplasmic fractions from γ-S-ATP-treated MC (which confer protective 
properties towards cytokine-induced MMP-9 mRNA) were preincubated for 1h with a 
monoclonal anti-HuR antibody (a total amount of 400 ng antiserum) before the decay of 
MMP-9 RNA was monitored by Northern blot analysis. Total cellular RNA was isolated after 
a further 2h coincubation with total cellular RNA, a time point where the stabilizing effects by 
γ- S-ATP are most obvious (Fig. 27). As a negative control the same volume of control    Results 
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immunoglobulins (mouse IgG) was preincubated. As shown in Fig. 31 the level of MMP-9 
mRNA was reduced when HuR was neutralized by the anti-HuR antibody. In contrast, mouse 
IgG on its own had no effects on the MMP-9 level (Fig. 31). Again, the steady-state mRNA 
level of GAPDH was not affected in the degradation assay thus indicating that the modulation 
of mRNA stability by HuR is not observed with a none-ARE-containing mRNA.   
 
 
 
 
 
 
 
 
 
 
Figure 31.  Neutralization of HuR reduces the stability of MMP-9 mRNA. Portions of 20 µg of total RNA from a common pool of total 
RNA isolated from cytokine-stimulated MC were mixed with 130 µg of cytoplasmic extract derived from MC treated for 4h with γ-S-ATP. 
The cytoplasmic extracts were kept either untreated (vehicle), or, alternatively pretreated for 1 h with 0.4 µg of a monoclonal anti-HuR 
antibody (+ a HuR) or with the same volume of mouse IgG (+ mouse IgG) before the cytoplasmic extracts were incubated with the total 
RNA portions. Incubation with the RNA was stopped after additional 120 min before RNA was extracted for Northern blot analysis. Equal 
transfer and loading of total RNA was ascertained by hybridization to a GAPDH probe. Samples derived from one cytoplasmic extract were 
subjected to RNA in duplicates. Similar results were obtained in two independent experiments.  
 
The ATP-induced nucleo-cytoplasmic shuttling  of HuR is inhibited by suramin  
We next investigated the subcellular localization of HuR by confocal microscopy. Several 
reports have documented a predominant nuclear localization of HuR [Fan and Steitz, 1998; 
Peng et al., 1998; Keene, 1999] although fractions of HuR protein have also been found in the 
cytoplasm [Antic et al., 1999]. Under basal conditions (0 min, Fig. 32A) we observed a strong 
fluorescence in the cell nuclei but almost no staining within the cytoplasm thus indicating that 
HuR shows an almost exclusive nuclear distribution. Treatment of MC with 30 µM γ-S-ATP 
triggered a substantial increase in cytoplasmic HuR as is indicated by the appearance and 
increased fluorescence in punctated structures outside the nucleus (Fig. 32A, upper panel) A 
maximal density of immunopositive grains in the cytoplasm was observed after 2 hours of    Results 
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treatment with γ-S-ATP. A granular distribution of HuR within the cytoplasm has also been 
shown for the ELAV homologous proteins Hel-N1 and Hel-N2 [Gao and Keene, 1996]. 
Incubations of longer than 2h reduced the degree of cytosolic staining (Fig. 32A). These 
results indicate that the rise in  binding to UTR of MMP-9 is paralleled by an increased 
nuclear- cytoplasmic shuttling of the RNA stabilizing protein HuR. To investigate whether the 
P2Y2 purinoreceptor subtype is involved in the γ-S-ATP-dependent increase in cytoplasmic 
staining of HuR we tested the effects of the putative  P2Y2 antagonist suramin [Boarder and 
Hourani, 1998]. Interestingly, the γ-S-ATP-mediated effects on HuR translocation were 
inhibited at all time points tested (Fig. 32A, lower panel) which again indicates the 
involvement of P2Y2–dependent signaling in the regulation of HuR by extracellular ATP. The 
subcellular localization of endogenous HuR was also monitored by Western blot analysis. MC 
were treated for 4 h with different concentrations of γ-S-ATP (3, 10 and 30 µM) and 
subsequently fractionated into nuclear and cytoplasmic fractions. We observed that untreated 
MC contain low HuR protein levels in the cytoplasm (Fig. 32B) which is consistent with the 
weak fluorescence in the perinuclear region observed by confocal microscopy (Fig. 32A). 
Stimulation with γ-S-ATP caused a dose-dependent increase in the level of cytosolic HuR 
with a maximal effect seen at 30 µM γ-S-ATP (Fig. 32B, left panel). The addition of suramin 
to ATP (30 µM) resulted in a strong reduction of HuR accumulation again demonstrating a 
P2Y2-dependent mechanism (Fig. 32B, left panel).  Finally, we tested for possible γ-S-ATP-
induced changes in the nuclear HuR content. We observed that the nuclear amount of HuR is 
dramatically higher than that of cytoplasmic HuR (Fig. 32C). Therefore,   no significant 
change in the nuclear HuR level was detectable when cells were treated with γ-S-ATP (Fig.  
32B, right panel) despite the marked changes in cytoplasmic HuR. In summary, our data 
indicate that the γ-S-ATP-dependent rise in the IL-1ß-induced MMP-9 expression in MC is 
functionally linked to mechanisms which involve increased RNA-binding of HuR.     Results 
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Figure 32 (A). Suramin inhibits the γ-S-ATP-triggered nucleo-cytoplasmic shuttling of the ELAV-protein HuR. Indirect 
immunofluorescence showing the changes in the localization of HuR during stimulation of cells with γ-S-ATP. Quiescent mesangial cells 
were stimulated for the indicated time periods with either vehicle (0 min) or γ-S-ATP (30 µM) in the absence (upper panel) or presence of 
100 µM suramin (lower panel). Thereafter cells were fixed and stained with an anti-HuR antibody and anti-mouse-Alexa 488 as a secondary 
antibody.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32 (B,C) : B. Western blot analysis showing ATP-induced redistribution of HuR from the nucleus to the cytoplasm. MC were 
stimulated for 4 h with different concentrations of γ-S-ATP as indicated and then lyzed for cellular fractionation. Protein lysates (100 µg) 
from cytoplasmic (left panel) or nuclear (right panel) fractions were subjected to SDS-PAGE and probed with a HuR-specific monclonal 
antibody. To correct for variations, the blot was either stripped and incubated with an α-actin antibody (left panel) or loading of equal 
amounts of total protein was proven by Ponceau-S staining (P.S., right panel). Data are representative of two independent experiments giving 
similar results. C. Relationship between the cytoplasmic and nuclear levels of HuR. Equal amount of total protein extracts (100 µg) from 
nuclear (n.) or cytoplasmic (c.) fractions from untreated MC were subjected on SDS-PAGE and probed with a HuR-specific antibody. 
Loading of equal amounts of total protein was proven by Ponceau-S staining (P.S.).    Results 
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Additionally, the increase in RNA-binding by ATP is paralleled by an increase in the nucleo-
cytoplasmic shuttling of HuR. 
 
Discussion 
MMP-9 is a protease which is strongly induced by inflammatory cytokines such as IL-1ß and 
tumor necrosis factor α in many cell types including glomerular MC. Here we have focused 
on possible modulatory effects on MMP-9 by extracellular ATP and UTP since both 
nucleotides can mediate a variety of cell responses in MC including cell growth and inhibition 
of apoptosis [Schulze-Lohoff et al., 1992;  Huwiler and Pfeilschifter, 1994]. Moreover, 
extracellular nucleotides have also been reported to modulate experimental forms of 
glomerulonephritis in vivo [Poelstra et al., 1992]. We demonstrate that the stable ATP analog 
γ-S-ATP as well as UTP potently amplify the IL-1ß-mediated expression of MMP-9. The 
stimulatory effects of ATP on MMP-9 expression could be potently inhibited by the addition 
of suramin, a potent although none selective antagonist of P2Y2 purinoceptors. The 
occupation of P2Y2 receptors in rat MC can activate different isoforms of  protein kinase C 
(PKC) [Pfeilschifter and Huwiler, 1996; Boarder and Hourani, 1998] but also different 
MAPK pathways including the extracellular signal-regulated kinases (ERKs) [Huwiler and 
Pfeilschifter, 1994] the stress-activated protein kinase (SAPK) and p38-MAPK cascade 
[Huwiler et al., 1997; 2000]. Interestingly, several studies have implicated MAPK pathways 
as well as PKC-dependent signaling cascades in the up-regulation of MMP-9 expression 
[Eberhardt et al., 2000b; 2002a; Simon et al., 1998; Esteve et al., 2002; Yokoo and 
Kitamura,1996] mainly via the activation of NF-kB and AP-1 transcription factors [Eberhardt 
et al., 2000b; 2002a; Simon et al., 1998; Esteve et al., 2002; Yokoo and Kitamura,1996].  In 
rat MC none of the nucleotides was able to induce MMP-9 expression on its own. Obviously, 
in MC none of the signaling pathways affected by extracellular nucleotides is sufficient to 
transcriptionally activate MMP-9 and an additional cytokine-triggered signal is essentially    Results 
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required. The assumption that  cytokines and extracellular nucleotides can activate two 
independent signaling pathways is further underlined by the observation that both ATP and 
UTP have only marginal effects on  the cytokine-evoked activity of a 1.3 kb fragment of the 
rat MMP-9 promoter, although this promoter region is sufficient to mediate a strong 
activation by IL-1ß in rat MC [Eberhardt et al., 2002a]. In line with these suggestions we 
found a substantial contribution of posttranscriptional regulation to the ATP-mediated 
amplification of cytokine-induced MMP-9 expression. However, we cannot exclude the 
additional involvement of transcriptional regulation by γ-S-ATP attributable to some enhancer 
elements upstream from the proximal 1.3 kb of MMP-9. Therefore, a possible contribution of 
transcriptional regulation exerted by extracellular nucleotides has to be checked by additional 
reporter gene experiments using  larger fragments of the rat MMP-9 promoter. By use of 
actinomycin D experiments and in vitro RNA degradation assay we further demonstrate that 
treatment of cells with γ-S-ATP significantly increased the stability of MMP-9 mRNA. The 
3´-UTR of rat MMP-9 contains several copies of AU-rich elements which are considered as 
important determinants of RNA turnover [Chen and Shyu, 1995; Ross, 1995;  Malter, 1989 ; 
Xu et al., 1997] Concomitantly, we demonstrate that the 3´-UTR of MMP-9 confers an ATP-
dependent increase of basal and cytokine-induced MMP-9 driven luciferase activity when 
fused downstream of the luciferase reporter gene. Focusing on the responsible cis regulatory 
regions we found four copies of AUUUA pentameric motifs within the 3´-UTR of the rat 
MMP-9 mRNA potentially involved in the regulation mRNA decay of MMP-9. Interestingly, 
these motifs have been implicated in the rapid turnover of many mRNA species. Proteins 
functionally targeting these AU-rich elements  (AREs) include destabilizing factors such as 
AUF 1 [Zhang et al., 1993] as well as mRNA stabilizing factors, most prominently members 
of the embryonic lethal abnormal vision (ELAV) protein family [Peng et al., 1998; Levy et 
al.,1996; Ma et al., 1996]. By  gel shift analysis we demonstrate binding of complexes to three 
different ARE motifs of the 3´-UTR of MMP-9 (“MMP-9-ARE-1”, “MMP-9-ARE-2”,    Results 
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“MMP-9-ARE-4”) the binding of these complexes being substantially increased in cells 
treated with γ-S-ATP but not with IL-1ß. We focused on the ELAV–like RNA-binding 
protein HuR  which is known to bind AREs with a high affinity thereby increasing the 
stability of respective mRNAs [Peng et al., 1998; Levy et al., 1996; Ma et al., 1996]. The 
binding affinity to the MMP-9 specific AREs was strongly impaired when the uracil base 
within the AUUUA pentameric motif was replaced by cytosine which confirms the 
functionality of the AU-rich elements within the 3´-UTR of MMP-9. Concomitantly, the 
presence of HuR in the cytoplasmic extracts from ATP-treated MC was confirmed by 
supershift analysis. In addition, we have previously demonstrated that the MMP-9-specific 
ARE displays a high binding affinity to recombinant HuR protein  thus demonstrating a 
functional  binding capacity of HuR to these ARE motifs within the 3´-UTR of MMP-9 
[Akool et al., 2003].  The RNA binding of HuR has been shown to parallel the in vivo ability 
of ARE sequences to direct mRNA degradation [Myer et al., 1997]. Consistent with these 
findings we here demonstrate the functional importance of HuR by in vitro degradation 
assays. The addition of a neutralizing HuR antibody to the lysates of ATP-treated MC results 
in a significant acceleration of the decay of MMP-9 mRNA but not of GAPDH mRNA which 
lacks AU-rich elements within its 3´-UTR  (Fig.31). Our findings suggest that ATP triggers 
an increase in HuR binding to the 3´-UTR of MMP-9 mRNA and thus conveys protection of 
MMP-9 transcripts from rapid degradation. It is interesting to note that in the in vitro 
degradation assays we did not observe degradation fragments of MMP-9 mRNA. The gradual 
shortening of the poly (A) tail of mRNA followed by a rapid exonuclease-dependent 3´- to –
5´-digestion is thought as a major mechanism of mRNA decay within eukaryotic cells [Van 
Hoof and Parker, 2002]. Moreover, the rate of deadenylation seems an important control point 
for the rate of mRNA degradation. The disappearance of the MMP-9 positive band without 
detectable intermediates observed in our experiments indicates a rapid  3´-to-5´-degradation 
which is consistent to the findings of Chen et al. [Chen et al., 2001]. Since the cDNA insert    Results 
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used for Northern blot analysis in this study covers a 3´-region of MMP-9 mRNA (1227-
1939) this probe is not optimal  for monitoring mRNA intermediates.  So far little is known 
about the exact mechanisms by which HuR regulates mRNA stability. Unlike the other 
members of the ELAV family (HuB, HuC, or HuD) which all show a tight tissue-specific 
regulation, HuR is ubiquitously expressed and is predominantly located in the nucleus [Peng 
et al., 1998; Brennan and Steitz, 2001;  Ma et al., 1996; Myer et al., 1997; Good, 1995; King 
et al ., 2000;  Dean et al., 2001]. Mechanisms of HuR dependent mRNA decay can involve a 
nuclear-cytoplasmic movement [Pinol-Roma and Dreyfuss, 1992; Atasoy et al., 1998; Keene, 
1999] but also changes in the HuR expression level [Akool et al., 2003; Klöss et al., 2003]. 
Using confocal fluorescence microscopy we demonstrate that HuR is predominantly nuclear 
but partially distributes into distinct punctuate structures in the cytoplasm following treatment 
with  γ-S-ATP. This is in agreement with a recent study which has shown that ATP in higher 
concentrations (1 mM) inhibits the activity of AMP-activated kinase (AMPK) and thereby 
elevates the HuR level in the cytoplasm of colorectal carcinoma RKO cells [Wang et al., 
2002]. AMPK is an enzyme which is considered to act as a cellular defense mechanism to 
protect cells from ATP depletion  [Moore et al., 1991]. Most intriguingly, the expression of 
HuR was shown to be downregulated in quiescent cells but increased following serum 
stimulation. Therefore, ATP as a proliferative stimulus may affect a default pathway of 
mRNA decay thereby regulating the expression of a variety of growth regulatory proteins. 
Besides AMPK  the activation of PKC plays a cardinal role in the enhanced stability of 
mRNAs coding for p21 and IL-1ß [Park et al., 2001; Gorospe et al., 1993]. Mapping of the 
protein sequence has revealed that HuR contains a multitude of putative PKC phosphorylation 
sites which makes it tempting to speculate that ATP might regulate HuR via PKC. Other 
studies have implicated the involvement of MAPK pathways in the regulation of the nucleo-
cytoplasmic shuttling of HuR [Winzen et al., 1999; Ming et al., 2001]. Whether changes in 
HuR phosphorylation either by different PKCs or by the MAPK pathway account for the    Results 
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ATP-induced HuR redistribution in MC is currently investigated in our laboratory. In this 
context it is noteworthy that ATP has been shown to activate different PKC isoenzymes 
[Pfeilschifter and Huwiler, 1996] as well as the three major MAPK cascades [Huwiler and 
Pfeilschifter, 1994; Huwiler et al., 1997; 2000]. The excessive degradation of extracellular 
matrix is an important feature in the progression of many acute inflammatory diseases 
accompanied by a cellular hyperproliferation. Our present findings present a molecular 
mechanism which may explain how extracellular nucleotides transiently potentiate the 
cytokine-mediated cellular capacities to degrade extracellular matrix without having any 
effects on MMP-9 expression in resting cells. To the best of our knowledge this is the first 
time that the stable ATP analog γ-S-ATP is shown to regulate the expression of MMPs by 
posttranscriptional mechanisms. Furthermore, our data emphasize the importance of 
modulation of mRNA stability in the tight regulation of MMP-9. 
          Summarizing discussion 
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Summarizing discussion 
 
MMPs play a pivotal role in the regulation of ECM turnover in the glomerulus. Various forms 
of glomerular diseases are characterized by a profound shift in the balance between matrix 
synthesis and degradation [Arthur, 1998]. While in the scarring process the balance is tilted 
toward increased synthesis, excess degradative activity promotes glomerular destruction in 
inflammatory diseases. Generally, glomerular diseases remain the most common causes of 
progressive renal failure and in late stages in many cases require dialysis or kidney 
transplantation [Pfeilschifter, 1994]. Most forms of progressive glomerular diseases are 
characterized by decreased turnover of extracellular matrix (ECM) and accumulation of 
interstitial collagens in the glomeruli. This increase in collagen mRNA may not merely mirror 
existing sclerosis, but may have a predictive value early in the disease. A lesser degree of 
structural damage in another model showed a correspondingly lesser elevation of type IV 
collagen [Peten et al., 1993]. In human renal tissue, correlation was also found between level 
of glomerulosclerosis and expression of collagen type IV mRNA [Peten et al., 1992]. Based 
on the knowledge that the activated MC itself can synthesize and release a myriad of 
inflammatory mediators, including  growth factors, cytokines and high expression levels of 
gelatinases (MMP-2 and MMP-9), I focused on the question how and by which mechanisms 
these mediators may orchestrate the tissue remodeling in glomerular MC. The inflammatory 
cytokines IL-1ß and TNFα are among the most potent transcriptional inducers of MMP-9 
gene expression [Yoko and Kitamura, 1996; Eberhardt et al., 2000a]. Searching for targets  
interfering with the cytokine-induced MMP-9 expression I investigated the effects of 
activators of the nuclear receptor superfamily the peroxisome proliferator-activated receptors 
(PPARs) [for review see Corton et al., 2000] . PPAR activators have been shown to exert anti-
inflammatory activities in various cell types by inhibiting the expression of proinflammatory 
genes such as cytokines [Delerive et al., 1999] and acute phase proteins [Delerive et al., 
2001]. Three subtypes of PPARs have been identified: PPARα, ß/δ, and γ each one showing a          Summarizing discussion 
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specific distribution and physiologic function. I focused on the α-subtype of PPAR receptors 
since a variety of other inflammatory genes has been shown to be modulated by PPARα [for 
review see: Delerive et al., 2001; Daynes and Jones, 2002]. In the present work,   I found that 
the structurally different PPARα agonists WY-14, 643, LY-171883 and bezafibrate potently 
inhibit the cytokine-induced  MMP-9 on both, the mRNA and the protein level. Most 
interestingly, the negative effects by PPARα agonists on cytokine-induced MMP-9 mRNA 
steady-state and zymogen levels is not attributable to an inhibition of MMP-9 gene 
transcription but results from some indirect, posttranscriptional regulatory events by NO 
generated via activation of PPARα by different PPARα agonists. This increase in NO 
production results from potentiation of cytokine-induced stimulatin of iNOS expression by the 
PPARα agonists. Previously, it has been reported that NO, given endogenously by stimulation 
of iNOS expression, potently inhibits the mRNA steady-state levels of cytokine-induced 
MMP-9 in mesangial cells [Eberhardt et al., 2000a]. Meanwhile, the negative modulation of 
MMP-9 expression has been confirmed in several other cell types thus suggesting a general 
mechanisms of NO-triggered tissue remodeling [Pfeilschifter et al., 2001; Upchurch et al., 
2001; Gurjar et al., 2001]. In contrast to the negative modulation of MMP-9 by NO, it has 
been reported recently that NO increases the expression of MMP-9 in vascular smooth muscle 
[Marcet-Palacios et al., 2003]. These conflicting results on amplification or inhibition of 
MMP-9 demonstrate the complexity of the interactions of NO with cell signaling cascades. 
Many factors may contribute to some of the differences observed such as cell type, 
stimulation time and stimulating agents. Searching for the underlying mechanisms, most 
interestingly,  I found that NO significantly reduced the half-life of MMP-9 mRNA 
[Eberhardt et al., 2002b]. From this observation, we suggest that the tight cross-talk between 
NO and PPAR-triggered signaling pathways found in MC, may contribute to  the anti-
inflammatory effects of PPARα agonists observed in some pathologies. Our findings          Summarizing discussion 
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furthermore imply that in the renal glomerulus the overall effect of PPARα activators on 
MMP-9 expression may critically depend on the simultaneous production of NO by cells 
exposed to an inflammatory environment. Future studies should investigate whether this NO-
dependent effects mediated by PPARα activation also occurs in other cells or tissues or even 
in vivo. 
Searching for the precise mechanisms of the NO-evoked mRNA decay, I found that the 
untranslated region (3´-UTR) of the MMP-9 gene is able to confer a NO-dependent reduction 
of cytokine-induced MMP-9 mRNA. The 3´-UTR of rat MMP-9 contains several copies of 
AU-rich elements which are considered as important determinants of RNA turnover [Chen 
and Shyu, 1995; Ross, 1995;  Malter, 1989 ; Xu et al., 1997] Meanwhile numerous ARE-
binding proteins have been implicated in the regulation of  mRNA turnover, among them 
proteins which can destabilize mRNA such as AUF1 [Zhang et al., 1993] but interestingly 
also proteins which can reduce mRNA degradation, most prominently members of the 
embryonic lethal abnormal vision (ELAV) protein family [Levy et al., 1996; Ma et al., 1996; 
Peng et al., 1998]. Unlike the other members of the ELAV family (HuB, HuC and HuD) 
which show a tissue-specific expression, HuR is ubiquitously expressed and shows a 
predominant nuclear distribution [Atasoy et al., 1998; . Dean et al., 2001 ; Peng et al., 1998]. 
However, a change of distribution between the nuclear and cytoplasmic compartment is 
considered as the main mechanism by which HuR can modulate mRNA decay [Ford et al., 
1999;  Peng et al., 1998]. Here I present an alternative mechanism by which a reduction of 
RNA binding is caused by the altered expression of HuR. Furthermore, I found that the NO-
dependent reduction of HuR is blocked in the presence of the specific guanylyl cyclase 
inhibitor LY-83583 thus demonstrating that the NO-mediated decrease in HuR expression 
depends on the activation of guanylyl cyclase and thus complements the mainly 
transcriptional regulation of other genes driven by NO in an cGMP-independent manner 
[Pfeilschifter et al., 2001; Schmidt and Walter, 1994]. Similar to MMP-9, the 3´-UTR of HuR          Summarizing discussion 
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contains several copies of AU-rich elements (AREs) implying a possible posttranscriptional 
regulation of HuR itself. Future studies are needed to investigate whether the change in HuR 
expression is mediated via transcriptional or posttranscriptional regulation.   From the 
previous experiments we can conclude that the expression of MMP-9, in addition to a 
transcriptional regulation, is controlled by post-transcriptional mechanisms including the 
modulation of mRNA stability by the mRNA stabilizing factor HuR. The increased 
production of NO which often does accompany the overall inflammatory responses  may have 
a causative role in the progression of fibrotic processes by altering matrix turnover via 
transcriptional as well as posttranscriptional mechanisms. Future work using animal models 
of inflammatory as well as fibrotic diseases should provide further insight to the in vivo 
relevance of this mechanism. 
Besides the proinflammatory cytokines, MC are able to respond to a variety of other 
biological mediators including eicosanoids, growth factors, reactive oxygen species, NO and 
to extracellular nucleotides such as ATP and UTP [Pfeilschifter, 1990; Pfeilschifter and 
Merriweather, 1993; Pfeilschifter et al., 2003].  In the last part of this thesis I focused on the 
modulatory effects on MMP-9 expression exhibited by extracellular ATP, since nucleotides 
can mediate a variety of cell responses in MC including cell growth and inhibition of 
apoptosis [Schulze-Lohoff et al., 1992;  Huwiler and Pfeilschifter, 1994]. Moreover, 
extracellular nucleotides have also been reported to modulate experimental forms of 
glomerulonephritis in vivo [Poelstra et al., 1992]. I found that the stable ATP analog γ-S-ATP 
potently amplifies the IL-1ß-mediated expression of MMP-9. In contrast to the degradative 
effects on MMP-9 mRNA by NO, I found that γ-S-ATP significantly can increase the stability 
of MMP-9 mRNA. As mentioned before, the 3´-UTR of rat MMP-9 contains several copies of 
AU-rich elements which are considered as important determinants of RNA turnover [Chen 
and Shyu, 1995; Ross, 1995;  Malter, 1989 ; Xu et al., 1997]. Again, I focused on the ELAV–
like RNA-binding protein HuR  which critically contributes to the posttranscriptional          Summarizing discussion 
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regulation of MMP-9 in rat MC [Akool et al., 2003]. Using confocal fluorescence microscopy 
I demonstrate that HuR is predominantly nuclear but partially distributes in distinct punctuate 
structures in the cytoplasm following treatment with  γ-S-ATP. This is in agreement with a 
recent study which has shown that ATP in higher concentrations (1 mM) inhibits the activity 
of AMP-activated kinase (AMPK) and thereby elevates the HuR level in the cytoplasm of 
colorectal carcinoma RKO cells [Wang et al., 2002]. Our findings suggest that ATP triggers 
an increase in HuR binding to the 3´-UTR of MMP-9 mRNA and thus conveys protection of 
MMP-9 transcripts from rapid degradation. This establishes an additional way of how 
signaling cascades affect the activity of HuR. However, the exact mechanisms by which HuR 
regulates mRNA stability is still poorly studied. HuR dependent changes in mRNA decay 
either can involve a nuclear-cytoplasmic movement (as shown by ATP) [Pinol-Roma and 
Dreyfuss, 1992; Atasoy et al., 1998; Keene, 1999] and/or changes in the HuR expression level 
as described for NO [Akool et al., 2003; Klöss et al., 2003].  The present findings present a 
molecular mechanism which may explain how extracellular nucleotides transiently potentiate 
the cytokine-mediated cellular capacities to degrade extracellular matrix without having any 
effects on MMP-9 expression in resting cells. Furthermore, our data emphasize the 
importance of modulation of mRNA stability in the tight regulation of MMP-9. Future in vivo 
studies investigating the modulatory effects exerted by different inflammatory mediators and 
nuclear hormon receptors such as PPARs may provide new targets to pharmacologically 
manipulate the abarrent expression of matrix degradative enzymes observed in various 
diseases.  
With the knowledge that MMPs not only regulate many physiological processes such as cell 
growth, apoptosis, angiogenesis, and immune responses but are also involved in different 
diseases such as arthritis, renal fibrosis, cancer, atherosclerosis and heart failure, it was very 
interesting to learn more details about the regulation of MMP activity. Meanwhile, it is known 
that MMP activity is tightly regulated at several levels (transcription, processing of the          Summarizing discussion 
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proenzyme, and inhibition by TIMPs) all of them providing new strategies to block or 
potentiate the effects mediated by these enzymes. Many clinical trials have been designed and 
currently are tested  to target these key regulatory points. The expression of MMP genes can 
be inhibited by targeting extracellular factor, cell-surface receptor, signal transduction 
pathways and nuclear factors that activate the expression of many of the inducible MMP 
genes. For example, the blocking of signaling induced by cytokines or growth factors that 
upregulate MMPs could be selected for therapy. One prominent example is the clinical use of 
monoclonal antibodies against TNF-α or soluble TNF receptor which both  are effectivly used  
in the therapy of rheumatoid arthritis. Also, selective inhibition of p38 MAPK activity can  
abolish the expression of MMP-1,9 and 13 in different cell types [ Simon et al., 1998; 
Johansson et al., 2000]. A future focus to manipulate the expression of MMPs will be 
transcription factors such as AP-1 and NF-ĸB which control the expression of most of the  
inducible MMP genes. Recently, it has been reported that some natural flavonoids have the 
ability to inhibit AP-1 binding activity and thus were able to suppress the production of 
MMP-1 and MMP-9 by human fibrosarcoma cells resulting in decreased invasive properties 
of these cells. Also, many of the well known antiinflammatory drugs such as glucocorticoids  
can block the production of some MMPs by negative  interference with the NF-ĸB pathway 
[Eberhardt et al., 2002a]. The activation of MMPs can be controled by targeting other 
proteases that cleave or activate MMPs as has been demonstrated by the successful inhibition 
of the proteolytic activity of some MMPs by use of neutralizing MT1-MMP antibodies 
[Galvez et al., 2001]. Another strategy to inhibit MMP activity is the use of TIMPs which 
were among the first approaches to block MMP activities. Those studies have reported that 
TIMPs can inhibit tumor growth in transgenic mouse models. However, the clinical 
application seems to be limited because of the general poor pharmacokinetics of TIMPs 
[Kruger et al., 1997; Martin et al., 1999]. Therefore, in the last few years many trials have 
tried to  develop synthetic MMP-inhibitors (MMPIs) for the treatment of different diseases          Summarizing discussion 
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most prominent rheumatoid arthritis and cancer. In this thesis, I present the posttranscriptional 
regulation of MMP-9 gene expression which possibly could provide a new target for 
modulating the expression of many  genes involved in inflammation and tumor progression 
since mRNA stability plays an important role in the regulation of many other genes such as 
TNF α [Biragyn and Nedospasov, 1995; Dean et al., 2001], IL-2 [Bohjanen et al., 1991; 
Henics et al., 1994] and VEGF [Levy et al., 1996]. Meanwhile, different studies have shown 
that the regulation of factors which are critically involved in the stability of mRNA will affect 
not only the expression of MMP-9 but also of other genes that are similar to MMP-9, 
regulated at the level of mRNA stability. Most interestingly, recent studies could demonstrate 
that the expression of several genes regulated via the 3´-UTR are changed in the course of 
cardiovascular diseases [Misquitta et al., 2001]. Prominent example includes the ß1 and ß2 
adrenergic receptors [Blaxall et al., 2000; Danner et al., 1998], eNOS which is mainly 
expressed in vascular endothelium and in the endocardial endothelium of the heart 
[Forstermann et al., 1998] as well as the inducible type of NOS ( iNOS) which is mainly 
expressed in macrophages [Galea and Feinstein,1999]. A further study could document  that 
the level of AUF-1 protein is higher in individuals suffering from myocardial failure [Pende et 
al., 1996]. In summary, these data indicate that posttranscriptional regulation may be a 
mechanism which is responsible for aberrant expression of some genes functionally involved  
in cardiovascular diseases. Similar to cardiovascular diseases, changes in  the expression level 
of factors involved in mRNA stability are involved during tumorigenesis. E.g., 
cyclooxygenase-2 and VEGF mRNA which both contain AREs were reported to be 
abnormally stable in colon carcinoma cells  indicating the role of the ARE-binding and RNA-
stabilizing factor HuR in cancer progression [Dixon et al., 2001]. 
In conclusion, the posttranscriptinal regulation of gene expression may represent an attractive 
target to manipulate or modulate the expression of genes which in addition to transcriptional 
regulation display a modulation via mRNA stability.            Summary 
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Summary 
 
Remodeling of extracellular matrix (ECM) is an important physiologic feature of normal 
growth and development. In addition to this critical function in physiology many diseases 
have been associated with an imbalance of ECM synthesis and degradation. In the kidney, 
dysregulation of ECM turnover can lead to interstitial fibrosis, and glomerulosclerosis. The 
major physiologic regulators of ECM degradation in the glomerulus are the large family of 
zinc-dependent proteases, collectively refered to matrix metalloproteinases (MMPs). The tight 
regulation of most of these proteases is accomplished by different mechanisms, including the 
regulation of MMP gene expression, the processing  and conversion of the inactive zymogen 
by other proteases such as serine proteases and finally the inhibition of active MMPs by 
endogenous inhibitors of MMPs, denoted as tissue inhibitors of metalloproteinases (TIMPs). 
Namely, the MMP-9 has been shown to be critically involved in the dysregulation of ECM 
turnover associated with severe pathologic conditions such as rheumatoid arthritis  or fibrosis 
of lung, skin and kidney. In the present work I searched for a possible modulation of MMP-9 
expression and/or activity in glomerular mesangial cells which are thought as key players of 
many inflammatory and non-inflammatory glomerular diseases. I found that various 
structurally different PPARα agonists such as WY-14,643, LY-171883 and fibrates potently 
suppress the cytokine-induced MMP-9 expression in renal MC. Furthermore, I demonstrate 
that the inhibition of MMP-9 expression   by PPARα agonists was paralleled by  a strong 
increase of cytokine-induced iNOS expression  and subsequent NO formation, suggesting  
that PPARα-dependent effects on MMP-9 expression level primarily result from alterations in 
NO production which in turn reduces the MMP-9 mRNA half-life. Searching for the detailed 
mechanism of NO-dependent effects on MMP-9 mRNA stability, I found that NO either 
given from exogenous sources or endogenously produced increases the MMP-9 mRNA 
degradation by decreasing the expression of the mRNA stabilizing factor HuR. Furthermore, I 
demonstrate a reduction in the RNA-binding capacity of HuR containing complexes to MMP-           Summary 
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9 ARE motifs in cells treated with NO. Since the reduction of HuR expression can be 
mimicked by the cGMP analog 8-Bromo-cGMP, I suggest that NO reduces in a cGMP-
dependent manner the expression of HuR. Finally, I elucidated the modulatory effect of 
extracellular nucleotides, mainly ATP, on cytokine-triggered MMP-9 expression. 
Interestingly, I found that in contrast to NO, γ-S-ATP the stable analog of ATP potently 
amplifies the IL-ß mediated MMP-9 expression. The increase in mRNA stability was 
paralleled by an increase in the nuclear-cytosolic shuttling of the mRNA stabilizing factor 
HuR. Furthermore, I demonstrate an increase in the RNA-binding capacity of HuR containing 
complexes to the 3´-UTR of MMP-9 by ATP.   
In summary, the data presented here may help to find new targets (posttranscriptional 
regulation) that could be used to  manipulate or modulate the expression of not only MMP-9 
but also other genes regulated on the level of  mRNA stability. 
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7. Abbreviations 
 
 
AP-1     activator  protein  1 
APMA     p-aminophenylmercuric  acetate 
AREs        AU-rich  elements 
ATP     adenosine  triphosphate 
BCA     bicinchonic  acid 
BSA     bovine  serum  albumin 
bFGF     basic  fibroblast  growth  factor 
cAMP     cyclic  adenosine  monophosphate 
cGMP     cyclic  guanosine  monophosphate   
COX-2     cyclooxygenase  2 
CTP     cytidine  triphosphate 
DDT     dithiothreitol 
DEPC     diethylpyrocarbonate 
DETA-NO      diethylene triamine nitric oxide 
DMEM   Dulbecco’s  modified  Eagle
,s media 
dNTPs     deoxynucleotides 
ECL     enhanced  chemiluminescence 
ECM        extracellular matrix     
EDTA                                     ethylenediaminetetraacetic acid 
EGTA                                     ethylene glycol-bis (ß-aminoethyl ether)-N,N,N´,N´-                  
 tetraacetic  acid 
ELAV     embryonic  lethal  abnormal  vision 
EMSA                                    electromobility shift assay 
e NOS                                    endothelial nitric oxide synthase  
ERK                 extracellular signal-regulated kinase 
FCS     fetal  calf  serum 
GAPDH    glyceraldehyde-3-phosphate  dehydrogenase 
GST                                        glutathione transferase 
GTP                                        guanosine triphosphate 
IFN-γ                                      interferon γ 
IGF     insulin-like  growth  factor    Abbreviations 
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IkB                                          inhibitor of kB 
IL-1ß       interleukin  1ß 
iNOS          inducible nitric oxide  synthase 
JNK     c-Jun-N-terminal  kinase 
LB     Luria  Bertani 
L-NMMA                               N
G-monomethyl-L-arginine 
LPS     lipopolysaccharides 
MAPK     mitogen  activated  protein  kinase 
MC     mesangial  cell 
M-MLV      Moloney murine leukemia virus 
MMPs     matrix  metalloproteinases 
NF-κB     nuclear  factor  κB 
n NOS       neuronal nitric oxide synthase 
NO     nitric  oxide 
OD     optical  density 
PAGE     polyacrylamide  gel  electrophoresis 
PBS     phosphate  buffered  saline 
PDGF     platelet-derived  growth  factor   
PKC     protein  kinase  C 
PMSF     phenylmethylsulfonyl  fluoride 
PNK     polynucleotide  kinase 
PPAR-α      peroxisome proliferator activated receptor α 
PPRE     peroxisome  proliferator  responsive  element 
PVDF     polyvinylidene  difluoride 
ROS     reactive  oxygen  species 
RPMI     Roswell  Park  Memorial  Institute 
γ-S-ATP     γ-thio-ATP 
SDS     sodium  dodecyl  sulfate 
SNAP     S-nitroso-N-acetyl  penicillamine 
sPLA2     secretory  phospholipase  A2 
SSC buffer      saline-sodium citrate buffer 
STAT        signal transducer and activator of transcription 
sv  40     simian  virus  40 
TGF-ß     transforming  growth  factor  ß    Abbreviations 
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TIMPs     tissue  inhibitor  of  metalloproteinases 
TNF-α     tumor  necrosis  factor-α  
TSR     template  suppression  reagent 
UTP     uridine  triphosphate 
UTR     untranslated  region 
VEGF       vascular endothelial growth factor  
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Deutsche Zusammenfassung   
 
Umbauprozesse der Extrazellulären Matrix (ECM) spielen eine wichtige Rolle für normale 
Wachstums-und Entwicklungsprozesse. In der Niere kann ein nicht adäquater Umsatz von 
ECM beispielsweise zur interstitiellen Fibrose und Glomerulosklerose führen. Diese gelten als 
gemeinsame Endstrecke einer Vielzahl von entzündlichen Erkrankungen der Niere 
unterschiedlicher Genese. Progressive interstitielle Fibrosen sind u.a. durch eine 
Akkumulation von Leukozyten und Fibroblasten, durch eine Atrophie des Tubulus sowie 
durch eine massive Anhäufung von Extrazellulären Matrix (ECM) im Glomerulus 
charakterisiert. Zu den wichtigsten physiologischen Regulatoren des Abbaus von ECM im 
Glomerulus zählen Zink-abhängige Proteasen, die zur Familie der Matrixmetalloproteasen 
(MMPs) zusammengefasst werden. Hauptproduzenten der renalen MMPs sind glomeruläre 
Mesangiumzellen, die neben der MMP Synthese an zahlreichen anderern physiologischen und 
pathologischen Prozessen der Niere beteiligt sind. Die genau abgestimmte Regulation dieser 
Proteasen wird über verschiedene Mechanismen erreicht, u.a. über die Regulation von 
Genexpression, über die Prozessierung und Aktivierung des inaktiven Proenzyms durch 
andere Proteasen (z.B. Serinproteasen) und schliesslich über die Hemmung der aktiven MMPs 
durch die endogenen MMP Inhibitoren, die als „tissue inhibitors of metalloproteases“ 
(TIMPS) zusammengefasst werden. Zu den potentesten Aktivatoren der MMP-9 Expression 
zählen proinflammatorische Zytokine wie Interleukin 1β und tumor necrose factor α (TNFα) 
als auch Tumorpromotoren wie Phorbolester und das virale src Onkogen (v-src).  
 
Das Hauptziel der vorliegenden Arbeit galt der Aufklärung der molekularen Mechanismen der 
MMP-9 Expression und/oder MMP-Aktivität in glomerulären Mesangiumzellen der Ratte. 
Mesangiumzellen gelten als Hauptakteure von glomerulären Erkrankungen mit entzündlicher- 
als auch nicht entzündlicher Genese. Im Verlauf der glomerulären Entzündung können im 
Mesangium durch den Einfluss von Zytokinen und Wachstumsfaktoren auch grössere Deutsche Zusammenfassung 
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Mengen reaktiver Sauerstoffverbindungen (reactive oxygen species: “ROS“) und 
Stickstoffmonoxid (NO) gebildet werden. ROS und NO können neben ihrer rein zelltoxischen 
Wirkung z.B. durch Schädigung von DNA oder Strukturproteinen über eine Aktivierung 
redox-sensitiver Signalkaskaden auch als Botenstoffe der Zelle wirken und damit spezifische 
Zellantworten, wie z.B die Gentranskription oder das Auslösen von Apoptose beeinflussen. 
Die Bedeutung dieser Zellantworten bei den oben aufgeführten pathologischen Prozessen ist 
bislang noch wenig bekannt. In Mesangiumzellen kann die über Zytokine induzierte 
Expression von MMP-9 durch exogenes und endogen gebildetes NO gehemmt werden, ohne 
dass die Aktivität von MMP-9 verändert wird. Mittlerweile ist eine Regulation der MMP-9 
Expression durch NO nicht nur in Mesangiumzellen, sondern auch in einer Reihe anderer 
Zellsysteme wie z.B. glatten Muskelzellen oder in Gefässendothelzellen nachgewiesen 
worden. 
Im ersten Teil meiner Arbeit untersuchte ich die molekularen Mechanismen der über eine 
Aktivierung der Peroxisomen Proliferation aktivierten Rezeptoren (PPAR)-vermittelten 
MMP-9 Expression in glomerulären Mesangiumzellen. Aus vorherigen Studien war bekannt, 
dass Liganden von nukleären Hormonrezeptoren wie z.B. Glukokortikoide, über eine 
Hemmung der Transkriptionsfaktoren „nuklear factor κB“ (NF-κB) und „activated protein-1“ 
(AP-1) die Zytokin-induzierte MMP-9 Expression stark herabsetzen können.  Als weitere 
nukleären Hormonrezeptoren, die als Modulatoren der MMP-9 Expression wirken können, 
haben wir Liganden der PPARs identifizieren können. PPARs können durch die Bindung von 
sowohl physiologischen (z.B. Retinolsäure, langkettige Fettsäuren und Eikosanoide) als auch 
pharmakologischen Liganden (z.B. Fibrate und Glitazone) aktiviert werden. Von besonderem 
Interesse ist, dass Aktivatoren der PPARs neben ihren Funktionen beim Fettabbau, zusätzlich 
wichtige antiinflammatorische Wirkungen vermitteln können.  Mechanistisch kann die 
Aktivierung der PPARs über eine direkte Bindung an spezifische DNA-Erkennungsmotive, 
sogenannte  „PPAR-responsible elements“ („PPREs“), oder indirekt, durch die Deutsche Zusammenfassung 
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Wechselwirkungen mit anderen Transkriptionsfaktoren ohne einen direkten Kontakt zur 
DNA, zu einer veränderten Transkriptionsrate der über PPAR-regulierten Gene führen. Wie 
ich zeigen konnte sind unterschiedliche Aktivatoren des PPARα Rezeptortyps wie 
beispielsweise WY-14,643, LY-171883 oder Bezafibrat in der Lage, die Zytokin-induzierte 
MMP-9 Expression in Mesangiumzellen in potenter Weise zu hemmen. Im Gegensatz hierzu 
haben „Nuclear run-off“ Experimente und Promotoranalysen gezeigt, dass die 
expressionshemmende Wirkung der PPARα Aktivatoren nicht auf eine Hemmung der 
Transkriptionsrate zurückgeführt werden können.  Auf der Suche nach weiteren PPAR-
modulierten Genen der Entzündungskaskade fand ich die induzierbare NO Synthase (iNOS), 
deren Expression durch PPARα Aktivatoren verstärkt wird was letzlich zu einer gesteigerten 
NO Freisetzung führt. In Mesangiumzellen kann die Expression der iNOS, ähnlich wie die 
Expression der MMP-9, durch Stimulaton mit proinflammatorischen Zytokinen um ein 
Vielfaches gesteigert werden. In der vorliegenden Arbeit konnte die Existenz eines 
funktionellen „Crosstalks“ zwischen diesen beiden prominenten inflammatorischen 
Genprodukten (NO und MMP-9) nachgewiesen werden. Dieser Crosstalk äussert sich darin, 
dass die MMP-9 hemmenden Effekte der PPARα Aktivatoren in der Gegenwart eines iNOS 
Aktivitäthemmstoffes zu einer massiven Verstärkung der Zytokin-induzierten MMP-9 
Expression konvertiert werden können. Die Umkehrung in Gegenwart des NO 
Synthesehemmers zeigt, dass die PPARα-vermittelten Effekte in erster Linie durch die 
Hemmung der NO Synthese hervorgerufen werden. Auf der Suche nach den mechanistischen 
Grundlagen dieser NO Effekte konnte ich mit Hilfe des Transkriptionshemmstoff 
Actinomycin D zeigen, dass sowohl exogen zugeführtes NO als auch durch eine Induktion der 
iNOS entstandenes NO in der Lage ist, den Abbau der Zytokin-induzierten MMP-9 mRNA zu 
beschleunigen. Weiterhin konnte der Nachweis erbracht werden, dass die Expression des 
mRNA stabilisierenden Faktors HuR durch NO sowohl auf Protein- als auch auf mRNA 
Ebene signifikant gehemmt wird. HuR ist ein Protein der ELAV Genfamilie (embryonic lethal Deutsche Zusammenfassung 
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abnormal vision), deren Mitglieder als RNA-bindende Proteine bei der Regulation des 
zellulären mRNA Abbaus und damit bei der Regulation der posttranskriptionellen 
Genexpression massgeblich beteiligt sind. Die über HuR vermittelte Stabilisierung von 
mRNA erfolgt über eine hochaffine Bindung des HuR Proteins an AU-reiche Sequenzmotife 
innerhalb des untranslatierten 3´-Bereichs der mRNA (3´-UTR) . 
Durch die Behandlung der Zellen mit einem membranpermeablen cGMP Analogon (z.B. 8-
Bromo-cGMP) konnte ich nachweisen, dass die NO-abhängige Stabilisierung von MMP-9 
mRNA über cGMP-aktivierte Signalkaskaden vermittelt wird. Entsprechend konnte durch die 
Zugabe eines spezifischen Hemmstoffes der löslichen Guanylatzyklase (z.B. LY-83,583) die 
über NO-vermittelte Hemmung der HuR Expression signifikant gehemmt werden. 
Über die Klonierung des etwa 800 Basen langen 3´-UTR des MMP-9 Gens gelang es mir, die 
für die Stabilisierung der MMP-9 mRNA verantwortlichen „cis-regulatorischen“ DNA-
Bereiche mit Hilfe der Punktmutagenese zu identifizieren. Die funktionelle Bedeutung konnte 
nachfolgend mit der Hilfe von transienten Transfektionen von Mesangiumzellen mit 
verschiedenen mutierten Reportergenkonstrukten demonstriert werden.  
Die funktionelle Konsequenz einer über NO -vermittelten Stabilitätsminderung von MMP-9 
mRNA konnte ausserdem mit der Hilfe von in vitro RNA-Degradationsexperimenten belegt 
werden. Diese Experimente haben gezeigt, dass die endogene MMP-9 mRNA nach der 
Inkubation mit zytoplasmatischen Zellextrakten von NO behandelten Zellen einem im 
Vergleich nach Inkubation mit Zellhomogenaten aus unbehandelten Mesangiumzellen, 
beschleunigten RNA Abbau unterliegt. Entsprechend konnte durch Neutralisierung des HuRs 
mit einem spezifischen Antikörper der über NO vermittelte Abbau der MMP-9 mRNA nahezu 
vollständig blockiert werden, während durch die Inkubation mit einem Kontrollserum keine 
Verzögerung der mRNA Degradation beobachtet werden konnte.  
Auf RNA-Ebene konnte ich mit Hilfe von RNA-Gelschift und Superschiftanalysen eine 
starke, konstitutive Bindung von HuR-haltigen Proteinkomplexen an MMP-9-genspezifische Deutsche Zusammenfassung 
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AU-reiche Sequenzmotive nachwiesen. Die hohe Bindungsaffinität des HuRs an diese AU-
reichen Sequenzmotife zeigt sich auch anhand der hohen Bindungsaffinität des in E.coli 
exprimierten HuR Proteins. Durch Mutation der MMP-9-spezifischen AU-reichen 
Sequenzmotive, konnte die RNA-Bindugsaffinität des HuRs (unabhängig davon ob 
fremdexprimiert oder aus Mesangiumzellen isoliert) stark vermindert werden. Die hier 
zusammengefassten Untersuchungen zeigen nach unserem Wissen erstmalig die Möglichkeit 
einer durch NO-vermittelten Genexpressionsänderung von MMP-9 durch Modulation der 
mRNA-Stabilität. 
 
In einem weiteren Projekt untersuchte ich, ob extrazellulären Nukleotide in der Lage sind, 
einen modulierenden Einfluss auf die Zytokin-induzierte MMP-9 Expression auszuüben. 
Extrazelluläre Nukleotide wie das Adenosintriphosphat (ATP) und Uraciltriphosphat (UTP) 
sind nicht nur für die Nukleinsäuresynthese und den Energiestoffwechsel der Zelle von 
zentraler Bedeutung, sondern sind über eine Bindung an zellmembranständige Rezeptoren 
(sogenannte Purin Rezeptoren) in der Lage, eine Reihe weiterer zellphysiologischer Prozesse 
wie z.B. Apoptose oder Zellproliferation zu steuern. Letztere ist zusammen mit dem 
extensiven Abbau der ECM ein Hauptcharakteristikum vieler chronisch entzündlichen 
Erkrankungen der Niere. In den hier vorgestellten Untersuchungen konnte ich zeigen, dass 
das chemisch stabile ATP-Analogon γ-S-ATP in der Lage ist, einen über IL-1β-vermittelten 
Anstieg der MMP-9 Expression noch weiter zu verstärken. Interessanterweise korreliert der 
Anstieg der MMP-9 mRNA Stabilität mit einer Zunahme des intrazellulären Transports von 
HuR aus dem Zellkern in das Zytoplasma. Der verstärkte Export von HuR aus dem Zellkern 
ist auch mit einer Zunahme der RNA Bindungsaffinität der HuR-haltigen Komplexe an die 
AU-reichen Sequenzenmotife innerhalb des 3´-untranslatierten Bereichs (3´-UTRs) des 
MMP-9 Gens verbunden.  Deutsche Zusammenfassung 
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Im Unterschied zu der im ersten Teil meiner Arbeit beschriebenen Veränderung der MMP-9 
mRNA Stabilität durch eine über NO-hervorgerufene Expressionsänderung von HuR, beruht 
die durch ATP-induzierte Stabilitätszunahme von MMP-9 mRNA hauptsächlich auf einem 
verstärkten intrazellulären Transport des HuR Proteins, ohne dass dabei seine Expression 
verändert wird. Jeder dieser Mechanismen könnte für das Verständnis der molekularen 
Ursachen von Krankheiten, die u.a auf fehlerhafte Matrixumbauprozesse in der Niere oder 
anderen Organen wie Leber oder Lunge zurückzuführen sind , von grosser Bedeutung sein.  
Die in der vorliegenden Arbeit zusammengefassten Erkenntnisse können ausserdem dazu 
beitragen, neue insbesondere posttranskriptionelle Ansätze der spezifischen Manipulation von 
MMP-9 und möglicherweise anderer auf Ebene der mRNA Stabilität regulierten Gene zu 
finden. 
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